image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
5bb86068fa044128a025db6922fd083ec33a4017495b156bebce383993d9667b.png | simple | <table><tr><td>Particle</td><td>Loading capacity (%)</td><td>Loading efficiency (%)</td><td>Size (nm)</td><td>Administration route</td><td>In vitro/in vivo results</td><td>Ref.</td></tr><tr><td>NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan)</td><td>3</td><td>99</td><td>50</td><td>Oral</td><td>High stability in both acidic and neutral environments.In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol.</td><td>[27]</td></tr><tr><td>NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate)</td><td>10</td><td>96</td><td>108</td><td>N/A</td><td>Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1.</td><td>[28]</td></tr><tr><td>Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol</td><td>N/A</td><td>N/A</td><td>30–80</td><td>Oral</td><td>Enhanced EGCG oral bioavailability in vivo and induction of <i>α</i>-secretase activity in neuronal cells in vitro.</td><td>[29]</td></tr><tr><td>NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80)</td><td>2.7–3.6</td><td>99</td><td>126–167</td><td>Topical</td><td>Photodegradation of EGCG under UVA radiation.</td><td>[30]</td></tr><tr><td>SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68)</td><td>N/A</td><td>67</td><td>157</td><td>N/A</td><td>Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145.</td><td>[31]</td></tr><tr><td>Cationic lipid nanocarriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB)</td><td>N/A</td><td>N/A</td><td>~150</td><td>Ocular</td><td>Prolonged release of EGCG in biological medium. Permeation of rabbit cornea and sclera.</td><td>[32]</td></tr></table> |
dab64efa2d5d74cb05a674909181ed876baa8baf86738648459fcf8af7efe7c1.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="2">Adherence</td><td rowspan="2">OR (95% CI)</td><td rowspan="2">p-value</td></tr><tr><td>Yes [n,(%)]</td><td>No [n,(%)]</td></tr><tr><td>Perceived benefits of DM drugs</td><td></td><td></td><td></td><td></td></tr><tr><td>A lot of benefits</td><td>251 (85.9)</td><td>41 (14.1)</td><td>1.00</td><td></td></tr><tr><td>Some benefits</td><td>182 (75.2)</td><td>42 (24.8)</td><td>0.64 (0.40 – 1.02)</td><td>0.063</td></tr><tr><td>Duration on DM drugs</td><td></td><td></td><td></td><td></td></tr><tr><td>Less or equal to 3years</td><td>198 (77.6)</td><td>57 (22.4)</td><td>1.00</td><td></td></tr><tr><td>More than 3 years</td><td>235 (88.7)</td><td>30 (11.3)</td><td>2.25 (1.38 – 3.66)</td><td><0.001</td></tr><tr><td>Type of DM drugs taken</td><td></td><td></td><td></td><td></td></tr><tr><td>Orals only</td><td>241 (80.3)</td><td>50 (19.3)</td><td>1.00</td><td></td></tr><tr><td>Injections only</td><td>182 (87.9)</td><td>25 (12.1)</td><td>1.78 (1.07 – 2.96)</td><td>0.024</td></tr><tr><td>Both oral and injections</td><td>10 (81.8)</td><td>3 (18.2)</td><td>1.10 (0.23 – 5.24)</td><td>0.903</td></tr><tr><td>Do you get all the prescribed drugs</td><td></td><td></td><td></td><td></td></tr><tr><td>Sometimes</td><td>133(74.2)</td><td>43 (25.8)</td><td>1.00</td><td></td></tr><tr><td>Always</td><td>297 (87.9.)</td><td>41 (12.1)</td><td>2.56 (1.56 – 4.16)</td><td>0.001</td></tr><tr><td>Ever experienced side effects</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>56 (76.7)</td><td>17 (23.3)</td><td>1.00</td><td></td></tr><tr><td>No</td><td>365 (84.9)</td><td>65 (15.1)</td><td>1.70 (0.93 – 3.12)</td><td>0.080</td></tr><tr><td>Time when last seen by the health worker</td><td></td><td></td><td></td><td></td></tr><tr><td>Less or equal to one month</td><td>211 (82.4)</td><td>45 (17.6)</td><td>1.00</td><td></td></tr><tr><td>More than one month</td><td>214 (84.6)</td><td>39 (15.6)</td><td>1.17 (0.73 – 1.87)</td><td>0.430</td></tr><tr><td>Use of alternative medicine</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>53 (69.7)</td><td>23 (30.3)</td><td>1.00</td><td></td></tr><tr><td>No</td><td>367 (85.9)</td><td>60 (14.1)</td><td>2.65 (1.50 – 4.68)</td><td><0.001</td></tr><tr><td>Ever had diabetic education</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>8 (61.5)</td><td>5 (38.5)</td><td>1.00</td><td></td></tr><tr><td>Yes</td><td>421 (84.2)</td><td>79 (15.8)</td><td>3.33 (1.06 – 11.10)</td><td>0.029</td></tr><tr><td>Understanding the drug regimen</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>415 (83.5)</td><td>82 (16.5)</td><td>1.00</td><td></td></tr><tr><td>No</td><td>16 (73.7)</td><td>7 (26.3)</td><td>0.55 (0.19 – 1.58)</td><td>0.262</td></tr><tr><td>Reminders to take drugs</td><td></td><td></td><td></td><td></td></tr><tr><td>Radio/TV</td><td>87 (86.1)</td><td>14 (13.9)</td><td>1.00</td><td></td></tr><tr><td>Watch/clock</td><td>126 (84.0)</td><td>24 (26.0)</td><td>0.84 (0.41- 1.72)</td><td>0.643</td></tr><tr><td>Phones</td><td>73 (84.9)</td><td>13 (15.1)</td><td>0.90 (0.39 - 2.04)</td><td>0.808</td></tr><tr><td>Shadows</td><td>8 (88.9)</td><td>1 (11.1)</td><td>1.28 (0.14 – 11.2)</td><td>0.818</td></tr><tr><td>Others</td><td>108 987.1)</td><td>16 (12.9)</td><td>1.08 (0.50 – 2.35)</td><td>0.833</td></tr><tr><td>None</td><td>30 (61.2)</td><td>19 (38.8)</td><td>0.25 (0.10 – 0.56)</td><td>0.006</td></tr></table> |
ea056cba5bab12c0d233b476723405c72f6e88a34c2a3c1276565e88edd6efa1.png | complex | <table><tr><td>Model</td><td>Unstandardized Coefficients <i>B</i></td><td>Unstandardized Coefficients <i>SE</i></td><td>Standardized Coefficient <i>ß</i></td><td><i>t</i></td><td><i>p</i></td></tr><tr><td colspan="6">A. Results of the linear Regression for Variables Predicting PTSD Symptoms</td></tr><tr><td> Constant</td><td>−3.28</td><td>1.75</td><td></td><td>−1.88</td><td><i>p</i> = .063</td></tr><tr><td> MACE SUM</td><td>0.21</td><td>0.06</td><td>.29</td><td>3.42</td><td><i>p</i> = .001</td></tr><tr><td> Physical Neglect at age 5</td><td>2.28</td><td>0.80</td><td>.24</td><td>3.86</td><td><i>p</i> = .005</td></tr><tr><td> Emotional Neglect at age 6</td><td>0.60</td><td>0.43</td><td>.12</td><td>1.41</td><td><i>p</i> = .161</td></tr><tr><td> Sexual Abuse at age 12</td><td>6.73</td><td>1.89</td><td>.25</td><td>3.56</td><td><i>p</i> = .001</td></tr><tr><td colspan="6">B. Results of the linear Regression for Variables Predicting Symptoms of Shutdown Dissociation</td></tr><tr><td> Constant</td><td>3.47</td><td>0.73</td><td></td><td>−1.88</td><td><i>p</i> < .001</td></tr><tr><td> Physical Neglect at age 5</td><td>0.70</td><td>0.48</td><td>.14</td><td>1.46</td><td><i>p</i> = .147</td></tr><tr><td> Emotional Neglect at age 4</td><td>0.57</td><td>0.26</td><td>.21</td><td>2.17</td><td><i>p</i> = .032</td></tr><tr><td> Parental Non-verbal Emotional Abuse at age 14</td><td>0.44</td><td>0.26</td><td>.16</td><td>1.73</td><td><i>p</i> = .086</td></tr><tr><td> Sexual Abuse at age 12</td><td>3.02</td><td>1.12</td><td>.22</td><td>2.69</td><td><i>p</i> = .008</td></tr><tr><td colspan="6">C. Results of the linear Regression for Variables Predicting Symptoms of Depression</td></tr><tr><td> Constant</td><td>14.82</td><td>1.29</td><td></td><td>11.48</td><td><i>p</i> < .001</td></tr><tr><td> F2 diagnosis</td><td>−5.12</td><td>0.14</td><td>−.34</td><td>−4.49</td><td><i>p</i> < .001</td></tr><tr><td> MACE duration</td><td>0.01</td><td>0.01</td><td>.15</td><td>1.39</td><td><i>p</i> = .166</td></tr><tr><td> Emotional Neglect at age 9</td><td>0.51</td><td>0.30</td><td>.17</td><td>1.67</td><td><i>p</i> = .097</td></tr><tr><td> Sexual Abuse at age 12</td><td>2.69</td><td>1.37</td><td>.16</td><td>1.97</td><td><i>p</i> = .051</td></tr></table> |
6e56fcac80ae20bcf9c50d9ddb55da4a8994ee66a3acfe651d88a269f046b155.png | simple | <table><tr><td>Phenotype</td><td>SNP</td><td>Chromosome</td><td>Position (bp)a</td><td>Alleleb</td><td>MAFc (%) in cases</td><td>MAFc (%) in controls</td><td>RRd (95% CI)</td><td><i>P</i> value</td><td>Nearby genee</td></tr><tr><td>BE</td><td>rs3072</td><td>2p24</td><td>20,741,887</td><td>G/A</td><td>38.1</td><td>37.0</td><td>1.05 (0.91–1.21)</td><td>5.32 × 10<sup>−01</sup></td><td><i>GDF7</i></td></tr><tr><td>BE</td><td>rs2701108</td><td>12q24</td><td>113,158,644</td><td>G/A</td><td>35.5</td><td>38.6</td><td>0.87 (0.75–1.01)</td><td>6.38 × 10<sup>−02</sup></td><td><i>TBX5</i></td></tr><tr><td>BE</td><td>rs3784262</td><td>15q22</td><td>56,040,398</td><td>G/A</td><td>40.7</td><td>46.4</td><td>0.79 (0.68–0.91)</td><td>9.70 × 10<sup>−04</sup></td><td><i>ALDH1A2</i></td></tr><tr><td>EAC</td><td>rs3072</td><td>2p24</td><td>20,741,887</td><td>G/A</td><td>41.3</td><td>37.0</td><td>1.20 (1.07–1.34)</td><td>1.48 × 10<sup>−03</sup></td><td><i>GDF7</i></td></tr><tr><td>EAC</td><td>rs2701108</td><td>12q24</td><td>113,158,644</td><td>G/A</td><td>35.6</td><td>38.6</td><td>0.88 (0.78–0.98)</td><td>2.47 × 10<sup>−02</sup></td><td><i>TBX5</i></td></tr><tr><td>EAC</td><td>rs3784262</td><td>15q22</td><td>56,040,398</td><td>G/A</td><td>44.3</td><td>46.4</td><td>0.92 (0.82–1.03)</td><td>1.30 × 10<sup>−01</sup></td><td><i>ALDH1A2</i></td></tr><tr><td>BE/EAC</td><td>rs3072</td><td>2p24</td><td>20,741,887</td><td>G/A</td><td>40.3</td><td>37.0</td><td>1.15 (1.04–1.27)</td><td>7.53 × 10<sup>−03</sup></td><td><i>GDF7</i></td></tr><tr><td>BE/EAC</td><td>rs2701108</td><td>12q24</td><td>113,158,644</td><td>G/A</td><td>35.6</td><td>38.6</td><td>0.88 (0.79–0.97)</td><td>1.12 × 10<sup>−02</sup></td><td><i>TBX5</i></td></tr><tr><td>BE/EAC</td><td>rs3784262</td><td>15q22</td><td>56,040,398</td><td>G/A</td><td>43.1</td><td>46.4</td><td>0.88 (0.79–0.97)</td><td>8.06 × 10<sup>−03</sup></td><td><i>ALDH1A2</i></td></tr></table> |
18794042706e5487ef6e391bc5233ded5701e247ed2d8b0fd02f940d9b91d140.png | simple | <table><tr><td>Characteristic</td><td>Rotavirus Diarrhea (n = 71)</td><td>Nonrotavirus Diarrhea (n = 149)</td><td><i>P</i> Value</td></tr><tr><td>Age, mo<sup>a</sup></td><td>9 (3–27)</td><td>10 (2–30)</td><td>.335</td></tr><tr><td>Male sex</td><td>42 (59.2)</td><td>78 (52.3)</td><td>.422</td></tr><tr><td>Prior hospital admission for diarrhea</td><td>22 (31.0)</td><td>37 (24.8)</td><td>.423</td></tr><tr><td>Home has a separate room for kitchen</td><td>40 (56.3)</td><td>88 (59.1)</td><td>.813</td></tr><tr><td>No. of bedrooms in home<sup>a</sup></td><td>2 (1–4)</td><td>2 (1–4)</td><td>.278</td></tr><tr><td>No. of people sleeping in home<sup>a</sup></td><td>7 (1–20)</td><td>6 (4–21)</td><td>.368</td></tr><tr><td>No. of children sleeping in home<sup>a</sup></td><td>4 (1–8)</td><td>3 (1–13)</td><td>.459</td></tr><tr><td>Family owns a mattress</td><td>51 (71.8)</td><td>98 (65.8)</td><td>.457</td></tr><tr><td>Family owns a mobile phone</td><td>70 (98.6)</td><td>130 (87.2)</td><td>.013</td></tr><tr><td>Family owns a radio</td><td>38 (53.5)</td><td>79 (53.0)</td><td>1.000</td></tr><tr><td>From the Iraqw tribe</td><td>37 (52.1)</td><td>95 (63.8)</td><td>.133</td></tr><tr><td>Maternal age<sup>a</sup></td><td>27 (16–47)</td><td>26 (17–41)</td><td>.919</td></tr><tr><td>Mother completed secondary school</td><td>50 (70.4)</td><td>87 (58.4)</td><td>.116</td></tr><tr><td>Protected drinking water source</td><td>27 (38.0)</td><td>70 (47.0)</td><td>.269</td></tr><tr><td>Child still breastfeeding</td><td>63 (88.7)</td><td>119 (79.9)</td><td>.151</td></tr></table> |
082dc3b7cfed1863d88b55421f223a10f0a02a82ba59b419eb12f4f6329edcce.png | simple | <table><tr><td>Author</td><td>Age</td><td>Symptoms</td><td>Site of tumor</td><td>Histology</td><td>Treatment</td><td>Relapse(months)</td><td>Treatment of relapse</td></tr><tr><td>Our case</td><td>56</td><td>Urinary symptomsLower abdominal distention</td><td>Corpus</td><td>IT</td><td>Hysterectomy</td><td>Yes (3)</td><td>BEP × 1</td></tr><tr><td>Newsom-Davis et al., 2009 [5]</td><td>82</td><td>Vaginal bleeding</td><td>Corpus</td><td>IT</td><td>Hysterectomy and bilateral salpingooophorectomy</td><td>Yes (6)</td><td>EP × 1, ET × 1, TP × 1 + surgery</td></tr><tr><td>Gomez-Lobo et al., 2007 [6]</td><td>15</td><td>Vaginal bleedingPelvic pain</td><td>ns</td><td>IT, high grade</td><td>Lesion excision + chemotherapy</td><td>ns</td><td>—</td></tr><tr><td>Iwanaga et al., 1993 [7]</td><td>36</td><td>Pelvic painLower abdominal distention</td><td>Fundus</td><td>IT, grade 3</td><td>Hysterectomy + chemotherapy (VAC × 2)</td><td>No</td><td>—</td></tr><tr><td>Ansah-Boateng et al., 1985 [8]</td><td>37</td><td>Vaginal bleeding</td><td>ns</td><td>IT, grade 2</td><td>Hysterectomy + radiotherapy</td><td>No</td><td>—</td></tr></table> |
ee83663a219587c26faae1496362e8f086f771b6b4033e69ccf512333432e378.png | simple | <table><tr><td>n</td><td></td><td>1108</td></tr><tr><td>Age (yrs)</td><td>Median</td><td>61.5</td></tr><tr><td></td><td>Range</td><td>40.2-79</td></tr><tr><td>PSA (ng/ml)</td><td>Median</td><td>6.99</td></tr><tr><td></td><td>Range</td><td>0.3-20</td></tr><tr><td>Pathological Stage</td><td>pT2</td><td>770 (69.6%)</td></tr><tr><td></td><td>pT3</td><td>335 (30.4%)</td></tr><tr><td>Tumour Grade</td><td>Low (GS 6)</td><td>153 (13.8%)</td></tr><tr><td></td><td>Intermediate (GS 7)</td><td>848 (76.5%)</td></tr><tr><td></td><td>GS 3+4</td><td>583 (68.8%)</td></tr><tr><td></td><td>GS 4+3</td><td>265 (31.3%)</td></tr><tr><td></td><td>High (GS 8-10)</td><td>107 (9.7%)</td></tr><tr><td>Extraprostatic Extension</td><td>Absent</td><td>782 (70.6%)</td></tr><tr><td></td><td>Present</td><td>326 (29.4%)</td></tr><tr><td>Seminal Vesicle Invasion</td><td>Absent</td><td>1042 (94.1%)</td></tr><tr><td></td><td>Present</td><td>66 (6%)</td></tr><tr><td>Recurrence</td><td>No</td><td>812 (76.8%)</td></tr><tr><td>(n=1057)</td><td>Yes</td><td>245 (23.2%)</td></tr><tr><td>Total Tumour Volume (cc)</td><td>Median</td><td>2.6</td></tr><tr><td></td><td>IQR</td><td>1.3-4.8</td></tr><tr><td>Prostate Volume (cc)</td><td>Median</td><td>32.2</td></tr><tr><td></td><td>IQR</td><td>24.2-43.5</td></tr></table> |
ae9806d081d6c1a515e0ac9059c31c96cfd7b800fbcdcede0c57f136a8b97d23.png | complex | <table><tr><td></td><td>Expected</td><td colspan="2">Jinan</td><td colspan="2">Xuzhou</td><td colspan="2">Hefei</td><td colspan="2">Shanghai 2000</td><td colspan="2">Shanghai 1986</td></tr><tr><td>Centile</td><td>(%)</td><td>Boys</td><td>Girls</td><td>Boys</td><td>Girls</td><td>Boys</td><td>Girls</td><td>Boys</td><td>Girls</td><td>Boys</td><td>Girls</td></tr><tr><td>3</td><td>3</td><td>2.6</td><td>2.8</td><td>2.7</td><td>3.1</td><td>2.8</td><td>3.1</td><td>2.6</td><td>2.8</td><td>2.7</td><td>2.8</td></tr><tr><td>5</td><td>2</td><td>1.8</td><td>2.0</td><td>1.6</td><td>1.7</td><td>1.7</td><td>1.8</td><td>1.8</td><td>1.8</td><td>0.5</td><td>1.7</td></tr><tr><td>10</td><td>5</td><td>4.6</td><td>4.4</td><td>4.9</td><td>4.7</td><td>4.7</td><td>4.7</td><td>5.0</td><td>4.7</td><td>5.1</td><td>3.4</td></tr><tr><td>25</td><td>15</td><td>16.5</td><td>14.8</td><td>15.9</td><td>14.8</td><td>15.8</td><td>14.6</td><td>16.1</td><td>15.4</td><td>15.5</td><td>15.7</td></tr><tr><td>50</td><td>25</td><td>26.0</td><td>27.2</td><td>26.0</td><td>26.3</td><td>25.8</td><td>25.6</td><td>25.7</td><td>25.8</td><td>27.1</td><td>26.8</td></tr><tr><td>75</td><td>25</td><td>23.1</td><td>24.4</td><td>23.6</td><td>25.1</td><td>24.4</td><td>25.8</td><td>23.5</td><td>24.8</td><td>25.9</td><td>26.5</td></tr><tr><td>90</td><td>15</td><td>14.0</td><td>13.9</td><td>14.3</td><td>14.2</td><td>14.1</td><td>14.8</td><td>14.7</td><td>14.6</td><td>15.0</td><td>13.3</td></tr><tr><td>95</td><td>5</td><td>5.7</td><td>4.9</td><td>5.3</td><td>5.0</td><td>5.4</td><td>4.3</td><td>5.5</td><td>4.8</td><td>3.8</td><td>5.2</td></tr><tr><td>97</td><td>2</td><td>2.6</td><td>2.3</td><td>2.6</td><td>1.7</td><td>2.1</td><td>1.9</td><td>2.3</td><td>2.0</td><td>1.2</td><td>1.9</td></tr><tr><td>100</td><td>3</td><td>3.1</td><td>3.5</td><td>3.1</td><td>3.4</td><td>3.2</td><td>3.3</td><td>3.0</td><td>3.3</td><td>3.2</td><td>2.8</td></tr></table> |
8b1eedc61b7a77c4d8f8f84bb6aa091d745023b86a56a00e72eb594aa1bed506.png | complex | <table><tr><td></td><td colspan="2">Non smokersn = 19</td><td colspan="2">Ex-smokersn = 6</td><td colspan="2">Current smokersn = 14</td></tr><tr><td>Males (n, %)</td><td>7</td><td>36,8</td><td>6</td><td>100</td><td>11</td><td>78,6</td></tr><tr><td>Age, years; mean+SD</td><td>46,6</td><td>4</td><td>46</td><td>4,5</td><td>45,6</td><td>4,6</td></tr><tr><td>Years of employment; mean ± SD</td><td>24,1</td><td>4,2</td><td>22,8</td><td>3,3</td><td>23,4</td><td>4,5</td></tr><tr><td>Respiratory PPE use (n, %)</td><td>3</td><td>15,8</td><td colspan="2">0</td><td>3</td><td>21,4</td></tr><tr><td>Spirometry</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> FVC; mean+SD</td><td>86,4</td><td>7,1</td><td>84</td><td>3,4</td><td>80,4</td><td>11,3</td></tr><tr><td>< 80% of pred. FVC (n, %)</td><td>1</td><td>5,3</td><td colspan="2">0</td><td>4</td><td>28,6</td></tr><tr><td> FEV1; mean+SD</td><td>87,8</td><td>10,3</td><td>87,9</td><td>4,9</td><td>82</td><td>11,5</td></tr><tr><td>< 80% of pred. FEV1 (n, %)</td><td>1</td><td>5,3</td><td colspan="2">0</td><td>4</td><td>28,6</td></tr><tr><td>FEV1/FVC, < 70% (n, %)</td><td>1</td><td>5,3</td><td colspan="2">0</td><td colspan="2">0</td></tr><tr><td>Asbestos bodies</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> in BALF</td><td>9</td><td>47,4</td><td>2</td><td>33,3</td><td>3</td><td>21,4</td></tr><tr><td> in IS</td><td>6</td><td>31,6</td><td colspan="2">0</td><td>2</td><td>14,3</td></tr></table> |
cfdde3ff3c0e533c8c349cc406146151c0dca69c12206d9f76db7b90ec03973b.png | complex | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Unit</td><td colspan="3">Tier within the breeding program</td></tr><tr><td>Nucleus</td><td>Multiplier</td><td>Commercial</td></tr><tr><td>Flock breeding ewes</td><td>Head</td><td>826</td><td>7000</td><td>180,000</td></tr><tr><td>Flock breeding rams</td><td>Head</td><td>10</td><td>70</td><td>1800</td></tr><tr><td>Ewes mated to terminal sires</td><td>%</td><td>0</td><td>0</td><td>20</td></tr><tr><td>Ewes/ram</td><td>Head</td><td>80</td><td>100</td><td>100</td></tr><tr><td>Ewe replacement rate</td><td>%</td><td>35</td><td>35</td><td>30</td></tr><tr><td>Mixed age ewe lambing rate<sup>a</sup></td><td>%</td><td>210</td><td>190</td><td>165</td></tr><tr><td>Ewe lamb lambing rate</td><td>%</td><td>100</td><td>90</td><td>80</td></tr><tr><td>Lamb survival</td><td>%</td><td>79</td><td>79</td><td>82</td></tr><tr><td>Weaning rate</td><td>%</td><td>166</td><td>150</td><td>135</td></tr><tr><td>Lambs sold as stores<sup>b</sup></td><td>%</td><td>–</td><td>–</td><td>20</td></tr></table> |
0084e2d895ff11c95eb967f66bb3a0bf80b780cc08cdf18e263155361da5f048.png | complex | <table><tr><td></td><td></td><td colspan="3">Direct</td><td colspan="3">Indirect</td></tr><tr><td>IC1</td><td><i>n</i></td><td>2.5</td><td>50</td><td>97.5</td><td>2.5</td><td>50</td><td>97.5</td></tr><tr><td>Eire</td><td>1949</td><td>0.1</td><td>0.2</td><td>0.2</td><td>0.0</td><td>0.0</td><td>0.1</td></tr><tr><td>Great Britain</td><td>1416</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Eastern Europe</td><td>61</td><td>0.2</td><td>0.5</td><td>1.0</td><td>0.1</td><td>0.3</td><td>0.7</td></tr><tr><td>Northern Europe</td><td>45</td><td>0.0</td><td>0.3</td><td>0.8</td><td>0.0</td><td>0.2</td><td>0.5</td></tr><tr><td>Southern Europe</td><td>60</td><td>0.0</td><td>0.2</td><td>0.5</td><td>0.0</td><td>0.1</td><td>0.3</td></tr><tr><td>Western Europe</td><td>13</td><td>0.1</td><td>0.7</td><td>2.1</td><td>0.0</td><td>0.5</td><td>1.8</td></tr><tr><td>Anglo New World</td><td>13</td><td>0.1</td><td>0.5</td><td>1.7</td><td>0.0</td><td>0.3</td><td>1.4</td></tr><tr><td>Latin America</td><td>25</td><td>0.5</td><td>1.3</td><td>2.4</td><td>0.6</td><td>1.3</td><td>2.4</td></tr></table> |
cbd0561839dc5bae697016af8ebb908cdd7fba57a5f9d7dbb30edde3f6d068dd.png | simple | <table><tr><td></td><td></td><td></td><td></td><td>Cluster</td><td></td><td></td></tr><tr><td></td><td></td><td>Professional</td><td>Consumer</td><td>Organizational</td><td>Financial</td><td>Regulatory</td></tr><tr><td></td><td>Breast</td><td>4</td><td>9</td><td>4</td><td>0</td><td>0</td></tr><tr><td></td><td>Gastrointestinal</td><td>2</td><td>2</td><td>2</td><td>0</td><td>0</td></tr><tr><td></td><td>Genitourinary</td><td>2</td><td>4</td><td>2</td><td>0</td><td>0</td></tr><tr><td></td><td>Gynecological</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>Head and neck</td><td>0</td><td>2</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Diagnosis</td><td>Hematologic</td><td>1</td><td>2</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>Lung</td><td>0</td><td>3</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td>Melanoma</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>Neuro-oncology</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td>Sarcoma</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>Not specified</td><td>5</td><td>6</td><td>5</td><td>0</td><td>0</td></tr></table> |
777437292bb9275519ee53d2572f7b08ce5e4145aeb5a8b6644cc3bb7157af46.png | simple | <table><tr><td></td><td>Laparoscopic cholecystectomy(n = 120)</td><td>Small-incision cholecystectomy(n = 137)</td><td>Statistical analysis</td></tr><tr><td>Mortality</td><td>0</td><td>0</td><td></td></tr><tr><td>Complications</td><td>21</td><td>16</td><td>p = 0.119</td></tr><tr><td>intra-operative</td><td>5</td><td>3</td><td>p = 0.363</td></tr><tr><td>postoperative</td><td>16</td><td>13</td><td>p = 0.331</td></tr><tr><td>Failed symptom relief</td><td>11 (9.2%)</td><td>14 (10.2%)</td><td>p = 0.777</td></tr><tr><td>Operative time (min):</td><td></td><td></td><td></td></tr><tr><td>mean (SD)</td><td>71.9 (25.8)</td><td>60.4 (18.3)</td><td>p < 0.001</td></tr><tr><td>median (range)</td><td>68.5 (26-215)</td><td>60.0 (29-105)</td><td></td></tr><tr><td>Conversion rate</td><td>14 (11.7%)</td><td>22 (16.1%)</td><td>p = 0.312</td></tr><tr><td>Operative team:</td><td></td><td></td><td></td></tr><tr><td>surgeon-resident</td><td>15 (12.5%)</td><td>21 (15.3%)</td><td>p = 0.515</td></tr><tr><td>resident-surgeon</td><td>84 (70.0%)</td><td>100 (73.0%)</td><td>p = 0.596</td></tr><tr><td>resident-resident</td><td>21 (17.5%)</td><td>18 (13.1%)</td><td>p = 0.331</td></tr><tr><td>Hospital stay*</td><td></td><td></td><td></td></tr><tr><td>mean (SD)</td><td>2.4 (4.6)</td><td>3.1 (12.4)</td><td>p = 0.560</td></tr><tr><td>median (range)</td><td>1 (1 - 36)</td><td>2 (1 - 144)</td><td></td></tr><tr><td>Hospital stay* (without 1 extreme value)mean (SD)</td><td>2.1 (3.4)</td><td>2.0 (2.4)</td><td>p = 0.877</td></tr><tr><td>Number of patients with:</td><td></td><td></td><td></td></tr><tr><td>1 night stay postoperative</td><td>67 (55.8%)</td><td>62 (45.3%)</td><td>p = 0.091</td></tr><tr><td>2 nights stay postoperative</td><td>38 (31.7%</td><td>56 (40.9%)</td><td>p = 0.127</td></tr></table> |
45eeafe47335ce78a008486fb520ef90ef47e1ac3cf7fab6ddfa78d2f7d3206d.png | complex | <table><tr><td rowspan="2">Category from the VIM tool</td><td>Phase 1</td><td>Phase 3</td></tr><tr><td>112 patients</td><td>16 patients</td></tr><tr><td>Management—investigations, e.g. fields test</td><td>88% (99)</td><td>100% (16)</td></tr><tr><td>Self-management—importance of taking eyedrops</td><td>83% (93)</td><td>100% (16)</td></tr><tr><td>Management—regular monitoring</td><td>63% (70)</td><td>81% (13)</td></tr><tr><td>Management—appointment issues</td><td>63% (70)</td><td>94% (15)</td></tr><tr><td>Treatment—options for eyedrops</td><td>60% (67)</td><td>100% (16)</td></tr><tr><td>Risk—family</td><td>55% (62)</td><td>100% (16)</td></tr><tr><td>Diagnosis</td><td>54% (60)</td><td>100% (16)</td></tr><tr><td>Treatment—side effects</td><td>43% (48)</td><td>100% (16)</td></tr><tr><td>Prognosis—loss of sight</td><td>24% (27)</td><td>100% (16)</td></tr><tr><td>Driving</td><td>16% (18)</td><td>94% (15)</td></tr><tr><td>Support—help with eyedrops</td><td>13% (15)</td><td>100% (16)</td></tr><tr><td>Prognosis—symptomless</td><td>11% (12)</td><td>100% (16)</td></tr><tr><td>Prognosis—sight can’t be recovered</td><td>10% (11)</td><td>100% (16)</td></tr><tr><td>Support—support groups</td><td>10% (11)</td><td>94% (15)</td></tr><tr><td>Prognosis—when treated most don’t go blind</td><td>3% (3)</td><td>100% (16)</td></tr><tr><td>Registration of loss of sight</td><td>2% (2)</td><td>6% (1)</td></tr></table> |
45210f9cfd362e4b38cd7911204ffbea489666395199ce40f009e12204ef112e.png | complex | <table><tr><td rowspan="2">Variables</td><td rowspan="2">Coefficient</td><td rowspan="2">Standard error</td><td rowspan="2">p-value</td></tr><tr><td>Course year</td><td>- 0.542</td><td>0.215</td><td>0.015</td></tr><tr><td>Participation in emergency course</td><td>- 0.903</td><td>0.437</td><td>0.044</td></tr></table> |
28d7744a454c39dc00233f16251be8fdda00cc97b8890a0ee5f527e229606f21.png | simple | <table><tr><td>Complication</td><td>Frequencyn</td><td>Percent%</td></tr><tr><td>Present</td><td>73</td><td>44.8</td></tr><tr><td>Absent</td><td>90</td><td>55.2</td></tr><tr><td>Total</td><td>163</td><td>100.0</td></tr></table> |
fed6486013eaafafa528f89fd76d9261c8c4a0292e9b4aec5e70fb81a2cf456d.png | complex | <table><tr><td>Warm-up 1.47 min</td><td>Front leaning stance</td><td>L stance</td></tr><tr><td>Begin with Postural alignment.Shoulders relaxed and in alignment with hips and feet and all facing forward. When standing, feet start shoulder width apart. Repeat each 4 times.</td><td>Step forward one stride length, toes first and facing forward as knee bends. Maintain feet shoulders width apart. Opposite foot, toes slightly turned out (30°) and leg straight. Shift weight to back foot. Bend back knee and straighten front knee when shifting weight to back foot. Both feet remain flat on floor at all times. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).</td><td>Step back with one foot, making an L with feet (creating a 90° angle). Feet should be a comfortable distance apart and the heel of the back foot should land in line with front foot. Shift weight to back foot and front foot should be settled on heel with toes pointing up in the air. Most of weight on the back foot with knee bent and front knee is straight. Shift weight from back to front foot and bend front knee as back knee straightens. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).</td></tr><tr><td>Sign Gestures 8.13 min</td><td>Description</td><td>Integration of Breath</td></tr><tr><td rowspan="3">Healthy, Happy, Holy Practiced from standing position, incorporating the front leaning stance</td><td>Healthy: Bring hands to chest with palms open. Extend arms forward in a powerful manner with hands clenched into fist as muscles in forearm and upper arm tighten, assuming the boxers posture. Follow timing of music.</td><td>Breath:Breathe in as hands placed on chest. Breathe out as arms extended.</td></tr><tr><td>Happy: Rolling your hands upward and outward, starting low in your abdomen. This rolling motion is continuous.</td><td>Breath: Breathe in as hands move in a continuous motion rolling outward. Breathe out with continuous motion.</td></tr><tr><td>Holy: The right index and middle finger (the H sign) glide across the palm of your left hand extending upward and out on an angle.</td><td>Breath: Breathe in as the right fingers are placed on the palm of left hand. Breathe out as fingers brush across palm and extend upward and outward.</td></tr><tr><td colspan="3">Check blood pressure and heart rate at 0, 5, and 10 min. (Record heart rate every minute, and up to 10 min following cessation of movement.)</td></tr></table> |
d330e5a5950386ed39245b5d85184add58b32ed0d100368724684835f7395741.png | simple | <table><tr><td>miRNA gene</td><td>upstream TATA-box</td><td>ISRE-IRF1 M00972</td><td>IRF1 M00747</td><td>PU.1</td><td>GAS</td><td>IRF3 M00772</td><td>IRF8 M01665</td><td>NF-kappaB M00051</td><td>ETS2 M00340</td><td>Genbank Accesion #</td></tr><tr><td>miR462a/731 cluster</td><td>1</td><td>2</td><td>1</td><td>1</td><td>2</td><td>1</td><td>1</td><td>-</td><td>-</td><td>gi|925216714:63629639-63631038 (NC_027314.1)</td></tr><tr><td>ssa-mir-462b</td><td>1</td><td>2</td><td>1</td><td>1</td><td>1</td><td>2</td><td>1</td><td>-</td><td>-</td><td>gi|925216718:28307432-28308831 (NC_027312.1)</td></tr><tr><td>ssa-mir-146a-1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>3</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216706:4556929-4558189 (NC_027317.1)</td></tr><tr><td>ssa-mir-146a-2</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216783:47301787-47303047 (NC_027300.1)</td></tr><tr><td>ssa-mir-146b</td><td>-</td><td>1</td><td>1</td><td>-</td><td>5</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216704:2641623-2642883 (NC_027318.1)</td></tr><tr><td>ssa-mir-146a-3</td><td>-</td><td>-</td><td>3</td><td>-</td><td>3</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216704:51691919-51693179 (NC_027318.1)</td></tr><tr><td>ssa-mir-21a-1</td><td>2</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216727:116610294-116611574 (NC_027308.1)</td></tr><tr><td>ssa-mir-21a-2</td><td>1</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>2</td><td>-</td><td>-</td><td>gi|925216702:60966622-60967902 (NC_027319.1)</td></tr><tr><td>ssa-mir-21b-1</td><td>1</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216769:50774080-50775360 (NC_027303.1)</td></tr><tr><td>ssa-mir-21b-2</td><td>-</td><td>-</td><td>1</td><td>-</td><td>1</td><td>1</td><td>1</td><td>-</td><td>-</td><td>gi|925216718:73813159-73814439 (NC_027312.1)</td></tr><tr><td>ssa-mir-1338</td><td>-</td><td>-</td><td>2</td><td>-</td><td>1</td><td>-</td><td>2</td><td>-</td><td>-</td><td>gi|925216772:45802741-45804012 (NC_027302.1)</td></tr><tr><td>ssa-mir-155-1</td><td>-</td><td>1</td><td>-</td><td>-</td><td>6</td><td>-</td><td>-</td><td>1</td><td>1</td><td>gi|925146043:6698-7958 (NW_012350889.1)</td></tr><tr><td>ssa-mir-92a-3</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925125935:50220-51479 (NW_012343521.1)</td></tr><tr><td>ssa-mir-7132b-1</td><td>2</td><td>-</td><td>-</td><td>1</td><td>4</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216780:44866633-44867894 (NC_027301.1)</td></tr><tr><td>ssa-mir-7132b-2</td><td>3</td><td>-</td><td>-</td><td>1</td><td>1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216720:24179665-24180926 (NC_027311.1)</td></tr><tr><td>ssa-mir-7132a-1</td><td>-</td><td>-</td><td>1</td><td>1</td><td>1</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216772:70457167-70458424 (NC_027302.1)</td></tr><tr><td>ssa-mir-7132a-2</td><td>-</td><td>-</td><td>1</td><td>1</td><td>1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216757:28942285-28943542 (NC_027305.1)</td></tr><tr><td>ssa-mir-734</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216691:29709642-29710902 (NC_027324.1)</td></tr><tr><td>ssa-mir-181b</td><td>1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1</td><td>-</td><td>-</td><td>-</td><td>gi|925216772:43728947-43730207 (NC_027302.1)</td></tr><tr><td>ssa-mir-181c</td><td>1</td><td>-</td><td>-</td><td>-</td><td>2</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216723:49524703-49525962 (NC_027310.1)</td></tr><tr><td>ssa-mir-2188-1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216702:26812353-26813612 (NC_027319.1)</td></tr><tr><td>ssa-mir-2188-2</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>gi|925216694:16936155-16937414 (NC_027323.1)</td></tr><tr><td>miR-223-1</td><td>1</td><td>-</td><td>1</td><td>-</td><td>4</td><td>-</td><td>1</td><td>-</td><td>-</td><td>gi|925216769:43698893-43700211 (NC_027303)</td></tr><tr><td>miR-223-2</td><td>-</td><td>-</td><td>1</td><td>-</td><td>2</td><td>1</td><td>1</td><td>-</td><td>-</td><td>gi|925216718:81008935-81010247 (NC_027312.1)</td></tr></table> |
09f509466b1e6127403f5b06167b3bab949060bbbc756a01fe509c14e25c57c0.png | simple | <table><tr><td>Groups</td><td>Treatment groups</td><td>Description</td></tr><tr><td>Group I</td><td>Normal control</td><td>Received only diet and water</td></tr><tr><td>Group II</td><td>Vehicle control</td><td>Received water and treated with SRBC</td></tr><tr><td>Group III</td><td>Positive control</td><td>Received Ginseng extract 200 mg/kg</td></tr><tr><td>Group IV</td><td>Low dosage treatment</td><td>Received 125 mg/kg of <i>D. morbifera</i></td></tr><tr><td>Group V</td><td>Intermediate dosage treatment</td><td>Received 250 mg/kg of <i>D. morbifera</i></td></tr><tr><td>Group VI</td><td>High dosage treatment</td><td>Received 500 mg/kg of <i>D. morbifera</i></td></tr></table> |
78c125a8d7a4ef10af1265b7761fa0f5c604a47706de55ead5ffcd04f4af8fc7.png | complex | <table><tr><td rowspan="2" colspan="2">Branch</td><td rowspan="2">Leading to<sup>a</sup></td><td rowspan="2">#Sets</td><td rowspan="2">#Genes in Sets</td><td colspan="3"># Significant Sets</td></tr><tr><td>Before Pruning</td><td>Without Top Scoring Gene</td><td>After Pruning</td></tr><tr><td>1</td><td>Homininae</td><td>African Apes(Hu, Ch, Go)</td><td>1,415</td><td>7,600</td><td>8</td><td>6</td><td>2</td></tr><tr><td>2</td><td>Hominidae</td><td>Great Apes(Hu, Ch, Go, Or)</td><td>1,424</td><td>7,849</td><td>34</td><td>32</td><td>7</td></tr><tr><td>3</td><td>Hominoidae</td><td>Apes(Hu, Ch, Go, Gi)</td><td>1,441</td><td>8,016</td><td>43</td><td>42</td><td>6</td></tr><tr><td>4</td><td>Catarrhini</td><td>Apes & Old World Monkeys (Hu, Ch, Go, Gi, Ma)</td><td>1,441</td><td>8,058</td><td>95</td><td>93</td><td>9</td></tr></table> |
2bbad3b4ab5a6c14ed1f6336667e4ebc383391f3ff46a71c2bd41742a2375961.png | simple | <table><tr><td>Gene ID</td><td>Annotation</td><td>FPKM Ctrl</td><td>FPKM -N</td><td>Log<sub>2</sub> FC</td></tr><tr><td>GRMZM2G326707</td><td>Inorganic phosphate transmembrane transporter, PHT1;4</td><td>73.0</td><td>305.5</td><td>2.07</td></tr><tr><td>GRMZM2G154090</td><td>Inorganic phosphate transmembrane transporter, PHT1;4</td><td>6.7</td><td>695.6</td><td>6.69</td></tr><tr><td>GRMZM2G112377</td><td>Inorganic phosphate transmembrane transporter, PHT1;4</td><td>1.4</td><td>271.3</td><td>7.64</td></tr><tr><td>GRMZM2G069542</td><td>Phosphoenolpyruvate carboxylase</td><td>92.7</td><td>154.5</td><td>0.74</td></tr><tr><td>GRMZM2G074122</td><td>Phosphoenolpyruvate carboxylase</td><td>42.7</td><td>73.6</td><td>0.79</td></tr><tr><td>GRMZM2G110714</td><td>Phosphoenolpyruvate carboxylase</td><td>3.2</td><td>22.9</td><td>2.83</td></tr><tr><td>GRMZM2G008507</td><td>Sucrose-phosphate synthase</td><td>1.2</td><td>77.9</td><td>6.02</td></tr><tr><td>GRMZM2G047995</td><td>Lipase class 3 family protein</td><td>4.0</td><td>87.0</td><td>4.45</td></tr><tr><td>GRMZM2G169562</td><td>Lipase class 3 family protein</td><td>2.9</td><td>27.3</td><td>3.23</td></tr><tr><td>GRMZM5G829946</td><td>Senescence-related gene 3, glycerophosphodiester phosphodiesterase</td><td>0.3</td><td>159.3</td><td>8.92</td></tr><tr><td>GRMZM2G064962</td><td>Glycerophosphoryl diester phosphodiester family protein</td><td>19.2</td><td>108.0</td><td>2.49</td></tr><tr><td>GRMZM2G315848</td><td>Protein nucleotide pyrophosphatase/phosphodiesterase</td><td>6.7</td><td>65.8</td><td>3.29</td></tr><tr><td>GRMZM2G477503</td><td>Sulfoquinovosyldiacylglycerol 2</td><td>6.5</td><td>348.0</td><td>5.75</td></tr><tr><td>GRMZM2G141320</td><td>1,2-diacylglycerol 3-beta-galactosyltransferase/UDP-galactosyltransferase</td><td>0</td><td>159.8</td><td>–</td></tr><tr><td>GRMZM2G152447</td><td>Acid phosphatase/protein serine/threonine phosphatase</td><td>1.0</td><td>318.8</td><td>8.34</td></tr><tr><td>GRMZM2G138756</td><td>Acid phosphatase/protein serine/threonine phosphatase</td><td>0.1</td><td>17.7</td><td>8.00</td></tr><tr><td>GRMZM5G836174</td><td>Phosphatase</td><td>0.5</td><td>1991.8</td><td>11.83</td></tr><tr><td>GRMZM2G015908</td><td>Phosphatase</td><td>3.9</td><td>309.9</td><td>6.30</td></tr><tr><td>GRMZM2G021106</td><td>Phosphatase</td><td>0.4</td><td>48.1</td><td>6.81</td></tr><tr><td>GRMZM2G171423</td><td>SPX domain gene 2</td><td>1.0</td><td>84.6</td><td>6.46</td></tr><tr><td>GRMZM5G805389</td><td>SPX domain gene 3</td><td>3.3</td><td>1246.0</td><td>8.57</td></tr><tr><td>GRMZM2G065989</td><td>SPX domain gene 3</td><td>2.5</td><td>1008.0</td><td>8.65</td></tr><tr><td>GRMZM5G828488</td><td>SPX domain gene 3</td><td>0.5</td><td>399.5</td><td>9.65</td></tr></table> |
63a4e5ecace13671e1ca8d29fc1dfa37a0cda107daf355ef6e9b7639377a89aa.png | simple | <table><tr><td></td><td>Metformin</td><td>Pioglitazone</td><td>Empagliflozin</td><td>Anticipated effect?</td></tr><tr><td>Cardiovascular death</td><td>↓</td><td>↔</td><td>↓↓</td><td>↓↓↓</td></tr><tr><td>All-cause death</td><td>↓</td><td>↔</td><td>↓↓</td><td>↓↓↓</td></tr><tr><td>Myocardial infarction</td><td>↓</td><td>↓</td><td>↔</td><td>↓↓</td></tr><tr><td>Stroke</td><td>↓</td><td>↓</td><td>↔</td><td>↓↓</td></tr><tr><td>Peripheral arterial disease</td><td>↓</td><td>↔</td><td>↔</td><td>↓</td></tr><tr><td>Fluid retention</td><td>↔</td><td>↑</td><td>↓</td><td>↔</td></tr><tr><td>Heart failure</td><td>↔</td><td>↑</td><td>↓</td><td>↔</td></tr><tr><td>Weight</td><td>↓</td><td>↑</td><td>↓</td><td>↓</td></tr><tr><td>Blood pressure</td><td>↔</td><td>↓</td><td>↓</td><td>↓↓</td></tr><tr><td>HbA1c</td><td>↓</td><td>↓</td><td>↓</td><td>↓↓↓</td></tr><tr><td>LDL-cholesterol</td><td>↓</td><td>↔</td><td>↑</td><td>↔</td></tr><tr><td>HDL-cholesterol</td><td>↔</td><td>↑</td><td>↑</td><td>↑↑</td></tr><tr><td>Albuminuria</td><td>↔</td><td>↓</td><td>↓</td><td>↓↓</td></tr><tr><td>Insulin sensitivity</td><td>↑</td><td>↑↑</td><td>↑</td><td>↑↑↑↑</td></tr></table> |
7019fdcb324cfc9ee6ee6619a04a97e1257baac1c382aa5401b2c11e725eb966.png | complex | <table><tr><td colspan="2">Year</td><td>Confirmed positive</td><td>Donor population</td><td>Prevalence by gender</td><td>Total prevalence</td></tr><tr><td rowspan="2">1<sup>st</sup> year</td><td>Male</td><td>124</td><td>80253</td><td>0.15%</td><td rowspan="2">0.18%</td></tr><tr><td>Female</td><td>36</td><td>6524</td><td>0.55%</td></tr><tr><td rowspan="2">2<sup>nd</sup> year</td><td>Male</td><td>133</td><td>81841</td><td>0.16%</td><td rowspan="2">0.19%</td></tr><tr><td>Female</td><td>34</td><td>6044</td><td>0.56%</td></tr><tr><td>Total</td><td></td><td>327</td><td>174662</td><td></td><td>0.18%</td></tr></table> |
85ac0e7734658de4f015eb075f92159a63a7b82c7341ddd9bc73db462db82e89.png | complex | <table><tr><td>Variable</td><td>Subgroups</td><td>Number of respondents</td><td>Percentages</td></tr><tr><td rowspan="3">Age (years)</td><td><20</td><td>33</td><td>11.3</td></tr><tr><td>20–25</td><td>221</td><td>75.4</td></tr><tr><td>>25</td><td>39</td><td>13.3</td></tr><tr><td rowspan="3">Age of menarche</td><td><13</td><td>83</td><td>28.3</td></tr><tr><td>13–15</td><td>161</td><td>54.0</td></tr><tr><td>> 15</td><td>49</td><td>16.7</td></tr><tr><td rowspan="3">Gynecological age (years)</td><td>< 5</td><td>14</td><td>4.8</td></tr><tr><td>5–10</td><td>214</td><td>73.0</td></tr><tr><td>> 10</td><td>65</td><td>22.2</td></tr><tr><td rowspan="2">Religious affiliation<sup>a</sup></td><td>Christianity</td><td>208</td><td>71.0</td></tr><tr><td>Islam</td><td>79</td><td>27.0</td></tr><tr><td rowspan="5">Type of accommodation at menarche<sup>a</sup></td><td>Single room</td><td>46</td><td>15.7</td></tr><tr><td>Chamber and hall</td><td>55</td><td>18.8</td></tr><tr><td>Several rooms in a compound house</td><td>52</td><td>17.7</td></tr><tr><td>Self-contained apartment</td><td>126</td><td>43.0</td></tr><tr><td>Mansion</td><td>10</td><td>3.4</td></tr><tr><td rowspan="3">Area of residence during vacation<sup>a</sup></td><td>Urban area</td><td>181</td><td>61.8</td></tr><tr><td>Sub-urban</td><td>88</td><td>30.0</td></tr><tr><td>Rural</td><td>21</td><td>7.2</td></tr></table> |
73133aaca543672c319c724dec7381d34781a64a4dae6a19967337a1ce51ac16.png | simple | <table><tr><td></td><td>Dyad 1</td><td>Dyad 2</td><td>Dyad 3</td><td>Dyad 4</td><td>Dyad 5</td></tr><tr><td>Mother age</td><td>43</td><td>31</td><td>52</td><td>45</td><td>48</td></tr><tr><td>Youth age</td><td>13</td><td>13</td><td>13</td><td>13</td><td>13</td></tr><tr><td>Youth grade</td><td>8</td><td>8</td><td>8</td><td>8</td><td>8</td></tr><tr><td>Youth gender</td><td>Girl</td><td>Girl</td><td>Girl</td><td>Boy</td><td>Boy</td></tr><tr><td>Mother income</td><td>$40–49K</td><td>$10–19K</td><td>$50–74K</td><td>$75–99K</td><td>$50–74K</td></tr><tr><td>Mother education level</td><td>Some college</td><td>Some college</td><td>College graduate</td><td>College graduate</td><td>College graduate</td></tr><tr><td>Race</td><td>White</td><td>African American</td><td>White</td><td>White</td><td>White</td></tr></table> |
137b506d6abe9c0e529c2708c018d0ae9c22746f9e2fce5ff5ba291d0013daaf.png | complex | <table><tr><td></td><td>Number of responses</td><td>%</td><td>Overall(<i>N</i> Trusts with at least one response/Total N Trusts in region<sup>b</sup>)</td><td>Diabetes(<i>N</i> Trusts with at least one response)</td><td>Cardiac(<i>N</i> Trusts at least one response)</td></tr><tr><td colspan="6">ENGLAND</td></tr><tr><td>London</td><td>27</td><td>15.2</td><td>15/22</td><td>13</td><td>13</td></tr><tr><td>South West</td><td>23</td><td>12.9</td><td>12/16</td><td>10</td><td>8</td></tr><tr><td>South Central</td><td>10</td><td>5.6</td><td>5/9</td><td>5</td><td>4</td></tr><tr><td>South East Coast</td><td>8</td><td>4.5</td><td>6/11</td><td>6</td><td>2</td></tr><tr><td>East England</td><td>16</td><td>9.0</td><td>11/17</td><td>9</td><td>5</td></tr><tr><td>Yorkshire & Humber</td><td>15</td><td>8.4</td><td>9/13</td><td>8</td><td>8</td></tr><tr><td>West Midlands</td><td>21</td><td>11.8</td><td>13/15</td><td>10</td><td>13</td></tr><tr><td>East Midlands</td><td>8</td><td>4.5</td><td>5/8</td><td>3</td><td>5</td></tr><tr><td>North East</td><td>16</td><td>9.0</td><td>6/8</td><td>4</td><td>6</td></tr><tr><td>North West</td><td>17</td><td>9.6</td><td>10/20</td><td>8</td><td>8</td></tr><tr><td>Total number in England</td><td>161</td><td>90.5</td><td>92/139</td><td>76</td><td>72</td></tr><tr><td>SCOTLAND</td><td>12</td><td>6.7</td><td>12 responses covering ≥7/14 health boards <i>(2 responses only identified as “Scotland”)</i></td><td>6</td><td>6</td></tr><tr><td>WALES</td><td>3</td><td>1.7</td><td>3 responses covering 3 of the 7 local health boards.</td><td>2</td><td>3</td></tr><tr><td>NORTHERN IRELAND</td><td>2</td><td>1.1</td><td>2 responses covering 2 of the 5 health and social care Trusts</td><td>2</td><td>2</td></tr><tr><td>Total</td><td>178<sup>a</sup></td><td>100.0</td><td></td><td></td><td></td></tr></table> |
90290c61a79dd3bdf256e251bd695601946f3fcd54fff01ceae6da913a8087d9.png | simple | <table><tr><td>Primer name</td><td>Sequence</td></tr><tr><td>Notch-1</td><td> </td></tr><tr><td> Forward</td><td>CACTGTGGGCGGGTCC</td></tr><tr><td> Reverse</td><td>GTTGTATTGGTTCGGCACCAT</td></tr><tr><td>Hes1</td><td> </td></tr><tr><td> Forward</td><td>AGCCAACTGAAAACACCTGATT</td></tr><tr><td> Reverse</td><td>GGAGTTTATGATTAGCAGTGG</td></tr><tr><td>Dll4</td><td> </td></tr><tr><td> Forward</td><td>GGTGACCTGGCGAACAGACGAGCAAAAT</td></tr><tr><td> Reverse</td><td>GGTGACCTGGCGAACAGACGAGCAAAAT</td></tr><tr><td>GAPDH</td><td> </td></tr><tr><td> Forward</td><td>GGCATCCTGGGCTACACT</td></tr><tr><td> Reverse</td><td>CCACCACCCTGTTGCTGT</td></tr></table> |
827edb6f2a1fc39bb7fe932d8a5a08489d7245e34b6526be96294ecc24cb8ad1.png | simple | <table><tr><td>Features used</td><td>Attribute type</td></tr><tr><td>Gene Neighborhood score, obtained from STRING</td><td>Real valued, ranges from 0-999</td></tr><tr><td>Gene Fusion score, obtained from STRING</td><td>Real valued, ranges from 0-999</td></tr><tr><td>Gene Co-occurrence score, obtained from STRING</td><td>Real valued, ranges from 0-999</td></tr><tr><td>Gene Co-expression score, obtained from STRING</td><td>Real valued, ranges from 0-999</td></tr><tr><td>GO Cellular component based feature</td><td>Real valued, ranges from 0-0.5</td></tr><tr><td>GO: Molecular function</td><td>Real valued, ranges from 0-0.5</td></tr><tr><td>GO: Biological process</td><td>Real valued, ranges from 0-0.5</td></tr></table> |
7d60ce5e1171b1dbd4fa4cc027c830b6eeaad23cf7954e6bd501b82f19043882.png | complex | <table><tr><td></td><td>Number of cases</td><td>Gender (%)</td><td>Age median (Range)</td><td>PDAC stage (%)</td></tr><tr><td colspan="5">Cohort 1 (Exploratory phase)</td></tr><tr><td>Healthy</td><td><i>n</i> = 16</td><td>M (62.5)F (37.5)</td><td>59 (54–65)</td><td rowspan="2">Stage IA (16)Stage IIA (24)Stage IIB (56)ND (4)</td></tr><tr><td>PDAC</td><td><i>n</i> = 25</td><td>M (40)F (60)</td><td>50 (47–82)</td></tr><tr><td colspan="5">Cohort 2 (Confirmatory phase)</td></tr><tr><td>Healthy</td><td><i>n</i> = 131</td><td>M (49.6)F (50.4)</td><td>55 (44–66)</td><td rowspan="3">Stage IA (1.5)Stage IB (0.8)Stage IIA (16.8)Stage IIB (66.4)Stage III (0.8)Stage IV (2.3)ND (11.4)</td></tr><tr><td>Chronic pancreatitis</td><td><i>n</i> = 30</td><td>M (73.3)F (26.7)</td><td>53 (34–79)</td></tr><tr><td>PDAC</td><td><i>n</i> = 131</td><td>M (49.6)F (50.4)</td><td>70 (38–88)</td></tr></table> |
747134fcefe6dfa6a07ae085f2a637779f4d398a29a17a4f2c2f350c913ea3e1.png | simple | <table><tr><td>Excipient</td><td>Recovery (% ± SD)<sup>(a)</sup></td></tr><tr><td>Starch (50)<sup>(b)</sup></td><td>99.46 ± 0.46</td></tr><tr><td>Glucose (10)</td><td>99.58 ± 1.23</td></tr><tr><td>Lactose (10)</td><td>100.37 ± 0.87</td></tr><tr><td>Acacia (10)</td><td>98.84 ± 0.39</td></tr><tr><td>Talc (5)</td><td>101.53 ± 1.02</td></tr><tr><td>MS<sup>(c)</sup>(10)</td><td>97.97 ± 1.26</td></tr><tr><td>Average ± SD</td><td>99.63 ± 1.23</td></tr></table> |
1ad7e3f6b7dbba9249d11eade85b5baaa913c1ab98e043b3399ec0dfb04b2dd2.png | simple | <table><tr><td>Haplotypes</td><td>n (%)</td><td>Number of mutated positions</td><td>95% CI</td></tr><tr><td>Single-type(n = 27)</td><td></td><td></td><td></td></tr><tr><td>YEYSNVD</td><td>17 (60.7)</td><td>1</td><td>42.62 - 78.8</td></tr><tr><td>NEFSNVD</td><td>3 (10.7)</td><td>1</td><td>0 - 22.16</td></tr><tr><td>YEFSNVD</td><td>1 (3.6)</td><td>2</td><td>0 - 10.44</td></tr><tr><td>NEYSNVD</td><td>6 (21.4)</td><td>0</td><td>6.23 - 36.63</td></tr><tr><td>Mixed-type (n = 1)</td><td></td><td></td><td></td></tr><tr><td>N/Y EFSNVD</td><td>1 (3.6)</td><td>2</td><td>0 - 10.44</td></tr></table> |
154243a5097233fc00a0a919eda52901249162f4453058fe903780c742fa17a6.png | complex | <table><tr><td>Characteristics</td><td>Cases (<i>n</i> = 394)</td><td>Controls (<i>n</i> = 794)</td><td><i>p</i> value<sup>a</sup></td></tr><tr><td colspan="4">Marital status (%)</td></tr><tr><td> United<sup>b</sup></td><td>304 (77.2%)</td><td>636 (80.1%)</td><td rowspan="2">0.24</td></tr><tr><td> Not united</td><td>90 (22.8%)</td><td>158 (19.9%)</td></tr><tr><td colspan="4">Educational level (%)</td></tr><tr><td> Elementary school or less</td><td>177 (44.9%)</td><td>358 (45.1%)</td><td rowspan="4">< 0.001</td></tr><tr><td> Junior high school</td><td>66 (16.7%)</td><td>199 (25.1%)</td></tr><tr><td> High school</td><td>70 (17.8%)</td><td>144 (18.1%)</td></tr><tr><td> University or more</td><td>81 (20.6%)</td><td>93 (11.7%)</td></tr><tr><td colspan="4">History of chronic diseases<sup>c</sup> (%)</td></tr><tr><td> Yes</td><td>229 (58.1%)</td><td>327 (41.2%)</td><td rowspan="2">< 0.001</td></tr><tr><td> No</td><td>165 (41.9%)</td><td>467 (58.8%)</td></tr><tr><td colspan="4">History of STD<sup>d</sup> (%)</td></tr><tr><td> Yes</td><td>105 (26.7%)</td><td>87 (11.0%)</td><td rowspan="3">< 0.001</td></tr><tr><td> No</td><td>288 (73.1%)</td><td>706 (88.9%)</td></tr><tr><td> Missing</td><td>1 (0.2%)</td><td>1 (0.1%)</td></tr><tr><td colspan="4">Family history of PC<sup>e</sup> (%)</td></tr><tr><td> Yes</td><td>41 (10.2%)</td><td>20 (2.6%)</td><td rowspan="2">< 0.001</td></tr><tr><td> No</td><td>353 (89.6%)</td><td>774 (97.5%)</td></tr><tr><td colspan="4">Dairy consumption (portion/d) (%)</td></tr><tr><td> Low</td><td>124 (32.1%)</td><td>286 (36.7%)</td><td rowspan="3">0.004</td></tr><tr><td> Middle</td><td>104 (26.1%)</td><td>251 (31.1%)</td></tr><tr><td> High</td><td>166 (41.8%)</td><td>257 (32.2%)</td></tr><tr><td colspan="4">Energy</td></tr><tr><td> Mean ± SD</td><td>2172.13 ± 717.81</td><td>1959.28 ± 681.88</td><td>< 0.001</td></tr><tr><td colspan="4">Life course PA patterns<sup>f</sup> (%)</td></tr><tr><td> None</td><td>58 (14.7%)</td><td>74 (9.3%)</td><td rowspan="4">< 0.001</td></tr><tr><td> A</td><td>98 (24.9%)</td><td>135 (17.0%)</td></tr><tr><td> B</td><td>218 (55.3%)</td><td>532 (67.0%)</td></tr><tr><td> C</td><td>20 (5.1%)</td><td>53(6.7%)</td></tr></table> |
65f75780de9df9e7c9d934c0dd5943671fcee6bb7021712cfd6b8b4649abc650.png | simple | <table><tr><td>Type of vaginal infections</td><td>Asymptomatic women (<i>N</i> = 261)</td><td>Symptomatic women (<i>N</i> = 148)</td><td><i>P</i>-value</td><td>Pregnant women (<i>N</i> = 214)</td><td>Non-pregnant women (<i>N</i> = 195)</td><td><i>P</i>-value</td><td>Total</td></tr><tr><td>Candidiasis</td><td>24 (9.2)</td><td>10 (6.8)</td><td>0.08</td><td>20 (9.3)</td><td>14 (7.2)</td><td>0.48</td><td>34 (8.2)</td></tr><tr><td>Bacterial vaginosis</td><td>6 (2.3)</td><td>6(4.1)</td><td>0.73</td><td>1 (0.5)</td><td>11 (5.6)</td><td>0.002</td><td>12 (2.9)</td></tr><tr><td>Trichomoniasis</td><td>6 (2.3)</td><td>2 (1.4)</td><td>1.00</td><td>3 (1.4)</td><td>5 (2.6)</td><td>0.49</td><td>8 (2)</td></tr><tr><td>Gonococcus</td><td>4 (1.6)</td><td>0.0 %</td><td>0.58</td><td>2 (1)</td><td>2 (0.93)</td><td>1.00</td><td>4 (1)</td></tr><tr><td>Group B <i>Streptococcus</i></td><td>4(1.5)</td><td>1 (0.7)</td><td>1.00</td><td>0</td><td>5 (2.6)</td><td>0.02</td><td>5 (1.2)</td></tr><tr><td>Total</td><td>44 (16.9)</td><td>19 (12.8)</td><td>0.82</td><td>26 (13.3)</td><td>37 (17.3)</td><td>0.03</td><td>63 (15.4)</td></tr></table> |
5b2c723d0b32b148d04c18fcb4af2cfda2af9eafa6410d2a0ed5d91a63528c57.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">KPNA2 expression</td><td rowspan="2"><i>P</i></td></tr><tr><td>Low (<i>N</i> = 23)</td><td>High (<i>N</i> = 80)</td></tr><tr><td>Mean age, y ± SD</td><td>66.9 ± 9.0</td><td>68.5 ± 8.9</td><td>0.513</td></tr><tr><td>Sex, <i>n</i> (%)</td><td></td><td></td><td>0.414</td></tr><tr><td> Male</td><td>14 (61)</td><td>56 (70)</td><td></td></tr><tr><td> Female</td><td>9 (39)</td><td>24 (30)</td><td></td></tr><tr><td>Histological type, <i>n</i> (%)</td><td></td><td></td><td>0.215</td></tr><tr><td> Well, moderately</td><td>19 (83)</td><td>56 (70)</td><td></td></tr><tr><td> Poor</td><td>4 (17)</td><td>24 (30)</td><td></td></tr><tr><td>T factor (UICC), <i>n</i> (%)</td><td></td><td></td><td>0.160</td></tr><tr><td> T1, 2</td><td>15 (65)</td><td>39 (49)</td><td></td></tr><tr><td> T3, 4</td><td>8 (35)</td><td>41 (51)</td><td></td></tr><tr><td>Tumor size, <i>n</i> (%)</td><td></td><td></td><td>0.978</td></tr><tr><td> <30 mm</td><td>11 (48)</td><td>38 (48)</td><td></td></tr><tr><td> ≥30 mm</td><td>12 (52)</td><td>42 (52)</td><td></td></tr><tr><td>Lymph node metastasis, <i>n</i> (%)</td><td></td><td></td><td>0.062</td></tr><tr><td> Absent</td><td>18 (78)</td><td>46 (58)</td><td></td></tr><tr><td> Present</td><td>5 (22)</td><td>34 (42)</td><td></td></tr><tr><td>Vascular invasion, <i>n</i> (%)</td><td></td><td></td><td>0.098</td></tr><tr><td> Absent</td><td>18 (78)</td><td>48 (60)</td><td></td></tr><tr><td> Present</td><td>5 (22)</td><td>32 (40)</td><td></td></tr><tr><td>Perineural invasion, <i>n</i> (%)</td><td></td><td></td><td>0.938</td></tr><tr><td> Absent</td><td>11 (48)</td><td>39 (49)</td><td></td></tr><tr><td> Present</td><td>12 (52)</td><td>41 (51)</td><td></td></tr><tr><td>TNM stage (UICC), <i>n</i> (%)</td><td></td><td></td><td>0.897</td></tr><tr><td> I-II</td><td>19 (83)</td><td>67 (84)</td><td></td></tr><tr><td> III-IV</td><td>4 (17)</td><td>13 (16)</td><td></td></tr><tr><td>Recurrence, <i>n</i> (%)</td><td></td><td></td><td>0.024*</td></tr><tr><td> Absent</td><td>15 (65)</td><td>31 (39)</td><td></td></tr><tr><td> Present</td><td>8 (35)</td><td>49 (61)</td><td></td></tr></table> |
0fadd8febe8ae384769f5306d626e3481f27b9966cc4754be0618a9476895738.png | simple | <table><tr><td>Run no.</td><td>Pretreatment conditions</td><td>H<sub>2</sub>O addition method</td><td>Solid residue (wt%)</td><td>Glucose yield (%)</td><td>Xylose yield (%)</td></tr><tr><td>1</td><td>105°C 6 h</td><td>Aliquot</td><td>34.9</td><td>20.7 ± 0.4</td><td>99.8 ± 2.6</td></tr><tr><td>2<sup>b</sup></td><td>105°C 6 h</td><td>Aliquot</td><td>34.8</td><td>24.2 ± 0.3</td><td>98.6 ± 1.8</td></tr><tr><td>3<sup>c</sup></td><td>105°C 6 h</td><td>Aliquot</td><td>34.8</td><td>27.4 ± 0.7</td><td>95.1 ± 2.0</td></tr><tr><td>4</td><td>160°C 1 h</td><td>Aliquot</td><td>13.7</td><td>37.1 ± 1.2</td><td>83.4 ± 3.8</td></tr><tr><td>5</td><td>160°C 1.5 h</td><td>Aliquot</td><td>6.7</td><td>69.4 ± 2.5</td><td>81. 9 ± 2.8</td></tr><tr><td>6</td><td>160°C 1.5 h</td><td>Pumped @ 10 min</td><td>13.8</td><td>38.6 ± 2.7</td><td>92.6 ± 5.5</td></tr><tr><td>7</td><td>160°C 1.5 h</td><td>Pumped @ 15 min</td><td>10.2</td><td>83.3 ± 1.9</td><td>52.1 ± 1.2</td></tr></table> |
11cd20efc60a947c217c9916e28dd05102c2ba05cf78b545e49b1bf117b347c6.png | simple | <table><tr><td>Variables</td><td>Evaluation instruments</td><td>Quality of instruments</td><td>Time application instruments</td></tr><tr><td>Demographic & obstetric data</td><td>Included in antenatal interview</td><td> </td><td>Antenatal</td></tr><tr><td>Antenatal risk of PPD</td><td>Interview (Riguetti-Veltema & et. al, [14])</td><td>Sensitivity = 84,5%, Specificity = 73%</td><td>Antenatal</td></tr><tr><td>Symptoms of depression</td><td>EPDS*<i>Edinburgh Postnatal Depression Scale</i> (Cox & et. al, [51])</td><td>Sensitivity = 86%, Specificity = 78%</td><td>Antenatal and postnatal</td></tr><tr><td>Relationship with partner</td><td>DASS*<i>Dyadic Adjustement Scale</i> (Spanier, [52])</td><td>Fidelity: <i>Cronbach Alpha</i> = 0.96</td><td>Antenatal and postnatal</td></tr><tr><td>Social support</td><td>FSSQ*<i>Functional Social Support Questionnaire</i> (Broadhead, [53])</td><td>Fidelity: <i>Cronbach Alpha = 0.90</i></td><td>Antenatal and postnatal</td></tr><tr><td>Stress</td><td>Stress events* (Holmes & Rahe, [54])</td><td> </td><td>Antenatal and postnatal</td></tr><tr><td>Birth outcomes</td><td>Hospital clinical data and post-partum questionnaire*</td><td> </td><td>Postnatal</td></tr></table> |
468621e558d972c63381abd425e8a4977bbf52436d5fd09fe3e833594a50ff16.png | complex | <table><tr><td>Characteristic</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Male</td><td>372</td><td>62.0</td></tr><tr><td> Female</td><td>228</td><td>38.0</td></tr><tr><td colspan="3">Age category</td></tr><tr><td> 1 (15–35)</td><td>287</td><td>47.8</td></tr><tr><td> 2 (36–55)</td><td>202</td><td>33.7</td></tr><tr><td> 3 (≥56)</td><td>111</td><td>18.5</td></tr><tr><td colspan="3">HIV status</td></tr><tr><td> Positive</td><td>162</td><td>27.0</td></tr><tr><td> Negative</td><td>438</td><td>73.0</td></tr><tr><td colspan="3">Mycobacterial testing results</td></tr><tr><td> ZN smear positive</td><td>34</td><td>12.1</td></tr><tr><td> LED-FM smear positive</td><td>16</td><td>5.0</td></tr><tr><td> Xpert positive</td><td>82</td><td>13.7</td></tr><tr><td> Culture (MGIT and/or LJ) positive</td><td>96</td><td>16.0</td></tr></table> |
c6890dbbf2e7eafcf45f5b5e8d38a26c290547dfc8b54844d6679c36da1edeeb.png | simple | <table><tr><td>BSI scale</td><td>UK outpatient mean/SD</td><td>Pretreatment score</td><td>Posttreatment score</td></tr><tr><td>PAR</td><td>M = 1.54/SD = 1.08∗</td><td>2.20</td><td>1.50</td></tr><tr><td>ANX</td><td>M = 1.87/SD = 1.03∗</td><td>2.50</td><td>1.60</td></tr></table> |
25e38c0757dcf13e8694434842f075260c2bb844c5a7b5d6a762f4553f3895f4.png | simple | <table><tr><td>Title</td><td>No of species</td><td>Authors</td><td>Reference</td></tr><tr><td>Sporadic study in India</td><td>20</td><td>Gosh A K, Maiti P K</td><td>[44]</td></tr><tr><td>Bhil of Rajasthan</td><td>17</td><td>Sharma S K</td><td>[43]</td></tr><tr><td>Bhil, Gamit, Kokna etc. of Maharastra</td><td>15</td><td>Patil S H</td><td>[42]</td></tr><tr><td>Chhattisgarh</td><td>10</td><td>Oudhia P</td><td>[41]</td></tr><tr><td>Chhattisgarh</td><td>7</td><td>Oudhia P</td><td>[40]</td></tr><tr><td>Kachch (Gujrat)</td><td>34</td><td>Gupta Leena et al.</td><td>[39]</td></tr><tr><td>Irular, Kurimba of Tamilnadu</td><td>26</td><td>Solvan A et al.</td><td>[38]</td></tr><tr><td>Kanikar, Paliyar of Taminadu</td><td>11</td><td>Ranjit Singh ASA</td><td>[37]</td></tr><tr><td>Mogya, Meena, Bawaria of Rajasthan</td><td>15</td><td>Mahawar, Jaroli</td><td>[33]</td></tr><tr><td>Saharia of Rajasthan</td><td>15</td><td>Mahawar, Jaroli</td><td>[36]</td></tr><tr><td>Monpas</td><td>11</td><td>Solanki GS and Chutia P</td><td>[11]</td></tr><tr><td>Mizoram</td><td>56</td><td>Lalramnghinglova</td><td>[12]</td></tr><tr><td>Chakhesang of Nagaland</td><td>23</td><td>Kakati and Doulo</td><td>[16]</td></tr><tr><td>Naga tribe of Nagaland</td><td>26</td><td>Jamir N S et al.</td><td>[14]</td></tr><tr><td>Dibrugarh (Assam)</td><td>4</td><td>Dilip Kalita</td><td>[15]</td></tr><tr><td>Ao tribe of Nagaland</td><td>25</td><td>Kakati L N et al.</td><td>[17]</td></tr><tr><td>Nyishi & Galo Tribe of Arunachal Pradesh</td><td>36</td><td>Chakravorty et al.</td><td>[13]</td></tr><tr><td>Biate Tribe, Dima Hasao, Assam</td><td>34</td><td>Present Study</td><td> </td></tr></table> |
dab0b532cce0b4cf833e80737ae229fd1e15a3f0e43a7007917a34326e33d95c.png | simple | <table><tr><td>Material</td><td>Total thermal conductivity (W/m-K)</td><td>LA (%)</td><td>TA (%)</td><td>ZA (%)</td><td>Optical (%)</td></tr><tr><td>Black phosphorene (zigzag)</td><td>110</td><td>32</td><td>22</td><td>31</td><td>15</td></tr><tr><td>Black phosphorene (armchair)</td><td>36</td><td>28</td><td>33</td><td>12</td><td>27</td></tr><tr><td>Blue phosphorene</td><td>78</td><td>26</td><td>27</td><td>44</td><td>3</td></tr><tr><td>MoS<sub>2</sub>29</td><td>108</td><td>28</td><td>24</td><td>39</td><td>9</td></tr><tr><td>Graphene30</td><td>3600</td><td>8</td><td>15</td><td>76</td><td>1</td></tr></table> |
fc495986fe02b56e3940a06ef3661b73a26f669633063a2099d380aabacf1bcb.png | simple | <table><tr><td>Parameters</td><td>NGT</td><td>Pre-diabetes</td><td>p value</td></tr><tr><td></td><td>(n = 24)</td><td>(n = 26)</td><td></td></tr><tr><td>Anthropometric measures</td><td></td><td></td><td></td></tr><tr><td>Age (years)</td><td>36 ± 2</td><td>39 ± 2</td><td>0.232</td></tr><tr><td>Weight (Kg)</td><td>69 ± 2</td><td>77 ± 3*</td><td>0.026</td></tr><tr><td>Body Mass Index (kg/m<sup>2</sup>)</td><td>24.0 ± 0.6</td><td>26.5 ± 0.6*</td><td>0.005</td></tr><tr><td>Waist Circumference (cm)</td><td>90.3 ± 1.7</td><td>98.3 ± 3.1*</td><td>0.032</td></tr><tr><td>Waist - Hip Ratio</td><td>0.96 ± 0.01</td><td>0.98 ± 0.01</td><td>0.070</td></tr><tr><td>Systolic Blood Pressure (mmHg)</td><td>119.0 ± 1.8</td><td>122.8 ± 2.6</td><td>0.240</td></tr><tr><td>Diastolic Blood Pressure (mmHg)</td><td>76.3 ± 1.6</td><td>76.6 ± 1.9</td><td>0.992</td></tr><tr><td>Biochemical parameters</td><td></td><td></td><td></td></tr><tr><td>OGTT</td><td></td><td></td><td></td></tr><tr><td>Fasting plasma glucose (mmol/l)</td><td>5.0 ± 0.1</td><td>5.7 ± 0.1**</td><td>0.0001</td></tr><tr><td>2Hr Post plasma glucose (mmol/l)</td><td>5.6 ± 0.2</td><td>8.1 ± 0.3**</td><td>0.0001</td></tr><tr><td>Glycated Hemoglobin [HbA1c] (%)</td><td>5.4 ± 0.1</td><td>5.8 ± 0.1*</td><td>0.0013</td></tr><tr><td>Fasting Insulin (pmol/l)</td><td>49.8 ± 5</td><td>95.1 ± 10**</td><td>0.0002</td></tr><tr><td>2Hr post Insulin (pmol/l)</td><td>325.8 ± 49</td><td>780.0 ± 75**</td><td>0.0001</td></tr><tr><td>HOMA-IR</td><td>1.9 ± 0.2</td><td>4.0 ± 0.4**</td><td>0.0001</td></tr><tr><td>Lipid profile</td><td></td><td></td><td></td></tr><tr><td>Total Cholesterol (mmol/l)</td><td>4.6 ± 0.2</td><td>4.9 ± 0.2</td><td>0.376</td></tr><tr><td>Serum Triglycerides (mmol/l)</td><td>1.51 ± 0.2</td><td>1.9 ± 0.2</td><td>0.166</td></tr><tr><td>HDL Cholesterol (mmol/l)</td><td>1.0 ± 0.04</td><td>0.9 ± 0.04</td><td>0.459</td></tr><tr><td>LDL Cholesterol (mmol/l)</td><td>2.9 ± 0.1</td><td>3.0 ± 0.2</td><td>0.632</td></tr><tr><td>VLDL Cholesterol (mmol/l)</td><td>0.7 ± 0.1</td><td>0.9 ± 0.1</td><td>0.163</td></tr><tr><td>Others</td><td></td><td></td><td></td></tr><tr><td>Serum Creatinine (μmol/l)</td><td>79.6 ± 1.8</td><td>106.9 ± 27.1</td><td>0.364</td></tr><tr><td>Hs-CRP (mg/l)</td><td>2.5 ± 0.5</td><td>3.1 ± 0.5</td><td>0.341</td></tr><tr><td>Microalbuminuria (μg/mg)</td><td>5.2 ± 0.8</td><td>7.6 ± 1.5</td><td>0.344</td></tr></table> |
f6524035e484ac4cbc9c77c0ae5d5517effecd86ae4fae167218bcd77dbe9143.png | simple | <table><tr><td>Strain</td><td>Fold-change (light:dark)</td></tr><tr><td>A0047</td><td>1.01 ± 0.38</td></tr><tr><td>A0255</td><td>1.01 ± 0.25</td></tr><tr><td>A0304</td><td>1.29 ± 0.089</td></tr><tr><td>A0318</td><td>1.39 ± 0.34</td></tr><tr><td>A0670</td><td>1.31 ± 0.20</td></tr><tr><td>A0740</td><td>1.44 ± 0.54</td></tr><tr><td>A1173</td><td>1.41 ± 0.34</td></tr><tr><td>A1181</td><td>1.79 ± 0.39</td></tr><tr><td>A1731</td><td>1.85 ± 0.79*</td></tr><tr><td>A1798 (<i>rbc</i>)</td><td>1.16 ± 0.13</td></tr><tr><td>A1929</td><td>−1.09 ± 0.30</td></tr><tr><td>A1930</td><td>1.11 ± 0.017</td></tr><tr><td>A1961</td><td>−1.33 ± 0.30</td></tr><tr><td>A1962</td><td>1.03 ± 0.39</td></tr><tr><td>A2062</td><td>1.46 ± 0.23</td></tr><tr><td>A2127</td><td>1.21 ± 0.40</td></tr><tr><td>A2165</td><td>1.45 ± 0.015*</td></tr><tr><td>A2210</td><td>−1.34 ± 0.44</td></tr><tr><td>A2520</td><td>2.02 ± 0.90</td></tr><tr><td>A2531</td><td>1.35 ± 0.031</td></tr><tr><td>A2579</td><td>1.14 ± 0.45</td></tr><tr><td>A2595</td><td>1.45 ± 0.42</td></tr><tr><td>A2596</td><td>−1.05 ± 0.10</td></tr><tr><td>A2663</td><td>1.13 ± 0.31</td></tr><tr><td>A2813</td><td>2.28 ± 0.73</td></tr></table> |
bac750b3db8f0b4ad36b8157f5f92cd672a336cb5ef932a68f237ba6521e7112.png | complex | <table><tr><td>Groups</td><td>Compared with groups</td><td>Mean difference (I-J)</td><td>Std. Error</td><td>Sig.</td><td>Lower bound</td><td>Upper bound</td></tr><tr><td rowspan="3">1</td><td>2</td><td>-.80000</td><td>2.49933</td><td>.999</td><td>−8.5278</td><td>6.9278</td></tr><tr><td>3</td><td>4.00000</td><td>2.49933</td><td>.606</td><td>−3.7278</td><td>11.7278</td></tr><tr><td>4</td><td>−7.40000</td><td>2.49933</td><td>.066</td><td>−15.1278</td><td>.3278</td></tr><tr><td rowspan="3">2</td><td>1</td><td>6.60000</td><td>2.49933</td><td>.126</td><td>−1.1278</td><td>14.3278</td></tr><tr><td>3</td><td>11.40000</td><td>2.49933</td><td>.002</td><td>3.6722</td><td>19.1278</td></tr><tr><td>4</td><td>7.40000</td><td>2.49933</td><td>.066</td><td>-.3278</td><td>15.1278</td></tr><tr><td rowspan="3">3</td><td>1</td><td>2.60000</td><td>2.49933</td><td>.899</td><td>−5.1278</td><td>10.3278</td></tr><tr><td>2</td><td>3.40000</td><td>2.49933</td><td>.749</td><td>−4.3278</td><td>11.1278</td></tr><tr><td>4</td><td>−4.00000</td><td>2.49933</td><td>.606</td><td>−11.7278</td><td>3.7278</td></tr><tr><td rowspan="3">4</td><td>1</td><td>−6.60000</td><td>2.49933</td><td>.126</td><td>−14.3278</td><td>1.1278</td></tr><tr><td>2</td><td>.80000</td><td>2.49933</td><td>.999</td><td>−6.9278</td><td>8.5278</td></tr><tr><td>3</td><td>4.80000<sup>a</sup></td><td>2.49933</td><td>.415</td><td>−2.9278</td><td>12.5278</td></tr></table> |
760b7231eb5d26c2807f0c00709ba745b7d2201f5cdcd9b30d31277b1c5b1ff4.png | simple | <table><tr><td></td><td>Case 1</td><td>Case 2</td><td>Case 3</td></tr><tr><td>Age, years</td><td>59</td><td>41</td><td>46</td></tr><tr><td>Sex</td><td>Female</td><td>Female</td><td>Female</td></tr><tr><td>Initial stage</td><td>1A</td><td>ND</td><td>2A</td></tr><tr><td>Histology</td><td>IDC</td><td>IDC</td><td>ILC</td></tr><tr><td>Histological grade</td><td>2</td><td>2</td><td>1</td></tr><tr><td>Nuclear grade</td><td>1</td><td>2</td><td>1</td></tr><tr><td>Estrogen receptor (AS)</td><td>Negative (0)</td><td>Positive (8)</td><td>Positive (8)</td></tr><tr><td>Progesterone receptor (AS)</td><td>Negative (0)</td><td>Positive (8)</td><td>Positive (8)</td></tr><tr><td>HER2 status (IHC score)</td><td>Negative (0)</td><td>Negative (0)</td><td>Negative (1+)</td></tr><tr><td><i>PIK3CA</i> hotspot mutation</td><td>H1047R</td><td>Negative</td><td>H1047R</td></tr><tr><td><i>TERT</i> hotspot mutation</td><td>C250T</td><td>C228T</td><td>C228T</td></tr><tr><td>Relapse-free survival, months</td><td>83</td><td>226</td><td>270</td></tr><tr><td>Overall survival, months</td><td>100</td><td>446</td><td>300</td></tr><tr><td>Status</td><td>Alive</td><td>Alive</td><td>Alive</td></tr></table> |
da3a12b857c73be510b74d79686568c73c664872b8c0096442f57b66ebb9d9e4.png | complex | <table><tr><td> </td><td> </td><td colspan="2">Women</td><td colspan="2">Men</td></tr><tr><td>Months from diagnosis</td><td>Services</td><td>IRR</td><td>95% CI</td><td>IRR</td><td>95% CI</td></tr><tr><td rowspan="3">−12 to −10</td><td>GP</td><td>1.07</td><td>1.06-1.09</td><td>1.13</td><td>1.12-1.15</td></tr><tr><td>Diagnostics</td><td>1.24</td><td>1.20-1.28</td><td>1.37</td><td>1.32-1.42</td></tr><tr><td>Hospital</td><td>1.21</td><td>1.18-1.25</td><td>1.31</td><td>1.28-1.35</td></tr><tr><td rowspan="3">−9 to −7</td><td>GP</td><td>1.10</td><td>1.09-1.11</td><td>1.17</td><td>1.16-1.19</td></tr><tr><td>Diagnostics</td><td>1.32</td><td>1.28-1.36</td><td>1.51</td><td>1.46-1.56</td></tr><tr><td>Hospital</td><td>1.24</td><td>1.21-1.28</td><td>1.38</td><td>1.35-1.42</td></tr><tr><td rowspan="3">−6 to −4</td><td>GP</td><td>1.20</td><td>1.19-1.21</td><td>1.34</td><td>1.33-1.36</td></tr><tr><td>Diagnostics</td><td>1.66</td><td>1.61-1.71</td><td>2.08</td><td>2.02-2.15</td></tr><tr><td>Hospital</td><td>1.39</td><td>1.35-1.43</td><td>1.64</td><td>1.60-1.68</td></tr><tr><td rowspan="3">−3 to −1</td><td>GP</td><td>1.97</td><td>1.96-1.99</td><td>2.38</td><td>2.36-2.39</td></tr><tr><td>Diagnostics</td><td>9.61</td><td>9.47-9.76</td><td>10.86</td><td>10.69-11.03</td></tr><tr><td>Hospital</td><td>5.27</td><td>5.20-5.34</td><td>5.16</td><td>5.09-5.23</td></tr><tr><td rowspan="3">1 to 3</td><td>GP</td><td>2.12</td><td>2.10-2.14</td><td>2.54</td><td>2.51-2.56</td></tr><tr><td>Diagnostics</td><td>24.49</td><td>24.11-24.87</td><td>29.20</td><td>28.73-29.67</td></tr><tr><td>Hospital</td><td>19.91</td><td>19.68-20.14</td><td>14.91</td><td>14.73-15.10</td></tr><tr><td rowspan="3">4 to 6</td><td>GP</td><td>1.67</td><td>1.65-1.69</td><td>2.05</td><td>2.02-2.07</td></tr><tr><td>Diagnostics</td><td>6.25</td><td>6.12-6.38</td><td>8.46</td><td>8.29-8.64</td></tr><tr><td>Hospital</td><td>15.11</td><td>14.89-15.34</td><td>12.08</td><td>11.90-12.27</td></tr><tr><td rowspan="3">7 to 9</td><td>GP</td><td>1.50</td><td>1.48-1.52</td><td>1.84</td><td>1.81-1.86</td></tr><tr><td>Diagnostics</td><td>4.88</td><td>4.77-4.99</td><td>6.42</td><td>6.27-6.57</td></tr><tr><td>Hospital</td><td>9.98</td><td>9.80-10.16</td><td>7.86</td><td>7.72-8.00</td></tr><tr><td rowspan="3">10 to 12</td><td>GP</td><td>1.43</td><td>1.41-1.45</td><td>1.73</td><td>1.70-1.75</td></tr><tr><td>Diagnostics</td><td>4.37</td><td>4.27-4.48</td><td>5.49</td><td>5.35-5.63</td></tr><tr><td>Hospital</td><td>5.29</td><td>5.19-5.40</td><td>5.82</td><td>5.71-5.94</td></tr></table> |
d79126e6388e30d6b10d7f162782a2aaeb625cfddf33b64bfafb87b1fb9c89aa.png | complex | <table><tr><td>(A)</td><td>Healthy controls (<i>n</i> = 19)</td><td>ARMS (<i>n</i> = 19)</td><td>First-episode schizophrenia (<i>n</i> = 19)</td><td>Chronic schizophrenia (<i>n</i> = 19)</td><td colspan="2">Group comparison</td></tr><tr><td>Male/female</td><td>9/10</td><td>9/10</td><td>9/10</td><td>9/10</td><td colspan="2">n.s.</td></tr><tr><td>Age (years)</td><td>19.4 (2.5)</td><td>19.4 (3.6)</td><td>22.8 (5.2)</td><td>22.9 (3.6)</td><td colspan="2"><i>F</i>(3,74) = 4.94, <i>p</i> = 0.004</td></tr><tr><td>Age of onset (years)</td><td>–</td><td>–</td><td>22.2 (5.2)</td><td>17.9 (3.9)</td><td colspan="2"><i>p</i> = 0.007</td></tr><tr><td>Duration of illness (years)</td><td>–</td><td>–</td><td>0.7 (0.6)</td><td>5.0 (2.3)</td><td colspan="2">–</td></tr><tr><td>Drug dose<sup>a</sup></td><td>–</td><td>0.1 (0.4)</td><td>1.7 (2.0)</td><td>3.7 (4.2)</td><td colspan="2"><i>F</i>(2,56) = 8.54, <i>p</i> = 0.001</td></tr><tr><td>SAPS</td><td>–</td><td>17.3 (7.4)</td><td>27.0 (16.9)</td><td>19.2 (18.0)</td><td colspan="2"><i>F</i>(2,56) = 2.29, <i>p</i> = 0.11</td></tr><tr><td>SANS</td><td>–</td><td>60.8 (24.3)</td><td>60.6 (27.2)</td><td>53.3 (22.9)</td><td colspan="2"><i>F</i>(2,56) = 0.52, <i>p</i> = 0.59</td></tr><tr><td>(B)</td><td>Healthy controls (<i>n</i> = 19)</td><td>ARMS (<i>n</i> = 19)</td><td>First-episode schizophrenia (<i>n</i> = 19)</td><td>Chronic schizophrenia (<i>n</i> = 19)</td><td colspan="2">Analyze of variance (df = 3,75), group effect</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><i>F</i></td><td><i>p</i></td></tr><tr><td colspan="7">dMMN amplitude (μV)</td></tr><tr><td> F3</td><td>−6.9 (1.7)</td><td>−6.2 (2.0)</td><td>−5.0 (1.8)</td><td>−4.6 (1.0)</td><td>7.505</td><td><0.001**</td></tr><tr><td> F4</td><td>−7.5 (1.4)</td><td>−6.5 (2.2)</td><td>−5.2 (2.1)</td><td>−4.6 (2.0)</td><td>7.767</td><td><0.001**</td></tr><tr><td> Fz</td><td>−7.4 (1.4)</td><td>−6.5 (2.0)</td><td>−5.4 (1.9)</td><td>−4.8 (1.5)</td><td>8.322</td><td><0.001**</td></tr><tr><td> Cz</td><td>−6.0 (1.4)</td><td>−5.6 (2.1)</td><td>−4.8 (1.9)</td><td>−3.7 (0.9)</td><td>6.831</td><td><0.001**</td></tr><tr><td> Pz</td><td>−4.2 (1.4)</td><td>−4.5 (4.0)</td><td>−3.3 (1.4)</td><td>−2.2 (0.9)</td><td>6.240</td><td>0.001**</td></tr><tr><td colspan="7">dMMN latency (ms)</td></tr><tr><td> F3</td><td>167.3 (15.1)</td><td>172.1 (17.5)</td><td>173.0 (23.0)</td><td>177.8 (30.7)</td><td>0.702</td><td>0.55</td></tr><tr><td> F4</td><td>169.1 (15.4)</td><td>175.8 (18.3)</td><td>172.5 (19.7)</td><td>176.6 (24.0)</td><td>0.404</td><td>0.75</td></tr><tr><td> Fz</td><td>172.2 (15.6)</td><td>177.3 (12.6)</td><td>173.0 (19.1)</td><td>176.8 (25.6)</td><td>0.364</td><td>0.77</td></tr><tr><td> Cz</td><td>168.4 (14.8)</td><td>182.3 (18.7)</td><td>174.6 (16.7)</td><td>177.6 (26.2)</td><td>1.675</td><td>0.18</td></tr><tr><td> Pz</td><td>173.0 (15.8)</td><td>188.6 (24.4)</td><td>178.3 (17.4)</td><td>174.8 (30.7)</td><td>1.753</td><td>0.16</td></tr><tr><td colspan="7">P3a amplitude (μV)</td></tr><tr><td> F3</td><td>1.6 (1.8)</td><td>1.1 (1.4)</td><td>1.3 (2.2)</td><td>1.5 (1.3)</td><td>0.277</td><td>0.84</td></tr><tr><td> F4</td><td>1.4 (2.3)</td><td>1.2 (1.8)</td><td>1.6 (2.1)</td><td>1.4 (1.4)</td><td>0.110</td><td>0.95</td></tr><tr><td> Fz</td><td>2.0 (2.3)</td><td>1.7 (1.5)</td><td>1.7 (2.2)</td><td>1.7 (1.1)</td><td>0.179</td><td>0.91</td></tr><tr><td> Cz</td><td>2.4 (2.4)</td><td>2.1 (1.6)</td><td>2.5 (2.1)</td><td>2.1 (1.4)</td><td>0.209</td><td>0.89</td></tr><tr><td> Pz</td><td>2.0 (2.2)</td><td>1.8 (1.4)</td><td>2.3 (1.8)</td><td>1.8 (1.3)</td><td>0.408</td><td>0.74</td></tr><tr><td colspan="7">P3a latency (ms)</td></tr><tr><td> F3</td><td>255.6 (23.5)</td><td>265.2 (25.0)</td><td>264.2 (28.3)</td><td>262.8 (23.0)</td><td>0.395</td><td>0.75</td></tr><tr><td> F4</td><td>256.9 (20.2)</td><td>269.7 (28.0)</td><td>262.9 (31.1)</td><td>255.2 (30.8)</td><td>0.755</td><td>0.52</td></tr><tr><td> Fz</td><td>254.6 (21.5)</td><td>268.7 (28.8)</td><td>261.8 (30.9)</td><td>262.3 (22.3)</td><td>0.314</td><td>0.81</td></tr><tr><td> Cz</td><td>255.1 (21.7)</td><td>266.0 (25.9)</td><td>254.8 (28.7)</td><td>262.2 (22.9)</td><td>0.509</td><td>0.67</td></tr><tr><td> Pz</td><td>255.7 (19.8)</td><td>272.2 (27.2)</td><td>254.7 (27.6)</td><td>261.4 (19.7)</td><td>0.359</td><td>0.78</td></tr><tr><td colspan="7">RON amplitude (μV)</td></tr><tr><td> F3</td><td>−4.4 (1.7)</td><td>−4.1 (1.7)</td><td>−3.5 (1.3)</td><td>−3.3 (1.3)</td><td>2.320</td><td>0.08</td></tr><tr><td> F4</td><td>−5.2 (1.8)</td><td>−4.2 (1.5)</td><td>−3.6 (1.7)</td><td>−3.4 (1.6)</td><td>4.191</td><td>0.009**</td></tr><tr><td> Fz</td><td>−5.1 (1.6)</td><td>−4.2 (1.8)</td><td>−3.9 (1.4)</td><td>−3.4 (1.7)</td><td>3.143</td><td>0.03*</td></tr><tr><td> Cz</td><td>−4.3 (1.9)</td><td>−3.8 (2.1)</td><td>−3.6 (1.6)</td><td>−3.2 (1.6)</td><td>1.143</td><td>0.33</td></tr><tr><td> Pz</td><td>−3.1 (1.8)</td><td>−2.7 (1.7)</td><td>−2.5 (1.5)</td><td>−2.6 (1.6)</td><td>0.391</td><td>0.76</td></tr><tr><td colspan="7">RON latency (ms)</td></tr><tr><td> F3</td><td>396.3 (51.8)</td><td>380.7 (49.4)</td><td>395.0 (42.7)</td><td>389.0 (52.6)</td><td>0.395</td><td>0.75</td></tr><tr><td> F4</td><td>392.7 (53.9)</td><td>404.0 (54.1)</td><td>409.1 (53.1)</td><td>385.4 (53.8)</td><td>0.755</td><td>0.52</td></tr><tr><td> Fz</td><td>396.2 (50.2)</td><td>397.2 (46.8)</td><td>409.3 (40.9)</td><td>397.7 (53.3)</td><td>0.314</td><td>0.81</td></tr><tr><td> Cz</td><td>401.2 (39.0)</td><td>398.3 (44.4)</td><td>412.5 (40.9)</td><td>397.0 (47.4)</td><td>0.509</td><td>0.67</td></tr><tr><td> Pz</td><td>409.5 (48.2)</td><td>401.7 (45.7)</td><td>411.7 (40.7)</td><td>397.4 (58.2)</td><td>0.359</td><td>0.78</td></tr></table> |
0e14d61bcc123f9d17a3985b78035c78018dd194c7a57d3efce55b8c32c7029d.png | simple | <table><tr><td>Code</td><td>Value</td><td>% Age</td><td>Description</td></tr><tr><td>J</td><td>165</td><td>2.51</td><td>Translation, ribosomal structure and biogenesis</td></tr><tr><td>A</td><td>0</td><td>0.00</td><td>RNA processing and modification</td></tr><tr><td>K</td><td>131</td><td>1.99</td><td>Transcription</td></tr><tr><td>L</td><td>620</td><td>9.44</td><td>Replication, recombination and repair</td></tr><tr><td>B</td><td>1</td><td>0.02</td><td>Chromatin structure and dynamics</td></tr><tr><td>D</td><td>47</td><td>0.72</td><td>Cell cycle control, Cell division, chromosome partitioning</td></tr><tr><td>V</td><td>67</td><td>1.02</td><td>Defense mechanisms</td></tr><tr><td>T</td><td>138</td><td>2.10</td><td>Signal transduction mechanisms</td></tr><tr><td>M</td><td>203</td><td>3.09</td><td>Cell wall/membrane biogenesis</td></tr><tr><td>N</td><td>30</td><td>0.46</td><td>Cell motility</td></tr><tr><td>U</td><td>52</td><td>0.79</td><td>Intracellular trafficking and secretion</td></tr><tr><td>O</td><td>152</td><td>2.31</td><td>Posttranslational modification, protein turnover, chaperones</td></tr><tr><td>C</td><td>185</td><td>2.82</td><td>Energy production and conversion</td></tr><tr><td>G</td><td>131</td><td>1.99</td><td>Carbohydrate transport and metabolism</td></tr><tr><td>E</td><td>215</td><td>3.27</td><td>Amino acid transport and metabolism</td></tr><tr><td>F</td><td>62</td><td>0.94</td><td>Nucleotide transport and metabolism</td></tr><tr><td>H</td><td>146</td><td>2.22</td><td>Coenzyme transport and metabolism</td></tr><tr><td>I</td><td>65</td><td>0.99</td><td>Lipid transport and metabolism</td></tr><tr><td>P</td><td>188</td><td>2.86</td><td>Inorganic ion transport and metabolism</td></tr><tr><td>Q</td><td>126</td><td>1.92</td><td>Secondary metabolites biosynthesis, transport and catabolism</td></tr><tr><td>R</td><td>535</td><td>8.14</td><td>General function prediction only</td></tr><tr><td>S</td><td>483</td><td>7.35</td><td>Function unknown</td></tr><tr><td>-</td><td>2,826</td><td>43.02</td><td>Not in COGs</td></tr></table> |
4c65d06762e002cf6e841aa6827c123a5ec9cdcf46ed357617716a32e1aacc56.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">rs3736228</td><td rowspan="2"><i>p</i>-value</td><td colspan="2">rs41494349</td><td rowspan="2"><i>p</i>-value</td><td colspan="2">rs2306862</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>CC</td><td>CT</td><td>AA</td><td>AG+GG</td><td>CC</td><td>CT+TT</td></tr><tr><td>Age (years)</td><td>58 (45–73)</td><td>55 (45–75)</td><td>0.002</td><td>58 (45–75)</td><td>57 (45–72)</td><td>0.989</td><td>58 (45–73)</td><td>56 (45–75)</td><td rowspan="2">0.224</td></tr><tr><td>N</td><td>210</td><td>67</td><td></td><td>245</td><td>30</td><td></td><td>193</td><td>68</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>22.77 (15.46–39.54)</td><td>22.88 (18.75–33.91)</td><td>0.804</td><td>22.77 (15.46–39.54)</td><td>23.14 (19.34–30.47)</td><td>0.878</td><td>22.55 (15.46–39.54)</td><td>23.06 (18.44–33.91)</td><td rowspan="2">0.350</td></tr><tr><td>N</td><td>210</td><td>67</td><td></td><td>245</td><td>30</td><td></td><td>193</td><td>68</td></tr><tr><td>Lumbar spine BMD (g/cm<sup>2</sup>)</td><td>1.018 (0.700–1.564)</td><td>0.983 (0.778–1.555)</td><td>0.584</td><td>1.013 (0.700–1.564)</td><td>1.003 (0.778–1.353)</td><td>0.388</td><td>1.013 (0.700–1.564)</td><td>0.993 (0.778–1.555)</td><td rowspan="2">0.787</td></tr><tr><td>N</td><td>160</td><td>45</td><td></td><td>183</td><td>22</td><td></td><td>147</td><td>46</td></tr><tr><td>Femoral neck BMD (g/cm<sup>2</sup>)</td><td>0.787 (0.434–1.204)</td><td>0.789 (0.612–1.224)</td><td>0.728</td><td>0.785 (0.434–1.204)</td><td>0.831 (0.562–1.224)</td><td>0.154</td><td>0.785 (0.434–1.141)</td><td>0.788 (0.548–1.224)</td><td rowspan="2">0.905</td></tr><tr><td>N</td><td>178</td><td>55</td><td></td><td>210</td><td>23</td><td></td><td>165</td><td>56</td></tr><tr><td>Total radial BMD (g/cm<sup>2</sup>)</td><td>0.469 (0.265–0.961)</td><td>0.500 (0.262–0.623)</td><td>0.011</td><td>0.475 (0.262–0.961)</td><td>0.475 (0.353–0.584)</td><td>0.702</td><td>0.471 (0.265–0.961)</td><td>0.485 (0.262–0.623)</td><td rowspan="2">0.191</td></tr><tr><td>N</td><td>210</td><td>67</td><td></td><td>245</td><td>30</td><td></td><td>193</td><td>68</td></tr><tr><td>Radial 33 BMD (g/cm<sup>2</sup>)</td><td>0.614 (0.315–0.785)</td><td>0.657 (0.350–0.818)</td><td>0.001</td><td>0.623 (0.315–0.818)</td><td>0.634 (0.447–0.722)</td><td>0.769</td><td>0.613 (0.315–0.785)</td><td>0.649 (0.350–0.818)</td><td rowspan="2">0.015</td></tr><tr><td>N</td><td>210</td><td>67</td><td></td><td>245</td><td>30</td><td></td><td>193</td><td>68</td></tr><tr><td>Total hip BMD (g/cm<sup>2</sup>)</td><td>0.870 (0.229–1.281)</td><td>0.875 (0.636–1.322)</td><td>0.565</td><td>0.870 (0.229–1.322)</td><td>0.909 (0.600–1.252)</td><td>0.625</td><td>0.869 (0.229–1.281)</td><td>0.876 (0.636–1.322)</td><td rowspan="2">0.636</td></tr><tr><td>N</td><td>178</td><td>55</td><td></td><td>210</td><td>23</td><td></td><td>165</td><td>56</td></tr></table> |
bfd9ea15fe9cf4d5aaf6b7c450cdcb7554572ff863817dc1fa7e753017bae9fd.png | simple | <table><tr><td>Period</td><td>Before education</td><td>First period of education</td><td>Second period of education</td><td>Total</td><td>p-value</td></tr><tr><td>Patients</td><td>276,541</td><td>78,052</td><td>56,950</td><td>411,543</td><td> </td></tr><tr><td>Age (years)</td><td>67.6 ± 17.3</td><td>68.5 ± 17.3</td><td>68.5 ± 17.3</td><td>67.9 ± 17.3</td><td>< 0.0001</td></tr><tr><td>Gender male (%)</td><td>139,350 (50.3)</td><td>39,063 (50.0)</td><td>28,376 (49.8)</td><td>206,789 (50.2)</td><td>0.0229</td></tr><tr><td>Charlson index</td><td>4.7 ± 1.8</td><td>4.8 ± 1.9</td><td>4.9 ± 1.9</td><td>4.7 ± 1.8</td><td>< 0.0001</td></tr><tr><td>Urgent admission (%)</td><td>208,660 (75.4)</td><td>59,088 (75.7)</td><td>43,241 (75.9)</td><td>310,989 (75.5)</td><td>0.0345</td></tr><tr><td>LOS (days)</td><td>11.0 ± 14.2</td><td>11.2 ± 13.8</td><td>10.6 ± 12.0</td><td>11.0 ± 13.8</td><td>< 0.0001</td></tr><tr><td>Hospital deaths (%)</td><td>17,270 (6.2)</td><td>5,237 (6.7)</td><td>3,732 (6.6)</td><td>26,239 (6.4)</td><td>< 0.0001</td></tr></table> |
6df0753687285f1e1b813b5890ea06e53018b3dd0aa7953c8e610623bbcb5251.png | simple | <table><tr><td>AA</td><td>Codon</td><td>N</td><td>RSCU</td><td>AA</td><td>Codon</td><td>N</td><td>RSCU</td></tr><tr><td>Ala</td><td>GCU</td><td>10137</td><td>0.61</td><td>Ile</td><td>AUU</td><td>4320</td><td>0.60</td></tr><tr><td></td><td>GCC</td><td>24014</td><td>1.45</td><td></td><td>AUC</td><td>15296</td><td>2.15</td></tr><tr><td></td><td>GCA</td><td>12455</td><td>0.75</td><td></td><td>AUA</td><td>1764</td><td>0.25</td></tr><tr><td></td><td>GCG</td><td>19668</td><td>1.19</td><td>Thr</td><td>ACU</td><td>3820</td><td>0.55</td></tr><tr><td>Gly</td><td>GGU</td><td>6589</td><td>0.52</td><td></td><td>ACC</td><td>9325</td><td>1.35</td></tr><tr><td></td><td>GGC</td><td>28815</td><td>2.28</td><td></td><td>ACA</td><td>4071</td><td>0.59</td></tr><tr><td></td><td>GGA</td><td>5724</td><td>0.45</td><td></td><td>ACG</td><td>10460</td><td>1.51</td></tr><tr><td></td><td>GGG</td><td>9391</td><td>0.75</td><td>Asn</td><td>AAU</td><td>3336</td><td>0.44</td></tr><tr><td>Val</td><td>GUU</td><td>4886</td><td>0.47</td><td></td><td>AAC</td><td>11992</td><td>1.56</td></tr><tr><td></td><td>GUC</td><td>15337</td><td>1.46</td><td>Lys</td><td>AAA</td><td>3143</td><td>0.20</td></tr><tr><td></td><td>GUA</td><td>1760</td><td>0.17</td><td></td><td>AAG</td><td>28292</td><td>1.80</td></tr><tr><td></td><td>GUG</td><td>19933</td><td>1.90</td><td>Tyr</td><td>UAU</td><td>2544</td><td>0.38</td></tr><tr><td>Phe</td><td>UUU</td><td>4949</td><td>0.46</td><td></td><td>UAC</td><td>10814</td><td>1.62</td></tr><tr><td></td><td>UUC</td><td>16637</td><td>1.54</td><td>Cys</td><td>UGU</td><td>1939</td><td>0.32</td></tr><tr><td>Leu</td><td>UUA</td><td>607</td><td>0.06</td><td></td><td>UGC</td><td>10191</td><td>1.68</td></tr><tr><td></td><td>UUG</td><td>9058</td><td>0.95</td><td>Asp</td><td>GAU</td><td>8318</td><td>0.50</td></tr><tr><td></td><td>CUU</td><td>6427</td><td>0.67</td><td></td><td>GAC</td><td>24990</td><td>1.50</td></tr><tr><td></td><td>CUC</td><td>17960</td><td>1.88</td><td>Glu</td><td>GAA</td><td>5918</td><td>0.27</td></tr><tr><td></td><td>CUA</td><td>1143</td><td>0.12</td><td></td><td>GAG</td><td>37809</td><td>1.73</td></tr><tr><td></td><td>CUG</td><td>22200</td><td>2.32</td><td>His</td><td>CAU</td><td>3460</td><td>0.49</td></tr><tr><td>Pro</td><td>CCU</td><td>5738</td><td>0.70</td><td></td><td>CAC</td><td>10620</td><td>1.51</td></tr><tr><td></td><td>CCC</td><td>10406</td><td>1.26</td><td>Gln</td><td>CAA</td><td>3321</td><td>0.27</td></tr><tr><td></td><td>CCA</td><td>6064</td><td>0.74</td><td></td><td>CAG</td><td>21528</td><td>1.73</td></tr><tr><td></td><td>CCG</td><td>10677</td><td>1.30</td><td>Arg</td><td>CGU</td><td>3247</td><td>0.48</td></tr><tr><td>Ser</td><td>UCU</td><td>3832</td><td>0.59</td><td></td><td>CGC</td><td>13515</td><td>1.98</td></tr><tr><td></td><td>UCC</td><td>9749</td><td>1.49</td><td></td><td>CGA</td><td>3447</td><td>0.51</td></tr><tr><td></td><td>UCA</td><td>3167</td><td>0.49</td><td></td><td>CGG</td><td>9678</td><td>1.42</td></tr><tr><td></td><td>UCG</td><td>7423</td><td>1.14</td><td></td><td>AGA</td><td>2479</td><td>0.36</td></tr><tr><td></td><td>AGU</td><td>2706</td><td>0.42</td><td></td><td>AGG</td><td>8501</td><td>1.25</td></tr><tr><td></td><td>AGC</td><td>12156</td><td>1.87</td><td></td><td></td><td></td><td></td></tr></table> |
027668a9a29ed5777922572a33337d195dfe9b2a835cf789ecb0558ca94f72a6.png | complex | <table><tr><td>Variable</td><td>EVAM (n = 85)</td><td>OVAM (n = 439)</td><td><i>P</i> value</td></tr><tr><td colspan="4">Demographics</td></tr><tr><td> Age (years, mean ± SD)</td><td>5.6 ± 3.0</td><td>5.3 ± 3.1</td><td>NS</td></tr><tr><td colspan="4">Sex [no. (%)]</td></tr><tr><td> Male</td><td>50 (58.8)</td><td>250 (56.9)</td><td>NS</td></tr><tr><td> Female</td><td>35 (41.2)</td><td>189 (43.1)</td><td></td></tr><tr><td colspan="4">Clinical symptoms [no. (%)]</td></tr><tr><td> Fever</td><td>67 (78.8.)</td><td>388 (88.4)</td><td>0.017</td></tr><tr><td> Headache</td><td>60 (70.6)</td><td>241 (54.9)</td><td>0.007</td></tr><tr><td> Neck stiffness</td><td>46 (54.1)</td><td>254 (57.9)</td><td>NS</td></tr><tr><td> Vomitting</td><td>62 (72.9)</td><td>284 (64.7)</td><td>NS</td></tr><tr><td> Convulsion</td><td>5 (5.8)</td><td>73 (16.6)</td><td>0.011</td></tr><tr><td> Lethargy</td><td>9 (10.6)</td><td>73 (16.6)</td><td>NS</td></tr><tr><td> Diarrhea</td><td>3 (3.5)</td><td>9 (2.0)</td><td>NS</td></tr><tr><td colspan="4">Laboratory findings [no. (%)]</td></tr><tr><td> EEG abnormal</td><td>50 (58.8)</td><td>261 (59.5)</td><td>NS</td></tr><tr><td> Skull CT abnormal</td><td>24 (28.2)</td><td>102 (23.2)</td><td>NS</td></tr><tr><td> CSF pleocytosis</td><td>36 (42.4)</td><td>199 (45.3)</td><td>NS</td></tr><tr><td> Elevated CSF protein</td><td>25 (29.4)</td><td>140 (31.9)</td><td>NS</td></tr></table> |
90586d05c8611cad3baaf69bba3fdc0d0f42a7529df584c25db109a833e23601.png | complex | <table><tr><td>outcome</td><td>PHFWs</td><td>CHWs</td><td>Total</td><td> P-value</td></tr><tr><td></td><td>Number (%)</td><td>Number (%)</td><td>Number (%)</td><td></td></tr><tr><td>Child recovered</td><td></td><td></td><td></td><td><0.001*</td></tr><tr><td>Yes </td><td>254 (71.7)</td><td>346 (85.2)</td><td>600 (78.9)</td><td></td></tr><tr><td>No</td><td>100 (28.2)</td><td>60 (14.8)</td><td>160 (21.0)</td><td></td></tr><tr><td>Total</td><td>354 </td><td>406 </td><td>760</td><td></td></tr><tr><td>Required extra treatment</td><td></td><td></td><td></td><td>0.362</td></tr><tr><td>Yes</td><td>25 (7.2)</td><td>32 (9.1)</td><td>57 (8.1)</td><td></td></tr><tr><td>No </td><td>322 (92.8)</td><td>320 (90.9)</td><td>642 (91.8)</td><td></td></tr><tr><td>Total</td><td>347</td><td>352 </td><td>699</td><td></td></tr><tr><td>Child died</td><td>0 (0)</td><td>0 (0)</td><td>0</td><td>N/A</td></tr><tr><td>Had complications</td><td></td><td></td><td></td><td>0.302</td></tr><tr><td>Yes</td><td>6 (1.7)</td><td>3 (0.9)</td><td>9 (1.3)</td><td></td></tr><tr><td>No</td><td>338 (98.3)</td><td>347 (99.1)</td><td>685 (98.7)</td><td></td></tr><tr><td>Total</td><td>344 </td><td>350 </td><td>694</td><td></td></tr><tr><td>Still on treatment</td><td></td><td></td><td></td><td>0.184</td></tr><tr><td>Yes</td><td>30 (7.5)</td><td>22 (5.2)</td><td>52 (6.4)</td><td></td></tr><tr><td>No</td><td>369 (92.5)</td><td>397 (94.7)</td><td>766 (93.6)</td><td></td></tr><tr><td>Total</td><td>399</td><td>419</td><td>818</td><td></td></tr><tr><td colspan="2">Behavioural change following treatment</td><td></td><td></td><td></td></tr><tr><td>Sleeping under a net</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>265 (66.7)</td><td>330 (79.3)</td><td>595 (73.2) </td><td><0.001*</td></tr><tr><td>No</td><td>132 (33.2)</td><td>86 (20.6)</td><td>218 (26.8)</td><td></td></tr><tr><td>Total</td><td>397</td><td>416</td><td>813</td><td></td></tr><tr><td>Drinking clean water</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>242 (60.8)</td><td>310 (74.7)</td><td>552 (67.9)</td><td><0.001*</td></tr><tr><td>No</td><td>156 (39.2)</td><td>105 (25.3)</td><td>261 (32.1)</td><td></td></tr><tr><td>Total</td><td>398</td><td>415</td><td>813</td><td></td></tr><tr><td>Feeding the sick child</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>266 (67.0)</td><td>330 (79.1)</td><td>596 (73.2)</td><td><0.001*</td></tr><tr><td>No</td><td>131 (33.0)</td><td>87 (20.9)</td><td>218 ( 26.8)</td><td></td></tr><tr><td>Total</td><td>397</td><td>417</td><td>814</td><td></td></tr></table> |
4211e18a919b810218a7a29263883d71fe38e811e8b85469f2e3a5cecbd0d2b8.png | complex | <table><tr><td></td><td colspan="2">Mailed questionnaire</td><td colspan="2">Telephone interview</td></tr><tr><td></td><td>%</td><td>N</td><td>%</td><td>N</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>Men</td><td>50.5</td><td>1319</td><td>49.0</td><td>681</td></tr><tr><td>Women</td><td>49.5</td><td>1292</td><td>51.0</td><td>708</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td>20 – 30</td><td>26.7</td><td>698</td><td>25.3</td><td>352</td></tr><tr><td>31 – 40</td><td>25.0</td><td>653</td><td>25.0</td><td>347</td></tr><tr><td>41 – 50</td><td>24.9</td><td>649</td><td>25.3</td><td>351</td></tr><tr><td>51 – 60</td><td>23.4</td><td>611</td><td>24.4</td><td>339</td></tr><tr><td>Total</td><td>100</td><td>2611</td><td>100</td><td>1389</td></tr></table> |
fdc5aa2497f4307ffcae96f72be36e6c34b6157f385783a3033315797082fbbe.png | complex | <table><tr><td></td><td colspan="3">Type of ringworm</td><td></td></tr><tr><td>Dermatophytes</td><td>Tinea capitisn (%)</td><td>Tinea pedisn (%)</td><td>Tinea corporisn (%)</td><td>Totaln (%)</td></tr><tr><td><i>E. floccosum</i></td><td>0 (0.0)</td><td>1 (9.1)</td><td>0 (0.0)</td><td>1 (2.4)</td></tr><tr><td><i>M. audouinii</i></td><td>2 (6.7)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>2 (4.8)</td></tr><tr><td><i>M. canis</i></td><td>14 (46.7)</td><td>0 (0.0)</td><td>1 (100.0)</td><td>15 (35.7)</td></tr><tr><td><i>T. mentagrophytes</i></td><td>4 (13.3)</td><td>4 (36.4)</td><td>0 (0.0)</td><td>8 (19.0)</td></tr><tr><td><i>T. rubrum</i></td><td>3 (10.0)</td><td>5 (45.5)</td><td>0 (0.0)</td><td>8 (19.0)</td></tr><tr><td><i>T. schoenleinii</i></td><td>1 (3.3)</td><td>1 (9.1)</td><td>0 (0.0)</td><td>2 (4.8)</td></tr><tr><td><i>T. violaceum</i></td><td>6 (20.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>6 (14.3)</td></tr><tr><td>Total</td><td>30 (100.0)</td><td>11 (100.0)</td><td>1 (100.0)</td><td>42</td></tr></table> |
c89647bdc36aba6dc5cf0879828bddbf0822c3bcec81fc07d0bd2566670c3761.png | complex | <table><tr><td>SSRs</td><td>Probes used in study</td><td colspan="2">References</td></tr><tr><td></td><td></td><td>Mitotic chromosomes</td><td>Polytene chromosomes</td></tr><tr><td>A</td><td>A<sub>20</sub></td><td></td><td>(21, 40)</td></tr><tr><td>C</td><td>C<sub>20</sub></td><td></td><td>(40)</td></tr><tr><td>AC; AG</td><td>(AC)<sub>10</sub>; (AG)<sub>10</sub></td><td>(27)</td><td>(27, 40)</td></tr><tr><td>AAC; AAG; AAT, AAC; AGC; ACT; AGC; AGG; ATC; CCG</td><td>(AAC)<sub>5</sub>; (AAG)<sub>5</sub>; (AAT)<sub>5; </sub>(ACC)<sub>5</sub>; (ACG)<sub>5; </sub>(ACT)<sub>5; </sub>(AGC)<sub>5</sub>; (AGG)<sub>5</sub>; (ATC)<sub>5; </sub>(CCG)<sub>5</sub></td><td></td><td></td></tr><tr><td>GACA</td><td>(GACA)<sub>5</sub></td><td></td><td>(21)</td></tr><tr><td>GATA</td><td>(GATA)<sub>5</sub></td><td>(31)</td><td>(21)</td></tr><tr><td>AAGAC; AAGAG; AATAC; AATAT</td><td>(AAGAC)<sub>3</sub>; (AAGAG)<sub>3</sub>; (AATAC)<sub>3</sub>; (AATAT)<sub>3</sub></td><td>(10)</td><td></td></tr><tr><td>AACAC</td><td>(AACAC)<sub>3;</sub></td><td>(11)</td><td>(11)</td></tr></table> |
ef61a19f279e852f9da201a122247a77037da9e43ff4c88aed4dc734f4bf69d2.png | complex | <table><tr><td></td><td></td><td><i>N</i> = 14 (%)</td></tr><tr><td>Clinical characteristics</td><td></td></tr><tr><td>Age (SAH), years (mean, SD)</td><td></td><td>46.1 ± 12Range: 20–63</td></tr><tr><td>Age (healthy controls), years (mean, SD)</td><td></td><td>47.1 ± 12Range: 20–64</td></tr><tr><td>Gender (SAH), female</td><td></td><td>8 (57)</td></tr><tr><td>Gender (healthy controls), female</td><td></td><td>8 (57)</td></tr><tr><td rowspan="3">Admission H&H grade</td><td>1</td><td>9 (64)</td></tr><tr><td>2</td><td>4 (29)</td></tr><tr><td>3</td><td>1 (7)</td></tr><tr><td>Loss of consciousness</td><td></td><td>0 (0)</td></tr><tr><td>Admission APACHE II score</td><td></td><td>4 (2–5)</td></tr><tr><td colspan="3">Admission radiological characteristics</td></tr><tr><td rowspan="5">mFisher scale</td><td>0</td><td>1 (7)</td></tr><tr><td>1</td><td>1 (7)</td></tr><tr><td>2</td><td>1 (7)</td></tr><tr><td>3</td><td>6 (43)</td></tr><tr><td>4</td><td>5 (36)</td></tr><tr><td>SAH sum score</td><td></td><td>13Range: 10–15</td></tr><tr><td>IVH sum score</td><td></td><td>0 (0–2)</td></tr><tr><td>Aneurysm location AcomA = anterior communicating artery</td><td></td><td>5 (36)</td></tr><tr><td>No aneurysm detected</td><td></td><td>9 (64)</td></tr><tr><td>Aneurysm size above 10 mm</td><td></td><td>0 (0)</td></tr><tr><td>Generalized cerebral edema</td><td></td><td>0 (0)</td></tr><tr><td>Intracerebral hematoma</td><td></td><td>0 (0)</td></tr><tr><td colspan="3">Surgical procedures</td></tr><tr><td>Hydrocephalus requiring EVD/Shunt</td><td></td><td>0 (0)</td></tr><tr><td>Coiling</td><td></td><td>5 (36)</td></tr><tr><td>Clipping</td><td></td><td>0 (0)</td></tr><tr><td>No aneurysm</td><td></td><td>9 (64)</td></tr><tr><td>Hemicraniectomy</td><td></td><td>0 (0)</td></tr><tr><td colspan="3">Complications</td></tr><tr><td>Pneumonia</td><td></td><td>0 (0)</td></tr><tr><td>Delayed cerebral infarction</td><td></td><td>0 (0)</td></tr><tr><td>Anemia requiring transfusion</td><td></td><td>0 (0)</td></tr><tr><td>Aneurysm rebleeding</td><td></td><td>0 (0)</td></tr><tr><td>Hyperosmolar therapy</td><td></td><td>0 (0)</td></tr><tr><td colspan="3">Outcome characteristics</td></tr><tr><td>Length of hospital stay, days</td><td></td><td>19.5Range: 17–21</td></tr><tr><td rowspan="2">Discharge mRS</td><td>0</td><td>9 (64)</td></tr><tr><td>1</td><td>5 (36)</td></tr><tr><td rowspan="2">3‐month mRS</td><td>0</td><td>9 (64)</td></tr><tr><td>1</td><td>5 (36)</td></tr><tr><td rowspan="2">12‐months mRS</td><td>0</td><td>11 (79)</td></tr><tr><td>1</td><td>3 (21)</td></tr></table> |
308b3d295b35bd63ba560dcb727878889a9fb7b7702ff3304d8fca39f5e1821f.png | complex | <table><tr><td></td><td colspan="4">Model 1</td><td colspan="4">Model 2</td></tr><tr><td>Variable</td><td><i>B</i></td><td><i>SE</i></td><td>β</td><td><i>t</i></td><td><i>B</i></td><td><i>SE</i></td><td>β</td><td><i>t</i></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td>–0.408</td><td>0.419</td><td>–0.084</td><td>–0.974</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td>0.090</td><td>0.075</td><td>0.106</td><td>1.204</td></tr><tr><td>Self-esteem</td><td>–0.611</td><td>0.195</td><td>–0.257</td><td>–3.14<sup>∗∗</sup></td><td>–0.680</td><td>0.215</td><td>–0.283</td><td>–3.16<sup>∗∗</sup></td></tr><tr><td>Condition (1 = materialism, –1 = control)</td><td>0.498</td><td>0.159</td><td>0.257</td><td>3.14<sup>∗∗</sup></td><td>0.509</td><td>0.160</td><td>0.261</td><td>3.19<sup>∗∗</sup></td></tr><tr><td>Self-esteem × Condition</td><td>0.487</td><td>0.195</td><td>1.265</td><td>2.497<sup>∗</sup></td><td>0.412</td><td>0.202</td><td>1.070</td><td>2.043<sup>∗</sup></td></tr><tr><td></td><td colspan="4"><i>R</i><sup>2</sup> = 0.176 <i>F</i>(3,123) = 8.780<sup>∗∗</sup></td><td colspan="4"><i>R</i><sup>2</sup> = 0.196 <i>F</i>(5,120) = 5.862<sup>∗∗</sup></td></tr></table> |
dc16416b7035dc3176dab664a0b7e5ad15a6291cd3c111be94f7b368661968af.png | complex | <table><tr><td>Location</td><td>Tissue</td><td>Date of collection</td><td>Time period reflected</td><td><i>N</i></td><td><i>N</i> males</td><td><i>N</i> females</td></tr><tr><td rowspan="2">Newfoundland</td><td>Claws</td><td>April 2016</td><td>Winter</td><td>24</td><td>8</td><td>16</td></tr><tr><td>Whole blood</td><td>December 2013 to January 2014</td><td>Winter</td><td>35</td><td>30</td><td>5</td></tr><tr><td rowspan="2">Nuuk, Greenland</td><td>Claws</td><td>April 2014</td><td>Winter</td><td>33</td><td>6</td><td>29</td></tr><tr><td>Whole blood</td><td>April 2014</td><td>Late winter</td><td>34</td><td>6</td><td>29</td></tr><tr><td rowspan="4">East Bay Island</td><td>Claws</td><td>June to July 2014</td><td>Winter</td><td>109</td><td>0</td><td>109</td></tr><tr><td>Red blood cells</td><td>June to July 2014</td><td>Spring migration</td><td>108</td><td>0</td><td>108</td></tr><tr><td>Claws</td><td>June to July 2015</td><td>Winter</td><td>115</td><td>43</td><td>72</td></tr><tr><td>Red blood cells</td><td>June to July 2015</td><td>Spring migration</td><td>125</td><td>51</td><td>74</td></tr></table> |
eb815b8a4d69aea5df6023e110a2666e06cb1ef17f76069cd23af20424e7319f.png | simple | <table><tr><td>Suggestions from COECSA partners</td><td>Suggestions from United Kingdom partners</td></tr><tr><td><i>Program planning and design</i>• There is need for continuous dialog and joint planning• COECSA to drive the process by demonstrating both demand and ownership• More opportunities for visits to the United Kingdom to “see how things are done”• LINK to facilitate setting up of more VISION 2020 twinning links in the region• LINK to provide more scope for interaction between the institutions in the ECSA region• Expand the scope of collaboration to include research, subspecialty programs, mentoring and instruments<i>Program implementation</i>• Build capacity of editors of the scientific journal• Involve middle-level eye care cadres in the LINK• Training of examiners should be more intensive than just 1 day before the exams, “perhaps even organized in modules”• Make the partnership equal and mutual• Strengthen leadership of the COECSA and the LINK<i>Evaluation</i>• Gather evidence to demonstrate impact of the LINK• Strengthen monitoring and evaluation, and source funding for it</td><td><i>Program planning and design</i>• Build on the successes of the partnership in future planning<i>Program implementation</i>• COECSA needs to build develop staff to take lead in all the activities• Ensure the right people are on board for LINK activities• Encourage continuity for lead roles or smooth handover/transition when new persons take up roles• Aim to make each activity effective and evaluate effectiveness• Ensure United Kingdom facilitators have clarity on their roles• Improve frequency and regularity of communication<i>Evaluation</i>• COECSA to strengthen reporting on LINK activities• Constantly evaluate if expectations of COECSA are being met</td></tr></table> |
967e843d1347b58b68caa33667f602b04d1fb3461e130937d318e89a60b0a2fe.png | complex | <table><tr><td></td><td colspan="6">BMI (<i>kg</i>/<i>m</i><sup>2</sup>)</td></tr><tr><td></td><td>Overall</td><td>Underweight</td><td>Normal</td><td>Overweight</td><td>Obese I</td><td>Obese II/III</td></tr><tr><td>Males (n = 55,303)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Diabetes mellitus</td><td>4.27</td><td>1.74 (106)</td><td>2.93 (100)</td><td>4.85 (144)</td><td>9.33 (168)</td><td>14.01 (155)</td></tr><tr><td> Hypertension</td><td>12.44</td><td>5.06 (107)</td><td>7.82 (100)</td><td>15.90 (141)</td><td>23.57 (159)</td><td>29.66 (141)</td></tr><tr><td> Varices</td><td>4.15</td><td>2.27 (89)</td><td>3.41 (100)</td><td>4.67 (128)</td><td>6.05 (129)</td><td>8.40 (109)</td></tr><tr><td> Respiratory diseases</td><td>5.75</td><td>8.45 (103)</td><td>4.66 (100)</td><td>6.32 (135)</td><td>8.84 (153)</td><td>11.75 (137)</td></tr><tr><td> Bronchial asthma</td><td>3.25</td><td>4.89 (123)</td><td>2.92 (100)</td><td>3.26 (115)</td><td>4.65 (138)</td><td>7.68 (122)</td></tr><tr><td> Thyroid diseases</td><td>1.01</td><td>0.83 (87)</td><td>0.74 (100)</td><td>1.18 (128)</td><td>1.76 (132)</td><td>1.46 (132)</td></tr><tr><td> Osteoarthritis</td><td>16.41</td><td>14.83 (112)</td><td>12.10 (100)</td><td>19.83 (140)</td><td>25.64 (156)</td><td>27.25 (124)</td></tr><tr><td> Lower back pain and sciatica</td><td>8.20</td><td>5.66 (114)</td><td>6.53 (100)</td><td>9.71 (124)</td><td>11.06 (133)</td><td>12.09 (157)</td></tr><tr><td> Osteoporosis</td><td>1.22</td><td>2.39 (141)</td><td>1.09 (100)</td><td>1.26 (145)</td><td>1.55 (130)</td><td>2.31 (198)</td></tr><tr><td> Cancer</td><td>0.97</td><td>3.29 (92)</td><td>0.85 (100)</td><td>0.98 (145)</td><td>1.36 (177)</td><td>1.44 (119)</td></tr><tr><td> Myocardial infarction</td><td>1.87</td><td>1.82 (99)</td><td>1.17 (100)</td><td>2.30 (148)</td><td>3.57 (172)</td><td>7.30 (191)</td></tr><tr><td> Angina pectoris</td><td>1.05</td><td>0.52 (52)</td><td>0.71 (100)</td><td>1.37 (146)</td><td>1.47 (169)</td><td>2.18 (169)</td></tr><tr><td> Thrombosis</td><td>1.05</td><td>1.69 (165)</td><td>0.79 (100)</td><td>1.14 (142)</td><td>1.93 (165)</td><td>3.19 (127)</td></tr><tr><td> MI – Angina pectoris – Thrombosis<sup>1</sup></td><td>3.41</td><td>3.56 (112)</td><td>2.27 (100)</td><td>4.16 (146)</td><td>6.05 (170)</td><td>10.62 (163)</td></tr><tr><td>Females (n = 59,716)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Diabetes mellitus</td><td>4.76</td><td>0.92 (73)</td><td>2.78 (100)</td><td>7.57 (173)</td><td>13.05 (171)</td><td>19.06 (171)</td></tr><tr><td> Hypertension</td><td>16.32</td><td>6.68 (73)</td><td>10.60 (100)</td><td>26.27 (161)</td><td>36.39 (169)</td><td>37.98 (151)</td></tr><tr><td> Varices</td><td>12.32</td><td>5.19 (72)</td><td>9.37 (100)</td><td>17.68 (135)</td><td>23.21 (149)</td><td>26.68 (141)</td></tr><tr><td> Respiratory diseases</td><td>4.60</td><td>3.12 (86)</td><td>3.40 (100)</td><td>6.33 (153)</td><td>9.35 (142)</td><td>10.39 (144)</td></tr><tr><td> Bronchial asthma</td><td>3.31</td><td>2.64 (93)</td><td>2.69 (100)</td><td>4.23 (129)</td><td>5.60 (119)</td><td>6.10 (124)</td></tr><tr><td> Thyroid diseases</td><td>5.47</td><td>3.27 (72)</td><td>4.76 (100)</td><td>6.77 (117)</td><td>8.40 (115)</td><td>8.91 (105)</td></tr><tr><td> Osteoarthritis</td><td>27.91</td><td>13.40 (70)</td><td>21.77 (100)</td><td>40.24 (153)</td><td>47.59 (160)</td><td>50.06 (162)</td></tr><tr><td> Lower back pain and sciatica</td><td>10.71</td><td>4.51 (77)</td><td>8.88 (100)</td><td>14.60 (127)</td><td>16.86 (131)</td><td>20.25 (127)</td></tr><tr><td> Osteoporosis</td><td>9.93</td><td>5.81 (69)</td><td>7.90 (100)</td><td>14.10 (172)</td><td>15.82 (187)</td><td>15.64 (173)</td></tr><tr><td> Cancer</td><td>1.29</td><td>0.82 (63)</td><td>1.06 (100)</td><td>1.72 (156)</td><td>1.90 (170)</td><td>2.62 (177)</td></tr><tr><td> Myocardial infarction</td><td>0.91</td><td>0.63 (77)</td><td>0.67 (100)</td><td>1.32 (175)</td><td>1.79 (181)</td><td>1.62 (162)</td></tr><tr><td> Angina pectoris</td><td>1.12</td><td>0.79 (79)</td><td>0.79 (100)</td><td>1.63 (173)</td><td>2.19 (184)</td><td>2.76 (166)</td></tr><tr><td> Thrombosis</td><td>1.06</td><td>0.72 (97)</td><td>0.76 (100)</td><td>1.50 (168)</td><td>1.93 (188)</td><td>3.83 (129)</td></tr><tr><td> MI – Angina pectoris – Thrombosis<sup>1</sup></td><td>2.73</td><td>1.87 (82)</td><td>1.98 (100)</td><td>3.90 (171)</td><td>5.12 (186)</td><td>7.40 (145)</td></tr></table> |
f6cb25e6ebf6ef0c341fcdd8ed614c7e4e8f39037a835cd51109bb941615ac6c.png | complex | <table><tr><td></td><td>STAV-AB xenograft</td><td>STAV-FCS xenograft</td><td>Localization</td></tr><tr><td colspan="4">MESOTHELIAL AND EPITHELIAL MARKERS</td></tr><tr><td>Calretinin</td><td>++</td><td>++</td><td>Cytoplasm and nucleus</td></tr><tr><td>EMA</td><td>+</td><td>+(+)</td><td>Cell membrane</td></tr><tr><td>E-cadherin</td><td>+ (Focal)</td><td>+</td><td>Cell membrane</td></tr><tr><td>CK-HMW</td><td>++</td><td>++</td><td>Cytoplasm</td></tr><tr><td>Cytokeratin 7</td><td>+</td><td>++</td><td>Cytoplasm</td></tr><tr><td>Cytokeratin 8</td><td>−</td><td>−</td><td>Cytoplasm</td></tr><tr><td>Cam 5.2</td><td>+++</td><td>++</td><td>Cell membrane and cytoplasm</td></tr><tr><td>Syndecan-1</td><td>+</td><td>+</td><td>Cell membrane</td></tr><tr><td>MNF-116</td><td>+++</td><td>+++</td><td>Cell membrane and cytoplasm</td></tr><tr><td colspan="4">DIFFERENTIATION-RELATED MARKERS</td></tr><tr><td>TrxR1</td><td>++</td><td>+++</td><td>Cytoplasm and nucleus</td></tr><tr><td>Integrin α5</td><td>+</td><td>+</td><td>Cytoplasm</td></tr><tr><td>HSP-47</td><td>+++</td><td>+++</td><td>Cell membrane and cytoplasm</td></tr><tr><td>Annexin-II</td><td>++</td><td>++</td><td>Cell membrane</td></tr><tr><td colspan="4">MESENCHYMAL MARKERS</td></tr><tr><td>Vimentin</td><td>++</td><td>++</td><td>Cytoplasm</td></tr><tr><td>SM actin</td><td>+(+)</td><td>+</td><td>Cytoplasm</td></tr><tr><td>Syndecan-2</td><td>++</td><td>++</td><td>Cytoplasm</td></tr><tr><td colspan="4">PROLIFERATION MARKER</td></tr><tr><td>Mib-1</td><td>>80%</td><td>40%</td><td>Nucleus</td></tr></table> |
decc994da4150d1be12cbfebf8ffcfff3e9034862defee23cef42df2b251ebec.png | complex | <table><tr><td></td><td></td><td>Poorest</td><td>Poorer</td><td>Middle</td><td>Richer</td><td>Richest</td><td>All</td></tr><tr><td rowspan="4">OOP</td><td>Non-chronic</td><td>2287.30</td><td>2550.10</td><td>2854.72</td><td>3057.06</td><td>4013.26</td><td>2952</td></tr><tr><td>Hypertension</td><td>2378.66</td><td>3352.36</td><td>2980.83</td><td>3096.64</td><td>4856.84</td><td>3330</td></tr><tr><td>Hypertension and else</td><td>3019.58</td><td>3420.42</td><td>4664.66</td><td>5920.34</td><td>6547.86</td><td>4709</td></tr><tr><td>p-value</td><td>0.031</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td rowspan="4">CTP</td><td>Non-chronic</td><td>5471.32</td><td>9215.98</td><td>13688.45</td><td>20350.67</td><td>38227.57</td><td>17380</td></tr><tr><td>Hypertension</td><td>4635.55</td><td>8450.70</td><td>11313.45</td><td>17624.12</td><td>37316.36</td><td>15835</td></tr><tr><td>Hypertension and else</td><td>4915.02</td><td>8260.34</td><td>13035.33</td><td>19446.03</td><td>36329.90</td><td>16361</td></tr><tr><td>p-value</td><td>0.905</td><td>0.187</td><td>0.004</td><td>0.006</td><td>0.548</td><td>0.004</td></tr><tr><td rowspan="4">CHE (%)</td><td>Non-chronic</td><td>35.37</td><td>15.75</td><td>8.30</td><td>4.39</td><td>2.76</td><td>13.33</td></tr><tr><td>Hypertension</td><td>57.14</td><td>32.41</td><td>16.59</td><td>7.37</td><td>3.72</td><td>23.48</td></tr><tr><td>Hypertension and else</td><td>71.19</td><td>38.66</td><td>30.17</td><td>18.64</td><td>11.11</td><td>34.01</td></tr><tr><td>p-value</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td><td><0.001</td></tr></table> |
fc45432ff6b9f8d2368a667af7d598ffe9656c4ab9ab05404dabfa2c886f4f28.png | simple | <table><tr><td>Antibody</td><td>Supplier</td><td>Western dilution</td></tr><tr><td>β-Actin</td><td>Sigma Aldrich</td><td>1 in 3000</td></tr><tr><td>CDK6</td><td>Santa Cruz</td><td>1 in 200</td></tr><tr><td>γH2AX (Ser139)</td><td>Cell Signaling</td><td>1 in 1000</td></tr><tr><td>Lamin a/c</td><td>Santa Cruz</td><td>1 in 500</td></tr><tr><td>MEK2</td><td>BD Biosciences</td><td>1 in 3000</td></tr><tr><td>PP1α</td><td>Bethyl Laboratory</td><td>1 in 1000</td></tr><tr><td>PP1β</td><td>Bethyl Laboratory</td><td>1 in 1000</td></tr><tr><td>PP1γ</td><td>Santa Cruz</td><td>1 in 200</td></tr><tr><td>p53</td><td>Oncogene</td><td>1 in 500</td></tr><tr><td>pATM (Ser1981)</td><td>Epitomics</td><td>1 in 500</td></tr><tr><td>p-p53 (Ser15)</td><td>Cell Signaling</td><td>1 in 500</td></tr><tr><td>Rad21 (SCC1)</td><td>abcam</td><td>1 in 1000</td></tr><tr><td>Rb</td><td>Santa Cruz</td><td>1 in 200</td></tr><tr><td>p73</td><td>Santa Cruz</td><td>1 in 100</td></tr><tr><td>p63</td><td>abcam</td><td>1 in 1000</td></tr><tr><td>p63(TA)</td><td>bioLegend</td><td>1 in 1000</td></tr></table> |
aec113edb2c1a92e04c56f26cbb98d3e2850360885b2adf8642add4f921399c2.png | complex | <table><tr><td></td><td></td><td></td><td colspan="3">three to five days</td><td colspan="3">17-19 days</td></tr><tr><td>Net</td><td>Family No.</td><td>Species*</td><td>N</td><td>No. Dead</td><td>% Mortality</td><td>N</td><td>No. Dead</td><td>% Mortality</td></tr><tr><td>LLIN#1</td><td>1</td><td>S</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>0</td><td>0.0</td></tr><tr><td></td><td>7</td><td>S</td><td>10</td><td>0</td><td>0.0</td><td>11</td><td>4</td><td>36.4</td></tr><tr><td></td><td>15</td><td><i>An. arabiensis</i></td><td>9</td><td>0</td><td>0.0</td><td>9</td><td>3</td><td>33.3</td></tr><tr><td></td><td>39</td><td>M</td><td>11</td><td>0</td><td>0.0</td><td>10</td><td>0</td><td>0.0</td></tr><tr><td></td><td>44</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>11</td><td>1</td><td>9.1</td></tr><tr><td></td><td>104</td><td>S</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>0</td><td>0.0</td></tr><tr><td></td><td>149</td><td><i>An. arabiensis</i></td><td>10</td><td>0</td><td>0.0</td><td>9</td><td>5</td><td>55.6</td></tr><tr><td></td><td>208</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>0</td><td>0.0</td></tr><tr><td></td><td>225</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>3</td><td>30.0</td></tr><tr><td></td><td>250</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>9</td><td>4</td><td>44.4</td></tr><tr><td></td><td>263</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>5</td><td>50.0</td></tr><tr><td></td><td>279</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>13</td><td>5</td><td>38.5</td></tr><tr><td>LLIN#2</td><td>803</td><td>M</td><td>11</td><td>0</td><td>0.0</td><td>11</td><td>4</td><td>36.4</td></tr><tr><td></td><td>815</td><td><i>An. arabiensis</i></td><td>11</td><td>4</td><td>36.4</td><td>11</td><td>11</td><td>100.0</td></tr><tr><td></td><td>843</td><td>M</td><td>9</td><td>5</td><td>55.6</td><td>10</td><td>5</td><td>50.0</td></tr><tr><td></td><td>858</td><td>M</td><td>10</td><td>3</td><td>30.0</td><td>10</td><td>1</td><td>10.0</td></tr><tr><td></td><td>875</td><td><i>An. arabiensis</i></td><td>10</td><td>8</td><td>80.0</td><td>13</td><td>13</td><td>100.0</td></tr><tr><td></td><td>883</td><td><i>An. arabiensis</i></td><td>8</td><td>7</td><td>87.5</td><td>15</td><td>13</td><td>86.7</td></tr><tr><td></td><td>1062</td><td>S</td><td>9</td><td>1</td><td>11.1</td><td>15</td><td>0</td><td>0.0</td></tr><tr><td>LLIN#3</td><td>1156</td><td>S</td><td>11</td><td>2</td><td>18.2</td><td>7</td><td>0</td><td>0.0</td></tr><tr><td></td><td>1157</td><td>S</td><td>9</td><td>0</td><td>0.0</td><td>7</td><td>0</td><td>0.0</td></tr><tr><td></td><td>1165</td><td>S</td><td>9</td><td>1</td><td>11.1</td><td>7</td><td>1</td><td>14.3</td></tr><tr><td></td><td>1196</td><td>S</td><td>11</td><td>0</td><td>0.0</td><td>5</td><td>0</td><td>0.0</td></tr><tr><td></td><td>1131</td><td>S</td><td>10</td><td>0</td><td>0.0</td><td>10</td><td>1</td><td>10.0</td></tr><tr><td></td><td>1135</td><td>S</td><td>9</td><td>0</td><td>0.0</td><td>8</td><td>0</td><td>0.0</td></tr><tr><td></td><td>1188</td><td>S</td><td>11</td><td>0</td><td>0.0</td><td>10</td><td>0</td><td>0.0</td></tr><tr><td></td><td>1198</td><td>M</td><td>10</td><td>0</td><td>0.0</td><td>9</td><td>1</td><td>11.1</td></tr><tr><td></td><td>1203</td><td>S</td><td>9</td><td>0</td><td>0.0</td><td>10</td><td>1</td><td>10.0</td></tr></table> |
d8040b9de7c073f56f96cc3e754b677d80abda40c56ceaacc9fb6d4a63537de1.png | complex | <table><tr><td>Characteristic</td><td>Boys 8 years of age (<i>n</i> = 304)</td><td>Boys 9 years of age (<i>n</i> = 185)</td><td>Total boys (<i>n</i> = 489)</td></tr><tr><td colspan="4">Growth and sexual maturation parameters</td></tr><tr><td>Age [years (mean ± SD)]</td><td>8.04 ± 0.10</td><td>9.02 ± 0.08</td><td>8.41 ± 0.49</td></tr><tr><td>Height [cm (mean ± SD)]</td><td>128.42 ± 5.91</td><td>133.00 ± 5.96</td><td>130.16 ± 6.32</td></tr><tr><td>Weight [kg (mean ± SD)]</td><td>26.49 ± 5.47</td><td>28.37 ± 5.65</td><td>27.20 ± 5.61</td></tr><tr><td>BMI (mean ± SD)</td><td>15.94 ± 2.30</td><td>15.94 ± 2.34</td><td>15.94 ± 2.31</td></tr><tr><td>Penile length [cm (mean ±SD)]a</td><td>5.49 ± 0.78</td><td>5.37 ± 0.67</td><td>5.45 ± 0.74</td></tr><tr><td colspan="4">TV (mL) [no. (%)]b</td></tr><tr><td> 1</td><td>8 (3)</td><td>4 (2)</td><td>12 (2)</td></tr><tr><td> 2</td><td>151 (50)</td><td>80 (44)</td><td>231 (48)</td></tr><tr><td> 3</td><td>108 (36)</td><td>66 (36)</td><td>174 (36)</td></tr><tr><td> 4</td><td>28 (9)</td><td>22 (12)</td><td>50 (10)</td></tr><tr><td> 5</td><td>5 (2)</td><td>8 (4)</td><td>13 (3)</td></tr><tr><td> 6</td><td>3 (1)</td><td>2 (1)</td><td>5 (1)</td></tr><tr><td>TV > 3 mL [no. (%)]b</td><td>36 (12)</td><td>32 (18)</td><td>68 (14)</td></tr><tr><td colspan="4">Tanner staging [no. (%)]</td></tr><tr><td colspan="4"> Genitalia</td></tr><tr><td>G1</td><td>237 (78)</td><td>107 (58)</td><td>344 (70)</td></tr><tr><td>G2</td><td>67 (22)</td><td>78 (42)</td><td>145 (30)</td></tr><tr><td colspan="4"> Pubarche</td></tr><tr><td>P1</td><td>293 (96)</td><td>154 (83)</td><td>447 (91)</td></tr><tr><td>P2</td><td>11 (4)</td><td>31 (17)</td><td>42 (9)</td></tr><tr><td colspan="4">Birth history</td></tr><tr><td>Birth weight [kg (mean ± SD)]c</td><td>3.34 ± 0.54</td><td>3.33 ± 0.52</td><td>3.34 ± 0.53</td></tr><tr><td>Gestational age [weeks (mean ± SD)]d</td><td>38.96 ± 1.88</td><td>39.15 ± 1.54</td><td>39.03 ± 1.76</td></tr><tr><td colspan="4">Household characteristics</td></tr><tr><td colspan="4">Family income (rubles/month) [no. (%)]e</td></tr><tr><td> < 2,200</td><td>16 (5)</td><td>15 (8)</td><td>31 (6)</td></tr><tr><td> 2,200–3,599</td><td>33 (11)</td><td>33 (18)</td><td>66 (14)</td></tr><tr><td> 3,500–4,999</td><td>41 (13)</td><td>35 (19)</td><td>76 (16)</td></tr><tr><td> 5,000–7,200</td><td>71 (24)</td><td>56 (30)</td><td>127 (26)</td></tr><tr><td> > 7,200</td><td>142 (47)</td><td>46 (25)</td><td>188 (38)</td></tr><tr><td>Mother’s age at son’s birth (mean ± SD)f</td><td>24.2 ± 5.3</td><td>23.6 ± 4.8</td><td>24.0 ± 5.1</td></tr><tr><td colspan="4">Blood lead levels (μg/dL)</td></tr><tr><td>Median (25th–75th percentile)</td><td>3 (2–4)</td><td>4 (3–5)</td><td>3 (2–5)</td></tr><tr><td>0–2 [no. (%)]</td><td>103 (34)</td><td>39 (21)</td><td>142 (29)</td></tr><tr><td>3–4 [no. (%)]</td><td>129 (43)</td><td>81 (44)</td><td>210 (43)</td></tr><tr><td>≥ 5 [no. (%)]</td><td>72 (24)</td><td>65 (35)</td><td>137 (28)</td></tr></table> |
35c072788bdd1723961143be8a76bd44a478496a39a4665d007b9f9c79e3a8be.png | simple | <table><tr><td>Tocopherol</td><td>Cell type/Cancer model</td><td>Result</td><td>References</td></tr><tr><td>α-Tocopherol</td><td>Human retinal pigment epithelial cells (ARPE-19)</td><td>↑ Nrf2 protein levels, ↑ glutamate cysteine ligase, NQO1, HO-1, GST, SOD</td><td>[90]</td></tr><tr><td>γ-TmT</td><td>Prostate carcinogenesis in TRAMP male mice</td><td>↑ Nrf2 protein levels, ↑ GSTm1, UGT1A1, HO-1, catalase, SOD, glutathione peroxidase,</td><td>[43]</td></tr><tr><td>γ-TmT</td><td>Estrogen-induced mammary hyperplasia in female ACI rats</td><td>↑ Nrf2 protein levels</td><td>[92]</td></tr></table> |
dd4d005cab9a0dd24485262640d5ec8cc112c04a2124cfd545a43870119de4f4.png | simple | <table><tr><td>Sample</td><td>Mean ± SD</td></tr><tr><td>Blank</td><td>1.247 ± 0.004</td></tr><tr><td>VC, 0.01 mM (1.7 mg/mL)</td><td>0.045 ± 0.003 *</td></tr><tr><td>BCE, 2.5 μL (875 μg/μL)</td><td>0.668 ± 0.016 *</td></tr><tr><td>BCE, 5 μL (875 μg/μL)</td><td>0.368 ± 0.018 *</td></tr><tr><td>BCE, 10 μL (875 μg/μL)</td><td>0.171 ± 0.008 *</td></tr><tr><td>BCE, 20 μL (875 μg/μL)</td><td>0.102 ± 0.007 *</td></tr><tr><td>BCE, 40 μL (875 μg/μL)</td><td>0.085 ± 0.004 *</td></tr><tr><td>BCE, 80 μL (875 μg/μL)</td><td>0.074 ± 0.003 *</td></tr></table> |
0b504c31c3f640e225ed5e65c5efb2ea56c81093c6e818261c97ae219e8219fa.png | simple | <table><tr><td> </td><td>CBHI (26)</td><td>Non-CBHI (114)</td><td>t-test</td></tr><tr><td>Population density (per km2)</td><td>184.62</td><td>46.42</td><td>-2.571*</td></tr><tr><td>Poverty rate (%)</td><td>29.6</td><td>40.1</td><td>3.386**</td></tr><tr><td>Literacy rate (%)</td><td>79.00</td><td>64.2</td><td>-4.061**</td></tr><tr><td>% of labor non-agriculture</td><td>33.38</td><td>12.09</td><td>-5.868**</td></tr><tr><td>% HHs with electricity</td><td>73.7</td><td>41.87</td><td>-5.948**</td></tr><tr><td>Avg time to nearest health center (mins)</td><td>57.65</td><td>161</td><td>4.5322**</td></tr><tr><td>% pop Lao-tai (vs. ethnic minority)</td><td>56.09</td><td>26.93</td><td>-3.741**</td></tr><tr><td>% pop Buddhist</td><td>79.48</td><td>53.29</td><td>-3.71**</td></tr></table> |
dd11dd085145bfd88f8fc31118787f11b6560c53f659f845139c9cdcd930a5b2.png | simple | <table><tr><td>Characteristic</td><td>Amiodarone n=20</td><td>Metaprolol n=30</td><td><i>P value</i></td></tr><tr><td>AF%age</td><td>20%</td><td>26.7%</td><td>NS</td></tr><tr><td>Time of Development of AF</td><td>62.15+ 18</td><td>48.4+ 10.2</td><td>NS</td></tr><tr><td>Duration of AF</td><td>12.04+ 10.2</td><td>18.8+ 10.4</td><td>NS</td></tr><tr><td>Maximum Ventricular rate during AF</td><td>118.+ 30.4</td><td>148+ 22.2</td><td>NS</td></tr><tr><td>AF on discharge</td><td>1</td><td>3</td><td>NS</td></tr><tr><td>Length of hospital stay</td><td>12.7+ 4.5</td><td>13.2+ 5.2</td><td>NS</td></tr><tr><td>Cost of Care</td><td>1.17+ 0.12</td><td>1.18+0.10</td><td>NS</td></tr></table> |
f116547cda6c48cb9d34d52f1648acbc2dd2f610012e533710aaf0d1a5cde017.png | simple | <table><tr><td>Characteristics</td><td>Number of patients (%)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Male</td><td>42 (98)</td></tr><tr><td>Female</td><td>1 (2)</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>Range</td><td>39–80</td></tr><tr><td>Median</td><td>66</td></tr><tr><td>Stage</td><td></td></tr><tr><td>T1</td><td>1 (2)</td></tr><tr><td>T2</td><td>16 (37)</td></tr><tr><td>T3</td><td>9 (21)</td></tr><tr><td>T4</td><td>17 (40)</td></tr><tr><td>N</td><td></td></tr><tr><td>Yes</td><td>3 (7)</td></tr><tr><td>No</td><td>39 (91)</td></tr><tr><td>NA</td><td>1 (2)</td></tr><tr><td>M</td><td></td></tr><tr><td>Yes</td><td>6 (14)</td></tr><tr><td>No</td><td>36 (84)</td></tr><tr><td>NA</td><td>1 (2)</td></tr><tr><td>Histological type</td><td></td></tr><tr><td>Papillary</td><td>3 (7)</td></tr><tr><td>Colonic</td><td>25 (58.1)</td></tr><tr><td>Solid</td><td>5 (11.6)</td></tr><tr><td>Mucinous</td><td>10 (23.3)</td></tr><tr><td>Wood dust exposure</td><td></td></tr><tr><td>Yes</td><td>26 (60)</td></tr><tr><td>No</td><td>9 (21)</td></tr><tr><td>NA</td><td>8 (19)</td></tr><tr><td>Recurrence</td><td></td></tr><tr><td>Yes</td><td>24 (56)</td></tr><tr><td>No</td><td>17 (40)</td></tr><tr><td>NA</td><td>2 (4)</td></tr><tr><td>Outcome</td><td></td></tr><tr><td>Alive</td><td>16 (37)</td></tr><tr><td>Died of disease</td><td>16 (37)</td></tr><tr><td>Died of other causes</td><td>9 (21)</td></tr><tr><td>NA</td><td>2 (5)</td></tr></table> |
89c862a9ef395009d9740724d114bb99bcdfc259cb8a13cb3906f006c4e09fa6.png | complex | <table><tr><td colspan="3">Before the phlebotomy training May 2014</td><td colspan="3">After the phlebotomy training July 2014</td></tr><tr><td>CHC/CDC</td><td>Blood registrations</td><td>Blood rejections <i>n</i> (%)</td><td>Blood registrations</td><td>Blood rejections <i>n</i> (%)</td><td><i>p</i></td></tr><tr><td>A</td><td>7557</td><td>60 (0.79)</td><td>10 218</td><td>79 (0.77)</td><td>0.876</td></tr><tr><td>B</td><td>3973</td><td>45 (1.13)</td><td>4114</td><td>48 (1.17)</td><td>0.886</td></tr><tr><td>C</td><td>2321</td><td>38 (1.64)</td><td>2279</td><td>37 (1.62)</td><td>0.971</td></tr><tr><td>D</td><td>589</td><td>8 (1.36)</td><td>630</td><td>7 (1.11)</td><td>0.696</td></tr></table> |
8cc6ae50dc12b042e30c5928fda156a27a70ba0ce8aff0b72fb57ab3606c2a01.png | simple | <table><tr><td>Subgroup</td><td>No. of datasets</td><td>RR (95% CI)</td><td><i>I</i><sup>2</sup></td><td><i>P</i><sub>heterogeneity</sub></td></tr><tr><td>Total</td><td>7</td><td>1.06 (0.89, 1.26)</td><td>25%</td><td>0.24</td></tr><tr><td>Geographical area</td><td></td><td></td><td></td><td></td></tr><tr><td> North America</td><td>4</td><td>1.11 (0.79, 1.56)</td><td>62%</td><td>0.05</td></tr><tr><td> Europe</td><td>3</td><td>1.05 (0.85, 1.32)</td><td>0%</td><td>0.98</td></tr><tr><td>Menopausal status</td><td></td><td></td><td></td><td></td></tr><tr><td> Postmenopausal</td><td>3</td><td>1.15 (0.92, 1.45)</td><td>0%</td><td>0.87</td></tr><tr><td> Premenopausal</td><td>0</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Coffee type</td><td></td><td></td><td></td><td></td></tr><tr><td> Caffeinated</td><td>3</td><td>1.09 (0.70, 1.68)</td><td>78%</td><td>0.01</td></tr><tr><td> Decaffeinated</td><td>3</td><td>0.89 (0.66, 1.20)</td><td>0%</td><td>0.99</td></tr><tr><td>Adjusted for smoking</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1</td><td>1.02 (0.62, 1.69)</td><td>NA</td><td>NA</td></tr><tr><td> Yes</td><td>6</td><td>1.07 (0.88, 1.31)</td><td>37%</td><td>0.16</td></tr><tr><td>Adjusted for BMI</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>2</td><td>1.13 (0.87, 1.45)</td><td>0%</td><td>0.76</td></tr><tr><td> Yes</td><td>5</td><td>1.05 (0.81, 1.36)</td><td>46%</td><td>0.12</td></tr><tr><td>Adjusted for education</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>2</td><td>0.89 (0.62, 1.27)</td><td>55%</td><td>0.14</td></tr><tr><td> Yes</td><td>5</td><td>1.17 (0.97, 1.41)</td><td>0%</td><td>0.69</td></tr><tr><td>Adjusted for alcohol intake</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>4</td><td>0.96 (0.76, 1.22)</td><td>26%</td><td>0.26</td></tr><tr><td> Yes</td><td>3</td><td>1.18 (0.95, 1.47)</td><td>0%</td><td>0.40</td></tr></table> |
2f7aa2f9a8289303fb8d00a9269cf26b016de08273e52f99266c0d1ea853ba7a.png | complex | <table><tr><td></td><td>K</td><td>AIC</td><td>ΔAICc</td><td>wi</td></tr><tr><td colspan="5">All species</td></tr><tr><td> Distance to road</td><td>2</td><td>2401.35</td><td>0</td><td>0.78</td></tr><tr><td> Constant survival</td><td>1</td><td>2405.17</td><td>3.82</td><td>0.11</td></tr><tr><td> Distance to edge</td><td>2</td><td>2406.59</td><td>5.24</td><td>0.06</td></tr><tr><td> Distance to power lines</td><td>2</td><td>2407.04</td><td>5.69</td><td>0.05</td></tr><tr><td> Macrohabitat type</td><td>5</td><td>2411.51</td><td>10.16</td><td>0.00</td></tr><tr><td> Species</td><td>16</td><td>2424.29</td><td>25.86</td><td>0.00</td></tr><tr><td colspan="5">BLGR</td></tr><tr><td> Distance to edge</td><td>2</td><td>201.684</td><td>0</td><td>0.48</td></tr><tr><td> Constant survival</td><td>1</td><td>207.16</td><td>1.19</td><td>0.26</td></tr><tr><td> Distance to power lines</td><td>2</td><td>208.28</td><td>2.59</td><td>0.13</td></tr><tr><td> Distance to road</td><td>2</td><td>209.26</td><td>3.15</td><td>0.10</td></tr><tr><td> Macrohabitat type</td><td>5</td><td>212.60</td><td>6.48</td><td>0.02</td></tr><tr><td colspan="5">BRTH</td></tr><tr><td> Constant survival</td><td>1</td><td>273.10</td><td>0</td><td>0.37</td></tr><tr><td> Distance to edge</td><td>2</td><td>274.11</td><td>1.01</td><td>0.22</td></tr><tr><td> Distance to road</td><td>2</td><td>274.90</td><td>1.80</td><td>0.15</td></tr><tr><td> Macrohabitat type</td><td>4</td><td>175.12</td><td>2.02</td><td>0.13</td></tr><tr><td> Distance to power lines</td><td>2</td><td>275.229</td><td>2.13</td><td>0.13</td></tr><tr><td colspan="5">INBU</td></tr><tr><td> Distance to power lines</td><td>2</td><td>188.55</td><td>0</td><td>0.83</td></tr><tr><td> Constant survival</td><td>1</td><td>193.48</td><td>4.93</td><td>0.07</td></tr><tr><td> Macrohabitat type</td><td>5</td><td>194.29</td><td>5.74</td><td>0.05</td></tr><tr><td> Distance to edge</td><td>2</td><td>195.51</td><td>6.96</td><td>0.03</td></tr><tr><td> Distance to road</td><td>2</td><td>195.71</td><td>7.16</td><td>0.02</td></tr><tr><td colspan="5">NOCA</td></tr><tr><td> Constant survival</td><td>1</td><td>1225.21</td><td>0</td><td>0.44</td></tr><tr><td> Distance to power lines</td><td>2</td><td>1226.68</td><td>1.47</td><td>0.21</td></tr><tr><td> Distance to road</td><td>2</td><td>1227.02</td><td>1.81</td><td>0.18</td></tr><tr><td> Distance to edge</td><td>2</td><td>1227.24</td><td>2.03</td><td>0.16</td></tr><tr><td> Macrohabitat type</td><td>5</td><td>1232.03</td><td>6.81</td><td>0.01</td></tr><tr><td colspan="5">WEVI</td></tr><tr><td> Constant survival</td><td>1</td><td>76.03</td><td>0</td><td>0.59</td></tr><tr><td> Distance to power lines</td><td>2</td><td>78.33</td><td>2.30</td><td>0.19</td></tr><tr><td> Distance to edge</td><td>2</td><td>79.38</td><td>3.34</td><td>0.11</td></tr><tr><td> Distance to road</td><td>2</td><td>79.39</td><td>3.36</td><td>0.11</td></tr><tr><td> Macrohabitat type</td><td>4</td><td>89.69</td><td>13.65</td><td>0.00</td></tr></table> |
b4cd3a4bff1213707ba132ebf85804b07c7011591b0f2ef74e6d50af37f21a83.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>CMV infection</td><td>No CMV infection</td><td rowspan="2">p</td></tr><tr><td><i>N</i> = 21</td><td><i>N</i> = 65</td></tr><tr><td>Age, mean ± SD, y</td><td>51.4 ± 13.8</td><td>46.8 ± 15.6</td><td>0.244</td></tr><tr><td>Gender, male (%)</td><td>57.1</td><td>69.2</td><td>0.308</td></tr><tr><td>Type of transplant, Kidney /Kidney + pancreas (%)</td><td>24.4/25.0</td><td>75.6/75.0</td><td>0.977</td></tr><tr><td colspan="4">Allograft function, (eGFR), mean ± SD</td></tr><tr><td> Day 30</td><td>44.0 ± 15.4</td><td>50.2 ± 23.3</td><td>0.347</td></tr><tr><td> Day 90</td><td>43.7 ± 17.4</td><td>52.6 ± 21.8</td><td>0.136</td></tr><tr><td>Blood transfusion, N Yes/No</td><td>12 /9</td><td>24 /38</td><td>0.140</td></tr><tr><td>Donor, D+/D- (%)</td><td>23.4/33.3</td><td>76.6/66.7</td><td>0.682</td></tr><tr><td>Pretransplant recipient CMV serostatus R+/R- (%)</td><td>22.4/33.1</td><td>77.6/66.9</td><td>0.410</td></tr><tr><td>The time of VGCV initiation after KTx (days); mean ± SD</td><td>9 ± 5</td><td>9 ± 5</td><td>0.905</td></tr><tr><td>The time of VGCV discontinuation after KTx (days); mean ± SD</td><td>94 ± 9</td><td>92 ± 14</td><td>0.458</td></tr><tr><td>Duration of antiviral prophylaxis (days); mean ± SD</td><td>85 ± 9</td><td>82 ± 15</td><td>0.382</td></tr><tr><td colspan="4">total IgG concentration (g/L) < 7 / ≥7%</td></tr><tr><td> Day 0</td><td>0.0/26.3</td><td>100.0/73.7</td><td>0.571</td></tr><tr><td> Day 90</td><td>41.1/18.0</td><td>58.9/82.0</td><td>0.057</td></tr><tr><td colspan="4">anti-CMV IgG titer (AU/ml) mean ± SD</td></tr><tr><td> Day 0</td><td>138 ± 113</td><td>168 ± 109</td><td>0.803</td></tr><tr><td> Day 90</td><td>113 ± 85</td><td>159 ± 109</td><td>0.087</td></tr><tr><td colspan="4">leukocyte blood count (G/L) mean ± SD</td></tr><tr><td> Day 0</td><td>7.8 ± 2.4</td><td>7.9 ± 2.3</td><td>1.000</td></tr><tr><td> Day 30</td><td>8.5 ± 2.7</td><td>9.2 ± 4.0</td><td>0.800</td></tr><tr><td> Day 90</td><td>6.6 ± 4.9</td><td>6.5 ± 3.2</td><td>0.080</td></tr><tr><td>Induction therapy (%)</td><td></td><td></td><td>0.026</td></tr><tr><td> Yes basiliximab</td><td>25.8</td><td>74.2</td><td rowspan="3"></td></tr><tr><td> Yes thymoglobulin</td><td>57.1</td><td>42.9</td></tr><tr><td> None</td><td>5.9</td><td>94.1</td></tr><tr><td colspan="4">QuantiFERON-CMV assay (IU/mL) < 0.2/≥0.2 (%)</td></tr><tr><td> All time points used</td><td>42.9/15.6</td><td>57.1/84.4</td><td>0.005</td></tr><tr><td> Day 7</td><td>39.0/14.6</td><td>61.0/85.4</td><td>0.015</td></tr><tr><td> Day 30</td><td>40.7/9.1</td><td>59.3/90.9</td><td>0.003</td></tr><tr><td> Day 90</td><td>42.8/16.4</td><td>57.2/83.6</td><td>0.008</td></tr><tr><td colspan="4">lymphocyte blood count (G/L) < 0.8/≥0.8 (%)</td></tr><tr><td> Day 0</td><td>0.0/25.3</td><td>100.0/74.7</td><td>1.000</td></tr><tr><td> Day 30</td><td>42.9/21.0</td><td>57.1/79.0</td><td>0.090</td></tr><tr><td> Day 90</td><td>53.8/20.0</td><td>46.2/80.0</td><td>0.015</td></tr><tr><td colspan="4">gammaglobulin blood concentration (g/dL) < 0.8/≥0.8 (%)</td></tr><tr><td> Day 0</td><td>18.2/24.8</td><td>81.8/75.2</td><td>0.623</td></tr><tr><td> Day 90</td><td>41.7/5.9</td><td>58.3/94.1</td><td>0.0004</td></tr></table> |
8c0d539b86da4c1596462b60a57fd48e652a9c31f075abd7a2d5d22955d37515.png | complex | <table><tr><td>Characteristic</td><td>Total Group (<i>n</i> = 270)</td><td>IR (<i>n</i> = 183)</td><td>ID/IDA (<i>n</i> = 87)</td><td><i>p</i>-Value <sup>1</sup></td></tr><tr><td>Age (years)</td><td>25.9 ± 5.0</td><td>26.3 ± 4.9</td><td>25.3 ± 5.2</td><td>0.131</td></tr><tr><td>Highest Educational Attainment <sup>2</sup> (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Secondary</td><td>75 (27.8)</td><td>41 (22.4)</td><td>34 (39.1)</td><td rowspan="3">0.014</td></tr><tr><td>Certificate/Diploma</td><td>43 (15.9)</td><td>33 (18.0)</td><td>10 (11.5)</td></tr><tr><td>Higher education</td><td>152 (56.3)</td><td>109 (59.6)</td><td>43 (49.4)</td></tr><tr><td>Location (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Rural</td><td>89 (33.0)</td><td>66 (36.1)</td><td>23 (26.4)</td><td rowspan="2">0.116</td></tr><tr><td>Urban</td><td>181 (67.0)</td><td>117 (63.9)</td><td>64 (73.6)</td></tr><tr><td>Ethnicity (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Asia</td><td>44 (16.3)</td><td>29 (15.8)</td><td>15 (17.2)</td><td rowspan="3">0.362</td></tr><tr><td>Europe</td><td>186 (68.9)</td><td>123 (67.2)</td><td>63 (72.4)</td></tr><tr><td>Other *</td><td>40 (14.8)</td><td>31 (16.9)</td><td>9 (10.3)</td></tr><tr><td>Weight Status (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Obese weight</td><td>126 (46.7)</td><td>89 (48.6)</td><td>37 (42.5)</td><td rowspan="2">0.347</td></tr><tr><td>Normal weight</td><td>144 (53.3)</td><td>94 (51.4)</td><td>50 (57.5)</td></tr><tr><td>Weight (kg)</td><td>77.9 ± 23.8</td><td>79.0 ± 23.4</td><td>75.7 ± 24.5</td><td>0.285</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>28.5 ± 8.6</td><td>28.8 ± 8.3</td><td>27.9 ± 9.4</td><td>0.453</td></tr><tr><td>Waist circumference (cm)</td><td>84.4 ± 18.6</td><td>85.3 ± 18.7</td><td>82.5 ± 19.1</td><td>0.252</td></tr><tr><td>Activity (MET-min/week)</td><td></td><td></td><td></td><td></td></tr><tr><td>Total</td><td>2573 ± 2137</td><td>2533 ± 2079</td><td>2658 ± 2263</td><td>0.654</td></tr><tr><td>Dietary Restraint (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Low</td><td>81 (30.0)</td><td>57 (31.1)</td><td>24 (27.6)</td><td rowspan="3">0.368</td></tr><tr><td>Medium</td><td>117 (43.3)</td><td>82 (44.8)</td><td>35 (40.2)</td></tr><tr><td>High</td><td>72 (26.7)</td><td>44 (24.0)</td><td>28 (32.2)</td></tr><tr><td>Energy Reporting (<i>n</i>, %)</td><td></td><td></td><td></td><td></td></tr><tr><td>Low energy reporting</td><td>156 (57.8)</td><td>95 (51.9)</td><td>61 (70.1)</td><td rowspan="2">0.005</td></tr><tr><td>Plausible energy reporting</td><td>114 (42.2)</td><td>88 (48.1)</td><td>26 (29.9)</td></tr><tr><td>Oral Contraceptive Pill (<i>n</i>, %) ^</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>76 (32.3)</td><td>52 (32.7)</td><td>24 (31.6)</td><td>0.863</td></tr><tr><td>No</td><td>159 (67.7)</td><td>107 (67.3)</td><td>52 (68.4)</td><td></td></tr></table> |
2eac6cb73cf919098b0ba55d7439015c6903e4febe9e664af6d823a182e7488b.png | simple | <table><tr><td></td><td>Gene name</td><td>Gene Accession number</td><td>Score (d)</td><td>Log<sub>2 </sub>expression ratio</td></tr><tr><td>Genes mainly expressed in skeletal muscle</td><td>Nebulette (Actin-binding Z-disk protein)</td><td>NM_006393</td><td>42.93</td><td>3.81</td></tr><tr><td></td><td>Troponin I, fast skeletal muscle (Troponin I, fast-twitch isoform)</td><td>NM_003282</td><td>34.39</td><td>2.60</td></tr><tr><td></td><td>Huntingtin interacting protein 1 (HIP-I)</td><td>NM_005338</td><td>33.55</td><td>2.59</td></tr><tr><td></td><td>Myosin light chain 2a</td><td>NM_021223</td><td>32.80</td><td>3.26</td></tr><tr><td></td><td>Troponin C, skeletal muscle</td><td>NM_003279</td><td>32.21</td><td>2.45</td></tr><tr><td></td><td>Myosin light chain 2</td><td>NM_013292</td><td>29.25</td><td>3.06</td></tr><tr><td></td><td>Myosin heavy chain, skeletal muscle, perinatal</td><td>NM_002472</td><td>28.14</td><td>2.80</td></tr><tr><td></td><td>Troponin T, fast skeletal muscle isoforms</td><td>NM_006757</td><td>26.04</td><td>2.71</td></tr><tr><td></td><td>Myosin heavy chain, cardiac muscle beta isoform</td><td>NM_000257</td><td>24.94</td><td>3.12</td></tr><tr><td></td><td>Actin, alpha skeletal muscle (Alpha-actin 1)</td><td>NM_001100</td><td>24.21</td><td>3.50</td></tr><tr><td></td><td>Troponin C, slow</td><td>NM_003280</td><td>21.31</td><td>2.54</td></tr><tr><td></td><td>Nebulin</td><td>NM_004543</td><td>20.17</td><td>2.78</td></tr><tr><td></td><td>Smoothelin</td><td>NM_134269</td><td>19.50</td><td>1.32</td></tr><tr><td></td><td>Tropomyosin 1 alpha chain (Alpha-tropomyosin)</td><td>NM_000366</td><td>18.92</td><td>1.99</td></tr><tr><td></td><td>Myotilin</td><td>NM_006790</td><td>18.07</td><td>1.56</td></tr><tr><td>Genes mainly expressed in MCF-7 cells</td><td>Actin, cytoplasmic 2 (Gamma-actin)</td><td>NM_001614</td><td>-30.24</td><td>-2.58</td></tr><tr><td></td><td>Elongation factor 1-beta (EF-1-beta)</td><td>NM_001959</td><td>-22.14</td><td>-1.26</td></tr><tr><td></td><td>Actin binding protein anillin,</td><td>NM_018685</td><td>-20.12</td><td>-1.13</td></tr><tr><td></td><td>Keratin, type I cytoskeletal 18</td><td>NM_000224</td><td>-18.78</td><td>-2.83</td></tr><tr><td></td><td>Ankyrin 3 (ANK-3) (Ankyrin G)</td><td>NM_020987</td><td>-16.43</td><td>-2.17</td></tr><tr><td></td><td>Gamma-parvin</td><td>NM_022141</td><td>-16.30</td><td>-1.03</td></tr><tr><td></td><td>Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta chain 2) (Beta-III spectrin)</td><td>NM_006946</td><td>-16.28</td><td>-0.84</td></tr><tr><td></td><td>Coronin 1B (Coronin 2)</td><td>NM_020441</td><td>-15.97</td><td>-0.84</td></tr><tr><td></td><td>Beta-centractin (Actin-related protein 1B) (ARP1B)</td><td>NM_005735</td><td>-15.79</td><td>-1.40</td></tr><tr><td></td><td>NB thymosin beta</td><td>NM_021992</td><td>-14.92</td><td>-1.42</td></tr><tr><td></td><td>Coronin 2A (WD-repeat protein 2) (IR10)</td><td>NM_052820</td><td>-14.39</td><td>-1.24</td></tr><tr><td></td><td>ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related protein 2/3 complex subunit 5)</td><td>NM_005717</td><td>-13.74</td><td>-1.06</td></tr><tr><td></td><td>Tight junction protein ZO-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1)</td><td>NM_003257</td><td>-13.70</td><td>-1.28</td></tr><tr><td></td><td>Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1)</td><td>NM_003202</td><td>-13.60</td><td>-0.67</td></tr><tr><td></td><td>Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-associated Src substrate) (CAS) (p120(cas))</td><td>NM_001331</td><td>-13.60</td><td>-0.77</td></tr></table> |
fc58b38499cd6e987e8b8f7083561daa3660c820e9140e8742402c661ce5b046.png | simple | <table><tr><td>Gene ID<sup>a</sup></td><td>Primers (5′-3′)</td><td>Accession No.</td><td>Amplicon length</td></tr><tr><td><i>Act- β</i></td><td>Forward: CGGCATCGAGGACAGGATReverse: CATCGTACTCCTGCTTGCTGAT</td><td>NM_173979.3</td><td>169</td></tr><tr><td><i>GAPDH</i></td><td>Forward: CCTGCCCGTTCGACAGATAReverse: GGCGACGATGTCCACTTTG</td><td>NM_001034034.1</td><td>150</td></tr><tr><td><i>FAU</i></td><td>Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC</td><td>NM_174731.3</td><td>154</td></tr><tr><td><i>RPS9</i></td><td>Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC</td><td>NM_001101152.2</td><td>188</td></tr><tr><td><i>HPRT1</i></td><td>Forward:GGATTACATCAAAGCACTGAACAReverse: CATTGTCTTCCCAGTGTCAATT</td><td>NM_001034035</td><td>194</td></tr></table> |
f47fe9fbf6eb0dddbe4dc76e2d0c8760c8f2824b14f92e28f1ea3322eaa9b1bb.png | complex | <table><tr><td rowspan="2">Characteristic/subcategory</td><td colspan="3">Discomfort of acupuncture: No. (%)</td><td colspan="2">No discomfort<sup>a</sup></td><td colspan="2">Slight discomfort<sup>a</sup></td></tr><tr><td>No</td><td>Slight</td><td>Moderate to severe</td><td>OR (95% CI)</td><td><i>P</i> value</td><td>OR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ≥70</td><td>20 (18.1)</td><td>51 (46.4)</td><td>39 (35.5)</td><td>1.00</td><td> </td><td>1.00</td><td> </td></tr><tr><td> ≤19</td><td>7 (12.3)</td><td>35 (61.4)</td><td>15 (26.3)</td><td>1.12 (0.37–3.41)</td><td>0.841</td><td>2.02 (0.94–4.32)</td><td>0.070</td></tr><tr><td> 20–29</td><td>8 (5.7)</td><td>76 (54.3)</td><td>56 (40.0)</td><td>0.35 (0.13–0.90)</td><td>0.030</td><td>1.16 (0.66–2.03)</td><td>0.605</td></tr><tr><td> 30–39</td><td>11 (9.8)</td><td>66 (58.9)</td><td>35 (31.3)</td><td>0.78 (0.32–1.94)</td><td>0.596</td><td>1.57 (0.86–2.85)</td><td>0.142</td></tr><tr><td> 40–49</td><td>22 (15.0)</td><td>88 (59.9)</td><td>37 (25.1)</td><td>1.37 (0.62–3.02)</td><td>0.443</td><td>1.85 (1.04–3.30)</td><td>0.037</td></tr><tr><td> 50–59</td><td>52 (22.7)</td><td>114 (49.8)</td><td>63 (27.5)</td><td>1.69 (0.84–3.39)</td><td>0.138</td><td>1.39 (0.82–2.37)</td><td>0.226</td></tr><tr><td> 60–69</td><td>26 (20.0)</td><td>69 (53.1)</td><td>35 (26.9)</td><td>1.21 (0.55–2.65)</td><td>0.638</td><td>1.31 (0.71–2.39)</td><td>0.379</td></tr><tr><td>Fear of needles: Are you afraid of acupuncture needles?</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>132 (18.1)</td><td>407 (55.8)</td><td>190 (26.1)</td><td>1.00</td><td> </td><td>1.00</td><td> </td></tr><tr><td> Yes</td><td>14 (7.2)</td><td>92 (46.9)</td><td>90 (45.9)</td><td>0.25 (0.14–0.48)</td><td><0.001</td><td>0.50 (0.36–0.72)</td><td><0.001</td></tr><tr><td>Fear of pain: How much are you afraid of pain?</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Not at all</td><td>79 (26.0)</td><td>171 (56.3)</td><td>54 (17.8)</td><td>1.00</td><td> </td><td>1.00</td><td> </td></tr><tr><td> A little </td><td>36 (10.7)</td><td>176 (52.5)</td><td>123 (36.7)</td><td>0.22 (0.13–0.37)</td><td><0.001</td><td>0.47 (0.32–0.69)</td><td><0.001</td></tr><tr><td> Very much</td><td>31 (10.8)</td><td>152 (53.1)</td><td>103 (36.0)</td><td>0.24 (0.14–0.41)</td><td><0.001</td><td>0.50 (0.33–0.75)</td><td>0.001</td></tr><tr><td>Knowledge of acupuncture: How much do you know about acupuncture?</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Not at all </td><td>51 (23.5)</td><td>110 (50.7)</td><td>56 (25.8)</td><td>1.00</td><td> </td><td>1.00</td><td> </td></tr><tr><td> A little </td><td>72 (13.6)</td><td>291 (54.9)</td><td>167 (31.5)</td><td>0.43 (0.26–0.71)</td><td>0.001</td><td>0.85 (0.58–1.24)</td><td>0.394</td></tr><tr><td> Very well </td><td>23 (12.9)</td><td>98 (55.1)</td><td>57 (32.0)</td><td>0.40 (0.21–0.77)</td><td>0.006</td><td>0.82 (0.51–1.32)</td><td>0.423</td></tr></table> |
47a22320ac4d1e6a0e386dc0b45162385b9ef4607beee2de69be7d30466df77e.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Category</td><td colspan="2">NSSIs</td><td rowspan="2">p-value</td></tr><tr><td>Present</td><td>Absent</td></tr><tr><td>Faculty</td><td>MBBS</td><td>18 (64.3)</td><td>10 (35.7)</td><td></td></tr><tr><td></td><td>BDS</td><td>9 (56.3)</td><td>7 (43.8)</td><td rowspan="2">0.042</td></tr><tr><td></td><td>B.Sc. Nursing</td><td>29 (39.7)</td><td>44 (60.3)</td></tr><tr><td></td><td>C. Nursing</td><td>34 (36.6)</td><td>59 (63.4)</td><td></td></tr><tr><td>Age Group (years)</td><td>≤22</td><td>51 (34.0)</td><td>99 (66.0)</td><td><0.001</td></tr><tr><td></td><td>>22</td><td>39 (65.0)</td><td>21 (35.)</td><td></td></tr><tr><td>Sex</td><td>Male</td><td>24 (61.5)</td><td>15 (38.5)</td><td></td></tr><tr><td></td><td>Female</td><td>66 (38.6)</td><td>105 (61.4)</td><td><0.001</td></tr><tr><td>Nationality</td><td>Nepalese</td><td>87 (42.4)</td><td>118 (57.6)</td><td>0.653</td></tr><tr><td></td><td>Indian</td><td>3 (60.0)</td><td>2 (40.0)</td><td></td></tr></table> |
6e00717f57a2ce0cb9b5acc8e91f757f0de250296db88ce6b72596540616be71.png | complex | <table><tr><td>Item</td><td>Descriptions</td></tr><tr><td>Number of stations</td><td>12</td></tr><tr><td>Date span </td><td>1–30 May 2015; 1–30 July 2016</td></tr><tr><td>Signal selection</td><td>GPS: L1/L2/L5; GLONASS: L1/L2; BeiDou: B1/B2/B3; Galileo: E1/E5a/E5b</td></tr><tr><td>Sampling interval</td><td>30 s</td></tr><tr><td>Elevation cut off</td><td>10°</td></tr><tr><td>Time system</td><td>GPS time</td></tr><tr><td>Tropospheric delay</td><td>Dry component: corrected with GPT model [26], wet component: estimated as random-walk process, GMF mapping function applied.</td></tr><tr><td rowspan="5">First order ionospheric delay</td><td>Single-frequency SPP:</td></tr><tr><td>GPS/GLONASS: Klobuchar model</td></tr><tr><td>BDS: Klobuchar model [27]</td></tr><tr><td>Galileo: The NeQuick model [28]</td></tr><tr><td>Dual-frequency: First order eliminated by ionosphere-free combination</td></tr><tr><td>Relativistic effect</td><td>IERS2010 [29]</td></tr><tr><td>Sagnac effect</td><td>IERS2010 [29]</td></tr><tr><td>Phase wind-up effect</td><td>Corrected [30]</td></tr><tr><td>Satellite PCO and PCV</td><td>GPS and GLONASS: Fixed to igs08_1861.atx values;</td></tr><tr><td>Tide displacement</td><td>IERS2010 [29]</td></tr><tr><td>Station reference coordinates</td><td>IGS SINEX solutions or daily GPS-only PPP solutions</td></tr></table> |
5208217a0cf4440035ef28e260176bdda86ffd7d1ee3fe71093e9aafaa0bddd5.png | complex | <table><tr><td rowspan="2">Ethnic group</td><td colspan="3"><i>α</i>-globin genotypes</td><td>Total</td></tr><tr><td>- -<i>α</i><sup>3.7</sup>/<i>αα</i></td><td>- -<i>α</i><sup>4.2</sup>/<i>αα</i></td><td>- -<sup>SEA</sup>/<i>αα</i></td></tr><tr><td>Malay (<i>n</i> = 315)</td><td>32</td><td>0</td><td>1</td><td>33</td></tr><tr><td>Chinese (<i>n</i> = 73)</td><td>2</td><td>1</td><td>1</td><td>4</td></tr><tr><td>Indian (<i>n</i> = 12)</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Total (<i>n</i> = 400)</td><td>34</td><td>1</td><td>2</td><td>37</td></tr></table> |
ece74e5f526bffcf8d87170862cfdc1699804123fa29822068e81f06b49bdf91.png | complex | <table><tr><td>Strain</td><td><i>D</i></td><td><i>Y</i><sub><i>xs</i></sub></td><td>r<sub>s</sub></td><td>r<sub>CO2</sub></td><td>r<sub>O2</sub></td><td>r<sub>etoh</sub></td><td>r<sub>acet</sub></td><td>RQ</td><td>C<sub>s</sub></td><td>C<sub>balance</sub></td><td>Tot<sub>sant</sub></td></tr><tr><td> </td><td>(h<sup>-1</sup>)</td><td>(g g<sup>-1</sup>)</td><td colspan="5">(mmol g biomass<sup>-1</sup>h<sup>-1</sup>)</td><td>(r<sub>CO2</sub>/r<sub>O2</sub>)</td><td>(mM)</td><td>(%)</td><td>(mg 24 h<sup>-1</sup>l<sup>-1</sup>)</td></tr><tr><td rowspan="2">SCIGS28</td><td>0.051 ±0.002</td><td>0.50 ±0.01</td><td>0.57 ±0.01</td><td>1.12 ±0.08</td><td>1.12 ±0.06</td><td>0</td><td>0</td><td>1.00 ±0.02</td><td>0.18 ±0.02</td><td>100.3 ±2.1</td><td>11.8 ±0.3</td></tr><tr><td>0.10 ±0.01</td><td>0.50 ±0.01</td><td>1.11 ±0.03</td><td>2.67 ±0.15</td><td>2.49 ±0.07</td><td>0</td><td>0</td><td>1.07 ±0.05</td><td>0.16 ±0.01</td><td>101.9 ±1.1</td><td>5.2 ±0.2</td></tr><tr><td rowspan="2">SCIGS29</td><td>0.050 ±0.003</td><td>0.29 ±0.01</td><td>0.97 ± 0.04</td><td>3.17 ±0.04</td><td>2.95 ±0.15</td><td>0.082 ±0.001</td><td>0.024 ±0.001</td><td>1.07 ±0.07</td><td>1.16 ±0.04</td><td>96.9 ±3.2</td><td>37.6 ±0.2</td></tr><tr><td>0.10 ±0.01</td><td>0.28 ±0.01</td><td>1.95 ±0.05</td><td>6.40 ±0.18</td><td>5.51 ±0.20</td><td>0.128 ±0.004</td><td>0.039 ±0.008</td><td>1.16 ±0.22</td><td>0.39 ±0.01</td><td>95.0 ±0.9</td><td>20.4 ±0.1</td></tr><tr><td rowspan="2">SCIGS30</td><td>0.051 ±0.001</td><td>0.28 ±0.02</td><td>1.09 ±0.05</td><td>3.60 ±0.09</td><td>3.41 ±0.22</td><td>0.099 ±0.015</td><td>0.024 ±0.003</td><td>1.05 ±0.09</td><td>1.15 ±0.04</td><td>94.7 ±0.4</td><td>39.4 ±0.4</td></tr><tr><td>0.10 ±0.02</td><td>0.25 ±0.01</td><td>2.26 ±0.09</td><td>7.70 ±0.19</td><td>6.37 ±0.29</td><td>0.161 ±0.007</td><td>0.032 ±0.005</td><td>1.21 ±0.14</td><td>0.40 ±0.01</td><td>93.5 ±1.2</td><td>20.1 ±0.1</td></tr><tr><td>SCIGS31</td><td>0.051 ±0.001</td><td>0.33 ±0.01</td><td>0.86 ±0.01</td><td>2.31 ±0.08</td><td>1.42 ±0.23</td><td>0.501 ±0.077</td><td>0.047 ±0.007</td><td>1.62 ±0.11</td><td>30.67 ±0.78</td><td>105.4 ±4.9</td><td>6.1 ±0.1</td></tr><tr><td>SCIGS24</td><td>0.051 ±0.001</td><td>0.24 ±0.01</td><td>1.16 ± 0.03</td><td>3.85 ±0.05</td><td>3.21 ±0.07</td><td>0.185 ±0.003</td><td>0.020 ±0.008</td><td>1.20 ±0.02</td><td>2.53 ±0.09</td><td>93.7 ±5.3</td><td>26.9 ±0.2</td></tr><tr><td>SCIGS25</td><td>0.048 ±0.003</td><td>0.21 ±0.01</td><td>1.26 ±0.02</td><td>4.41 ±0.04</td><td>3.82 ±0.04</td><td>0.195 ±0.005</td><td>0.027 ±0.007</td><td>1.16 ±0.03</td><td>2.91 ±0.14</td><td>93.8 ±2.9</td><td>24.9 ±0.3</td></tr></table> |
88346badf41ed8c653c7b679715cc8ac34a4fc79c023ac080be59a2358f6723b.png | complex | <table><tr><td>PPI Dataset</td><td>Methods</td><td>Precision</td><td>Recall</td><td><i>F</i>-score</td><td>Sn</td><td>PPV</td><td>Accuracy</td></tr><tr><td rowspan="10">DIP</td><td>CDUN</td><td>0.6</td><td>0.551</td><td>0.575</td><td>0.431</td><td>0.641</td><td>0.526</td></tr><tr><td>CSO</td><td>0.497</td><td>0.623</td><td>0.553</td><td>0.538</td><td>0.631</td><td>0.582</td></tr><tr><td>Cluster ONE</td><td>0.337</td><td>0.441</td><td>0.382</td><td>0.378</td><td>0.696</td><td>0.513</td></tr><tr><td>COAN</td><td>0.41</td><td>0.597</td><td>0.486</td><td>0.445</td><td>0.529</td><td>0.483</td></tr><tr><td>COACH</td><td>0.307</td><td>0.602</td><td>0.406</td><td>0.544</td><td>0.456</td><td>0.498</td></tr><tr><td>CMC</td><td>0.485</td><td>0.428</td><td>0.455</td><td>0.306</td><td>0.643</td><td>0.443</td></tr><tr><td>HUNTER</td><td>0.852</td><td>0.119</td><td>0.208</td><td>0.164</td><td>0.644</td><td>0.325</td></tr><tr><td>MCODE</td><td>0.423</td><td>0.14</td><td>0.21</td><td>0.282</td><td>0.362</td><td>0.32</td></tr><tr><td>TransClust</td><td>0.13</td><td>0.674</td><td>0.218</td><td>0.622</td><td>0.725</td><td>0.672</td></tr><tr><td>SpecClust</td><td>0.122</td><td>0.331</td><td>0.179</td><td>0.548</td><td>0.529</td><td>0.538</td></tr><tr><td rowspan="10">MIPS</td><td>CDUN</td><td>0.438</td><td>0.331</td><td>0.377</td><td>0.244</td><td>0.612</td><td>0.387</td></tr><tr><td>CSO</td><td>0.391</td><td>0.344</td><td>0.365</td><td>0.283</td><td>0.641</td><td>0.426</td></tr><tr><td>Cluster ONE</td><td>0.273</td><td>0.267</td><td>0.27</td><td>0.235</td><td>0.725</td><td>0.412</td></tr><tr><td>COAN</td><td>0.356</td><td>0.352</td><td>0.354</td><td>0.261</td><td>0.636</td><td>0.407</td></tr><tr><td>COACH</td><td>0.239</td><td>0.347</td><td>0.283</td><td>0.317</td><td>0.385</td><td>0.35</td></tr><tr><td>CMC</td><td>0.335</td><td>0.322</td><td>0.328</td><td>0.361</td><td>0.468</td><td>0.411</td></tr><tr><td>HUNTER</td><td>0.538</td><td>0.14</td><td>0.222</td><td>0.289</td><td>0.333</td><td>0.31</td></tr><tr><td>MCODE</td><td>0.365</td><td>0.153</td><td>0.215</td><td>0.189</td><td>0.572</td><td>0.329</td></tr><tr><td>TransClust</td><td>0.145</td><td>0.623</td><td>0.236</td><td>0.544</td><td>0.71</td><td>0.621</td></tr><tr><td>SpecClust</td><td>0.095</td><td>0.182</td><td>0.125</td><td>0.41</td><td>0.37</td><td>0.389</td></tr><tr><td rowspan="7">STRING</td><td>CDUN</td><td>0.446</td><td>0.674</td><td>0.537</td><td>0.715</td><td>0.518</td><td>0.609</td></tr><tr><td>Cluster ONE</td><td>0.13</td><td>0.343</td><td>0.188</td><td>0.671</td><td>0.494</td><td>0.569</td></tr><tr><td>COACH</td><td>0.181</td><td>0.458</td><td>0.26</td><td>0.963</td><td>0.154</td><td>0.385</td></tr><tr><td>HUNTER</td><td>0.5</td><td>0.017</td><td>0.033</td><td>0.107</td><td>0.353</td><td>0.194</td></tr><tr><td>MCODE</td><td>0.079</td><td>0.131</td><td>0.099</td><td>0.681</td><td>0.257</td><td>0.418</td></tr><tr><td>TransClust</td><td>0.11</td><td>0.517</td><td>0.181</td><td>0.842</td><td>0.528</td><td>0.667</td></tr><tr><td>SpecClust</td><td>0.066</td><td>0.347</td><td>0.111</td><td>0.652</td><td>0.519</td><td>0.582</td></tr></table> |
287ea07aaade575b9758e32c25ce34f7c3c4200a8d1e81e70cfc6858630b5c3d.png | simple | <table><tr><td></td><td><i>M</i></td><td>SD</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td></tr><tr><td>Threat appraisal</td><td>54.34</td><td>14.84</td><td></td><td>0.00</td><td>0.27*</td><td>0.14</td><td>0.05</td><td>−0.32*</td><td>−0.27*</td><td>−0.08</td><td>−0.12</td></tr><tr><td>Internality</td><td>27.72</td><td>6.04</td><td></td><td></td><td>0.28*</td><td>0.23</td><td>0.12</td><td>0.02</td><td>0.10</td><td>0.38**</td><td>0.00</td></tr><tr><td>Social externality</td><td>25.45</td><td>5.23</td><td></td><td></td><td></td><td>0.17</td><td>0.26</td><td>0.01</td><td>−0.20</td><td>0.09</td><td>0.14</td></tr><tr><td>Fatalistic externality</td><td>22.06</td><td>7.15</td><td></td><td></td><td></td><td></td><td>0.18</td><td>0.07</td><td>−0.15</td><td>0.02</td><td>0.24</td></tr><tr><td>Rumination</td><td>28.53</td><td>7.43</td><td></td><td></td><td></td><td></td><td></td><td>0.46***</td><td>0.30*</td><td>0.69***</td><td>0.49***</td></tr><tr><td>Search for affiliation</td><td>32.58</td><td>9.23</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.57***</td><td>0.40**</td><td>0.60***</td></tr><tr><td>Threat minimization</td><td>39.57</td><td>4.90</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.39**</td><td>0.39**</td></tr><tr><td>Search for information</td><td>28.11</td><td>7.36</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.26</td></tr><tr><td>Search for meaning in religion</td><td>8.46</td><td>4.25</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
0d608731d643f4c0e17b447a7372c1e3ce858447d6131c08eacf862f6191d57b.png | simple | <table><tr><td>Species Name</td><td>LC50/EC50 (95% Confidence Interval Limit)</td><td>Study</td></tr><tr><td><i>Oreochromis niloticus</i></td><td>3760 mg∙L<sup>−1</sup> (2990–4010)</td><td>Omoregie et al. (2009) [39]</td></tr><tr><td><i>Chironomus yoshimatsui</i></td><td>1520 mg∙L<sup>−1</sup></td><td>Kegley et al. (2014) [40]</td></tr><tr><td><i>Viviparus bengalensis</i></td><td>2280 mg∙L<sup>−1</sup></td><td>Kegley et al. (2014) [40]</td></tr><tr><td><i>Radix luteola</i></td><td>3000 mg∙L<sup>−1</sup></td><td>USEPA, (2015) [41]</td></tr></table> |
3cd5aad1750eccc665bb8196a0b256e5853e3a199533320e52950c281c91ddc1.png | complex | <table><tr><td rowspan="3"></td><td colspan="5">0.033 mg/kg/day</td><td colspan="5">0.067 mg/kg/day</td></tr><tr><td rowspan="2">Total</td><td rowspan="2">Glucose intolerant type</td><td colspan="3">Time point evaluated as the glucose intolerant type</td><td rowspan="2">Total</td><td rowspan="2">Glucose intolerant type</td><td colspan="3">Time point evaluated as the glucose intolerant type</td></tr><tr><td>Before</td><td>60 min<sup>a</sup></td><td>120 min</td><td>Before</td><td>60 min*</td><td>120 min</td></tr><tr><td>Baseline</td><td>31 (100 %)</td><td>3 (9.7 %)</td><td>1 (3.2 %)</td><td>0 (0.0 %)</td><td>2 (6.5 %)</td><td>34 (100 %)</td><td>1 (2.9 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>1 (2.9 %)</td></tr><tr><td>52 weeks</td><td>29 (100 %)</td><td>3 (10.3 %)</td><td>0 (0.0 %)</td><td>2 (6.9 %)</td><td>1 (3.4 %)</td><td>34 (100 %)</td><td>3 (8.8 %)</td><td>0 (0.0 %)</td><td>3 (8.8 %)</td><td>0 (0.0 %)</td></tr><tr><td>104 weeks</td><td>29 (100 %)</td><td>2 (6.9 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>2 (6.9 %)</td><td>32 (100 %)</td><td>2 (6.3 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>2 (6.3 %)</td></tr><tr><td>156 weeks</td><td>25 (100 %)</td><td>1 (4.0 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>1 (4.0 %)</td><td>29 (100 %)</td><td>2 (6.9 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>2 (6.9 %)</td></tr><tr><td>208 weeks</td><td>25 (100 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>28 (100 %)</td><td>3 (10.7 %)</td><td>0 (0.0 %)</td><td>2 (7.1 %)</td><td>1 (3.6 %)</td></tr><tr><td>260 weeks</td><td>23 (100 %)</td><td>1 (4.3 %)</td><td>1 (4.3 %)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>27 (100 %)</td><td>4 (14.8 %)</td><td>0 (0.0 %)</td><td>1 (3.7 %)</td><td>3 (11.1 %)</td></tr></table> |
699624555de8a0c9d0f986d43daeb22cb474764421dd6d845e7ead5906770bdb.png | simple | <table><tr><td></td><td>2010 audit<i>n</i> = 82</td><td>2011 re-audit<i>n</i> = 140</td></tr><tr><td>Patients who had at least one neuroimaging procedure (through MAS or previous), <i>n</i> (%)</td><td>56 (68)</td><td>106 (76)</td></tr><tr><td>Neuroimaging requested through MAS, <i>n</i> (%)</td><td>48 (59)</td><td>88 (63)</td></tr><tr><td>Previous neuroimaging, <i>n</i> (%)</td><td>8 (9)</td><td>18 (13)</td></tr><tr><td>Patients who declined assessment/scan, <i>n</i> (%)</td><td>13 (16)</td><td>29 (21)</td></tr><tr><td>Patients with documented reasons for not having neuroimaging (unable to tolerate scan, moved out of area, died), <i>n</i> (%)</td><td>0 (0)</td><td>4 (3)</td></tr><tr><td>Patients with no reason documented for not having neuroimaging, <i>n</i> (%)</td><td>13 (16)</td><td>1 (1)</td></tr><tr><td>Of the patients who did not have any neuroimaging, proportion with no reason documented, <i>n/N</i> (%)</td><td>13/26 (50)</td><td>1/34 (3)</td></tr><tr><td>Type of neuroimaging performed (through MAS and previous), <i>n/N</i> (%)</td><td></td><td></td></tr><tr><td>CT scan</td><td>49/56 (88)</td><td>92/106 (87)</td></tr><tr><td>MRI scan</td><td>5/56 (9)</td><td>14/106 (13)</td></tr><tr><td>Other (FDG-PET/CT, HMPAO-SPECT)</td><td>2/56 (4)</td><td>0/106 (0)</td></tr><tr><td>Coronal imaging on CT scans requested through MAS, <i>n/N</i> (%)</td><td>Data not available</td><td>45/78 (58)</td></tr><tr><td>Length of time between scan requests and scan appointments, days</td><td></td><td></td></tr><tr><td>Range</td><td>6-42</td><td>11-71</td></tr><tr><td>Mean</td><td>22</td><td>30</td></tr><tr><td>Range across different sectors of patients who had a neuroimaging procedure, %</td><td>33-100</td><td>58-84</td></tr></table> |
3e32bf3bc6ace359013f5f347f92efa37b2cdbab0168123d5778fb5b0dcfa0e3.png | simple | <table><tr><td> VA outcome</td><td>Fox (<i>n</i> = 19)</td><td>Clark (<i>n</i> = 36)</td><td>Al-Mezaine (<i>n</i> = 17)</td><td>Shirodkar (<i>n</i> = 26)</td><td>Overall (<i>n</i> = 98)</td></tr><tr><td>≥20/40</td><td>9 (47.3%)</td><td>18 (50%)</td><td>5 (29.4%)</td><td>13 (50%)</td><td>45 (45.9%)</td></tr><tr><td>20/50 ≥ 20/400</td><td>6 (31.5%)</td><td>10 (28%)</td><td>4 (23.5%)</td><td>6 (23%)</td><td>26 (26.5%)</td></tr><tr><td><20/400 ≥ 5/200</td><td>1 (5.2%)</td><td>2 (5%)</td><td>2 (11.7%)</td><td>2 (7.7%)</td><td>7 (7.1%)</td></tr><tr><td><5/200-NLP</td><td>3 (15.8%)</td><td>6 (17%)</td><td>6 (35%)</td><td>5 (19.2%)</td><td>20 (20.4%)</td></tr></table> |
baa80ddbc7e465c87aeb531eb30f4022acc001723396e2f4c6ea0d91bc78a585.png | simple | <table><tr><td>Parameter</td><td>Definition</td></tr><tr><td><i>N</i></td><td>Number of individuals in the population</td></tr><tr><td><i>Z</i></td><td>Probability to reproduce by self-fertilization</td></tr><tr><td><i>w</i></td><td>Fitness of an individual</td></tr><tr><td><i>n</i></td><td>Number of TE copies in the genome</td></tr><tr><td><i>s</i><sub><i>i</i></sub></td><td>Effect of insertion <i>i </i>on fitness</td></tr><tr><td><i>μ</i><sub><i>s</i></sub></td><td>Average effect of TE insertions on fitness</td></tr><tr><td><i>σ</i><sub><i>s</i></sub></td><td>Standard deviation of the effect on fitness</td></tr><tr><td><i>P</i><sub><i>s </i>> 0</sub></td><td>Proportion of TE insertions that improve the fitness</td></tr><tr><td><i>u</i></td><td>Replicative transposition rate</td></tr><tr><td><i>v</i></td><td>Deletion rate</td></tr><tr><td><i>a</i><sub><i>i</i></sub></td><td>Activity of a copy <i>i </i>(ability to produce the transposition machinery)</td></tr><tr><td><i>m</i></td><td>Mutation rate (toward a less active copy)</td></tr><tr><td><i>σ</i><sub><i>m</i></sub></td><td>Standard deviation of the effect of a mutation on activity</td></tr></table> |
6bd895bf47a58dd5df7c3566de7a8e68a34fcf868f004eb4a944fe6021d28473.png | complex | <table><tr><td rowspan="2">Gene list</td><td rowspan="2"><i>N</i> genes</td><td colspan="2">Proportion of genome</td><td colspan="2">SNP heritability (<i>P</i> value)</td></tr><tr><td>SNPs</td><td>Mb</td><td>All samples</td><td>Infliximab+Adalimumab</td></tr><tr><td>Whole genome</td><td>—</td><td>1</td><td>1</td><td>0.18 (0.02)</td><td>0.36 (0.005)</td></tr><tr><td>Drug metabolism*</td><td>215</td><td>0.07</td><td>0.10</td><td>0.05 (0.3)</td><td>0.04 (0.09)</td></tr><tr><td>Immune-related†</td><td>6,001</td><td>0.65</td><td>0.58</td><td>0.07 (0.2)</td><td>0.21 (0.01)</td></tr><tr><td>TNF/TNFR pathway‡</td><td>333</td><td>0.11</td><td>0.14</td><td>0.05 (0.04)</td><td>0.02 (0.3)</td></tr><tr><td>CD84 coexpression (ImmGen)</td><td>200</td><td>0.08</td><td>0.11</td><td>0 (0.5)</td><td>0 (0.5)</td></tr></table> |
44213c275d4d96ebbfe657bb946107affc0d04a10b30eecfa2a4fee8ef747bb7.png | simple | <table><tr><td>Sample</td><td>[M]/[I]</td><td>m<sub>M</sub>, g</td><td>m<sub>C</sub>, mg</td></tr><tr><td>MWS-1 MWS-2 MWS-3</td><td>1/1,000</td><td>5</td><td>14.05</td></tr><tr><td>MWS-4 MWS-5 MWS-6</td><td>1/5,000</td><td>5</td><td>2.81</td></tr><tr><td>MWS-7 MWS-8 MWS-9</td><td>1/10,000</td><td>5</td><td>1.41</td></tr></table> |
c277c51f747cd593c8f41af26f2ed557b01005d51a81e8a7ada3981b25019a19.png | simple | <table><tr><td>Human protein</td><td>Targeting DNA virus families</td><td>Targeting RNA virus families</td></tr><tr><td>HNRPK – heterogeneous nuclear ribonucleoprotein K</td><td>Asfarviridae, Herpesviridae, Papillomaviridae, Poxviridae</td><td>Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr><tr><td>YBOX1 – nuclease‐sensitive element‐binding protein 1</td><td>Herpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae</td><td>Arteriviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae</td></tr><tr><td>EF1A1 – elongation factor 1‐alpha 1</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae</td></tr><tr><td>IMA1 – Importin subunit alpha‐1</td><td>Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae, Poxviridae</td><td>Coronaviridae, Orthomyxoviridae, Paramyxoviridae</td></tr><tr><td>ADT2 – ADP/ATP translocase 2</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae,Togaviridae</td></tr><tr><td>TBA1C – Tubulin alpha‐1C chain</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae</td></tr><tr><td>ROA1 – heterogeneous nuclear ribonucleoprotein A1</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Arteriviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Togaviridae</td></tr><tr><td>GRP78 – 78 kDa glucose‐regulated protein</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Bunyaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae</td></tr><tr><td>TBB5 – Tubulin beta chain</td><td>Herpesviridae, Poxviridae</td><td>Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae</td></tr><tr><td>P53 – cellular tumor antigen p53</td><td>Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae</td><td>Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr><tr><td>NPM – nucleophosmin</td><td>Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae</td><td>Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr><tr><td>GBLP – guanine nucleotide‐binding protein subunit beta‐2‐like 1</td><td>Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae</td><td>Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr><tr><td>TCPG – T‐complex protein 1 subunit gamma</td><td>Adenoviridae, Herpesviridae, Papillomaviridae</td><td>Arenaviridae, Bunyaviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae</td></tr><tr><td>EF1A3 – putative elongation factor 1‐alpha‐like 3</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae</td></tr><tr><td>HNRPC – heterogeneous nuclear ribonucleoproteins C1/C2</td><td>Herpesviridae, Papillomaviridae, Poxviridae</td><td>Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae</td></tr><tr><td>TCPE – T‐complex protein 1 subunit epsilon</td><td>Adenoviridae, Herpesviridae</td><td>Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae</td></tr><tr><td>HS90B – heat shock protein HSP 90‐beta</td><td>Herpesviridae, Poxviridae</td><td>Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr><tr><td>HNRH1 – heterogeneous nuclear ribonucleoprotein H</td><td>Herpesviridae, Papillomaviridae</td><td>Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae</td></tr><tr><td>TBA1A – Tubulin alpha‐1A chain</td><td>Herpesviridae, Poxviridae</td><td>Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae</td></tr><tr><td>HNRPF – heterogeneous nuclear ribonucleoprotein F</td><td>Herpesviridae, Papillomaviridae</td><td>Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae</td></tr><tr><td>ROA2 – heterogeneous nuclear ribonucleoproteins A2/B1</td><td>Herpesviridae, Poxviridae</td><td>Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae</td></tr></table> |
c13f629e5b430c86f1357ec7ce14ba712f151a43347baed668f33391701d12db.png | simple | <table><tr><td>Stage of Lactation (Month)</td><td>2</td><td>5</td><td>9</td><td>12</td></tr><tr><td>Maternal age (years)</td><td>32.9 ± 4.21 (28–40)</td><td>33.4 ± 4.27 (24–40)</td><td>34.0 ± 4.57 (25–43)</td><td>34.1 ± 4.35 (26–44)</td></tr><tr><td>Maternal BMI</td><td>27.1 ± 7.15 (20.1–38.5)</td><td>23.5 ± 4.46 (18.0–35.2)</td><td>24.0 ± 5.15 (18.7–37.2)</td><td>24.8 ± 5.6 (18.2–34.6)</td></tr><tr><td>Parity</td><td>2.10 ± 0.75 (1–4)</td><td>2.13 ± 0.85 (1–4) </td><td>1.96 ± 0.94 (1–4)</td><td>2.05 ± 0.98 (1–4)</td></tr><tr><td>Infant sex (Male/Female)</td><td>12/9</td><td>16/16</td><td>17/13</td><td>12/12</td></tr><tr><td>Infant birth weight (kg)</td><td>3.58 ± 0.64 (2.66–4.23)</td><td>3.49 ± 0.45 (2.66–4.46)</td><td>3.49 ± 0.46 (2.82–4.46)</td><td>3.59 ± 0.46 (2.80–4.46)</td></tr><tr><td>Infant body length (cm)</td><td>57.6 ± 2.17 (54.2–61.3)</td><td>64.5 ± 2.09 (61.5–69.5)</td><td>70.9 ± 2.11 (68.0–74.5)</td><td>73.9 ± 2.38 (71.5–78.5)</td></tr></table> |
ea4e261ee1223fe99ca8478bcc4abe5548b993b1b04ed09891db77ad2bd2cd94.png | simple | <table><tr><td>Group</td><td><i>E</i><sub>1</sub>′ (MPa)</td><td><i>E</i><sub>2</sub>′ (MPa)</td><td><i>t<sub>s</sub></i> (min)</td><td><i>G</i><sub>∞</sub></td><td><i>R</i><sup>2</sup></td></tr><tr><td>L65</td><td>10.1408 ± 5.8173</td><td>16.4475 ± 5.8594</td><td>0.6501 ± 0.1888</td><td>0.4174 ± 0.0479</td><td>0.7877 ± 0.0257</td></tr><tr><td>L60</td><td>5.9513 ± 3.0988</td><td>9.1808 ± 2.9271</td><td>0.7275 ± 0.0806</td><td>0.3785 ± 0.0676</td><td>0.8254 ± 0.0134</td></tr><tr><td>R</td><td>1.2904 ± 0.6890</td><td>2.6453 ± 1.0379</td><td>0.8094 ± 0.2709</td><td>0.3273 ± 0.0706</td><td>0.8495 ± 0.0416</td></tr></table> |
d190e1141ad8cca78d53b58df7f1c57cfce82fcae54db22fbae1ff71b09548f3.png | complex | <table><tr><td rowspan="2" colspan="2">Characteristics</td><td rowspan="2">Yes <i>n</i> (%)</td><td colspan="3">Non-compliance to HPV vaccination</td></tr><tr><td>Prevalence</td><td><i>p</i> value</td><td>Odds Ratio (CI 95 %)</td></tr><tr><td rowspan="2">Parent’s religion</td><td>Protestant</td><td>262 (44,1 %)</td><td>17,9 %</td><td>ns</td><td>1,03 (0,576–1,45)</td></tr><tr><td>Non protestant</td><td>332 (55,9 %)</td><td>17,5 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Parent’s schooling</td><td>Elementary school</td><td>203 (26,8 %)</td><td>16,7 %</td><td>ns</td><td>0,98 (0,71–1,73)</td></tr><tr><td>High school / higher</td><td>554 (73,2 %)</td><td>16,9 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Monthly household income</td><td>Up to I$ 400</td><td>353 (49,5 %)</td><td>16,1 %</td><td>ns</td><td>1,02 (0,61–1,41)</td></tr><tr><td>More than I$ 400</td><td>360 (50,5 %)</td><td>18,6 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Type of school</td><td>Private school</td><td>99 (12,5 %)</td><td>43,7 %</td><td>0,003</td><td>4,51 (1,63–12,46)</td></tr><tr><td>Public school</td><td>698 (87,5 %)</td><td>15,9 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Correct answers in 10 knowledge questions</td><td>Less than 50 %</td><td>287 (38,8 %)</td><td>20,2 %</td><td>0,02</td><td>1,60 (1,05–2,42)</td></tr><tr><td>More than 50 %</td><td>453 (61,2 %)</td><td>13,6 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that HPV infections is not rare</td><td>Wrong</td><td>400 (50,2 %)</td><td>21,5 %</td><td>0,001</td><td>1,81 (1,24–2,64)</td></tr><tr><td>Right</td><td>397 (49,8 %)</td><td>13,1 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing the recommended age group for vaccination</td><td>Wrong</td><td>700 (87,8 %)</td><td>18,3 %</td><td>0,04</td><td>1,94 (1,02–3,86)</td></tr><tr><td>Right</td><td>97 (12,2 %)</td><td>10,3 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that the vaccine is effective in preventing HPV</td><td>Wrong</td><td>301 (37,7 %)</td><td>20,6 %</td><td>0,01</td><td>1,62 (1,08–2,41)</td></tr><tr><td>Right</td><td>496 (62,3 %)</td><td>14,0 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that the vaccine prevents cervical cancer</td><td>Wrong</td><td>152 (19,1 %)</td><td>24,4 %</td><td>0,01</td><td>1,73 (1,14–2,84)</td></tr><tr><td>Right</td><td>645 (80,9 %)</td><td>15,6 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that HPV is a STD</td><td>Wrong</td><td>248 (31,1 %)</td><td>17,7 %</td><td>ns</td><td>1,04 (0,73–1,66)</td></tr><tr><td>Right</td><td>549 (68,9 %)</td><td>17,1 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that men are affected by HPV</td><td>Wrong</td><td>449 (56,3 %)</td><td>18,0 %</td><td>ns</td><td>1,12 (0,71–1,60)</td></tr><tr><td>Right</td><td>348 (43,7 %)</td><td>16,3 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that HPV causes genital warts</td><td>Wrong</td><td>484 (60,7 %)</td><td>18,8 %</td><td>ns</td><td>1,41 (0,92–2,17)</td></tr><tr><td>Right</td><td>313 (39,3 %)</td><td>15,0 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that HPV causes CC</td><td>Wrong</td><td>152 (19,1 %)</td><td>19,7 %</td><td>ns</td><td>1,35 (0,85–2,16)</td></tr><tr><td>Right</td><td>645 (80,9 %)</td><td>16,7 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that the HPV infection is usually asymptomatic</td><td>Wrong</td><td>610 (76,5 %)</td><td>16,1 %</td><td>ns</td><td>0,71 (0,43–1,06)</td></tr><tr><td>Right</td><td>187 (23,5 %)</td><td>21,4 %</td><td></td><td>1</td></tr><tr><td rowspan="2">Knowing that there is no curative treatment for HPV</td><td>Wrong</td><td>731 (91,7 %)</td><td>17,6 %</td><td>ns</td><td>1,53 (0,63–3,67)</td></tr><tr><td>Right</td><td>66 (8,3 %)</td><td>13,6 %</td><td></td><td>1</td></tr></table> |
9e895e56080131bdb7cd0c964d77a55d7a9bf7cb7f4c4632d949d186d9e07b14.png | complex | <table><tr><td>Population</td><td>IDF guideline recommendation</td><td>Assessment in study</td></tr><tr><td>All acne patients</td><td>Assign treatment according to acne severity</td><td>Not assessed in study: could not be evaluated by computerized query (Disease severity not stated within diagnosis field)</td></tr><tr><td>All acne patients</td><td>Progress gradually between treatment lines</td><td>Correctness of treatment progression assessed for treatment courses of distinct acne medications (see Table 4)</td></tr><tr><td>Patients treated with oral retinoids</td><td>Rule out psychiatric diagnoses prior to treatment initiation, and refer to psychiatrist if necessary</td><td>Not assessed in study: information not available in computerized patient records</td></tr><tr><td>Patients treated with oral retinoids</td><td>Monitor laboratory test values (liver enzymes, plasma lipid profile) before and during treatment.</td><td>Not assessed in study: computerized laboratory test records were not available for cross analysis between databases.</td></tr><tr><td>Patients treated with oral retinoids</td><td>Prescribe supportive care if necessary.</td><td>Concomitant prescribing or dispensing of supportive care medications was assessed (see Table 5).</td></tr><tr><td>Patients treated with oral retinoids</td><td>Restrict patient participation in strenuous physical activity by temporarily adjusting medical profile.</td><td>Not assessed in study: documentation of temporary change in medical profile was not available after reinstatement of permanent profile.</td></tr><tr><td rowspan="3">Female patients treated with oral retinoids (teratogenic)</td><td>- Rule out pregnancy (laboratory test).</td><td rowspan="3">Documented concomitant prescribing or dispensing of oral contraceptives to female patients receiving OI’s.</td></tr><tr><td>- Inform the patient of potential hazards and explain about required birth control measures.</td></tr><tr><td>- Have the patient sign a statement and file in their medical record (see background).</td></tr></table> |
4c2e55aa7ded48d4d5452fb0c4e26b6a092d76f9f66d87e85a92f5cade747c4b.png | simple | <table><tr><td>Characteristic</td><td>No. of patients</td><td>%</td></tr><tr><td>Patients evaluable</td><td>70</td><td>100</td></tr><tr><td>Age, years</td><td> </td><td> </td></tr><tr><td> Median (range)</td><td>65 (32–75)</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td></tr><tr><td> Male</td><td>41</td><td>58.5</td></tr><tr><td> Female</td><td>29</td><td>41.5</td></tr><tr><td>Response to prior chemotherapy</td><td> </td><td> </td></tr><tr><td> Yes</td><td>44</td><td>63</td></tr><tr><td> No</td><td>26</td><td>37</td></tr><tr><td>Status of primary tumor</td><td> </td><td> </td></tr><tr><td> Resected</td><td>25</td><td>36</td></tr><tr><td> Unresected</td><td>45</td><td>64</td></tr><tr><td>Tumor histology</td><td> </td><td> </td></tr><tr><td> Diffuse</td><td>33</td><td>47.2</td></tr><tr><td> Intestinal</td><td>29</td><td>41.4</td></tr><tr><td> Unknown</td><td>8</td><td>11.4</td></tr><tr><td>ECOG PS</td><td> </td><td> </td></tr><tr><td> 0</td><td>10</td><td>14.5</td></tr><tr><td> 1</td><td>40</td><td>57</td></tr><tr><td> 2</td><td>20</td><td>28.5</td></tr><tr><td>Number of metastatic sites</td><td> </td><td> </td></tr><tr><td> 1</td><td>17</td><td>24</td></tr><tr><td> 2</td><td>32</td><td>46</td></tr><tr><td> 3</td><td>21</td><td>30</td></tr><tr><td>Site of metastases</td><td> </td><td> </td></tr><tr><td> Liver</td><td>48</td><td>68.5</td></tr><tr><td> Nodes</td><td>41</td><td>58.5</td></tr><tr><td> Peritoneum</td><td>41</td><td>58.5</td></tr><tr><td> Lung</td><td>13</td><td>18.5</td></tr><tr><td> Bone</td><td>6</td><td>8.5</td></tr><tr><td>PFS under first-line chemotherapy</td><td> </td><td> </td></tr><tr><td> ≥ 6 months</td><td>42</td><td>60</td></tr><tr><td> < 6 months</td><td>28</td><td>40</td></tr><tr><td>Chemotherapy-free interval</td><td> </td><td> </td></tr><tr><td> > 3 months</td><td>38</td><td>54</td></tr><tr><td> < 3 months</td><td>32</td><td>46</td></tr></table> |
99f9a631ead7412b09e0504a0bd9b1fc40d42fd74e693e3b86df037a7d218204.png | simple | <table><tr><td> </td><td>1995</td><td>1996</td><td>1997</td><td>1998</td><td>1999</td><td>2000</td><td>2001</td><td>2002</td><td>2003</td><td>2004</td><td>2005</td><td>2006</td><td>2007</td><td>2008</td><td>2009</td><td>2010</td><td>2011</td><td>Sum</td><td>%</td></tr><tr><td>jan</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>5</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>5</td><td>0,31</td></tr><tr><td>fev</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2</td><td> </td><td>9</td><td>7</td><td> </td><td> </td><td> </td><td> </td><td>32</td><td>1</td><td>3</td><td>1</td><td>55</td><td>3,38</td></tr><tr><td>mar</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2</td><td>3</td><td>8</td><td>2</td><td> </td><td>1</td><td>3</td><td> </td><td>13</td><td>8</td><td>2</td><td> </td><td>42</td><td>2,58</td></tr><tr><td>avr</td><td>23</td><td>128</td><td> </td><td>20</td><td>105</td><td>45</td><td>3</td><td>50</td><td>20</td><td>10</td><td>41</td><td>8</td><td>5</td><td>16</td><td>7</td><td> </td><td>2</td><td>482</td><td>29,59</td></tr><tr><td>may</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>8</td><td>1</td><td>12</td><td>2</td><td> </td><td>6</td><td>11</td><td>10</td><td> </td><td> </td><td>2</td><td>53</td><td>3,25</td></tr><tr><td>jun</td><td>3</td><td>129</td><td>1</td><td>14</td><td>69</td><td>21</td><td>1</td><td>33</td><td>2</td><td>19</td><td>29</td><td>9</td><td>46</td><td>6</td><td> </td><td> </td><td>25</td><td>407</td><td>24,98</td></tr><tr><td>jul</td><td>28</td><td>5</td><td> </td><td> </td><td>90</td><td> </td><td>1</td><td>53</td><td>5</td><td> </td><td>21</td><td>12</td><td>37</td><td>1</td><td> </td><td> </td><td>11</td><td>264</td><td>16,21</td></tr><tr><td>aug</td><td> </td><td> </td><td> </td><td> </td><td>25</td><td> </td><td> </td><td> </td><td> </td><td>1</td><td>3</td><td>2</td><td>54</td><td>18</td><td> </td><td> </td><td> </td><td>103</td><td>6,32</td></tr><tr><td>sep</td><td> </td><td> </td><td> </td><td> </td><td>49</td><td> </td><td>12</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>61</td><td>3,74</td></tr><tr><td>oct</td><td> </td><td> </td><td> </td><td> </td><td>15</td><td> </td><td> </td><td> </td><td>3</td><td>10</td><td>9</td><td>3</td><td>36</td><td> </td><td> </td><td> </td><td> </td><td>76</td><td>4,67</td></tr><tr><td>nov</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>5</td><td> </td><td> </td><td>8</td><td>1</td><td>8</td><td> </td><td>9</td><td>4</td><td> </td><td> </td><td>35</td><td>2,15</td></tr><tr><td>dec</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>7</td><td> </td><td>7</td><td>26</td><td>2</td><td>4</td><td> </td><td> </td><td>46</td><td>2,82</td></tr><tr><td>Sum</td><td>54</td><td>262</td><td>1</td><td>34</td><td>353</td><td>70</td><td>33</td><td>154</td><td>56</td><td>57</td><td>105</td><td>58</td><td>215</td><td>107</td><td>24</td><td>5</td><td>41</td><td>1629</td><td>100</td></tr><tr><td>%</td><td>3,31</td><td>16,08</td><td>0,06</td><td>2,09</td><td>21,67</td><td>4,30</td><td>2,03</td><td>9,45</td><td>3,44</td><td>3,50</td><td>6,45</td><td>3,56</td><td>13,20</td><td>6,57</td><td>1,47</td><td>0,31</td><td>2,52</td><td>100</td><td> </td></tr></table> |
ce8cb00dc3be216bae94abdec50453a878b5c15414a982fb63f2832b1531349b.png | complex | <table><tr><td></td><td>Lipid emulsion (n = 16)</td><td>Control (n = 11)</td></tr><tr><td>Initiation of enteral nutrition (h)</td><td>10.63 ± 5.49</td><td>9.27 ± 6.69</td></tr><tr><td>Age at feeds >100 mL/kg per day (days)</td><td>11.69 ± 4.75</td><td>7.55 ± 3.77*</td></tr><tr><td>Period of parenteral nutrition (days)</td><td>12.75 ± 5.84</td><td>8.91 ± 3.70*</td></tr><tr><td>Human milk/enteral nutrition at 2 weeks (%)</td><td>91.29 ± 21.55</td><td>73.84 ± 39.72</td></tr><tr><td colspan="3">Lipid emulsion</td></tr><tr><td> Initiation (day)</td><td>5.13 ± 2.31</td><td>–</td></tr><tr><td> Amount of initiation (g/kg per day)</td><td>0.60 ± 0.17</td><td>–</td></tr><tr><td> Period (days)</td><td>6.88 ± 3.61</td><td>–</td></tr><tr><td> Total amount of infusion (g/kg)</td><td>3.89 ± 3.22</td><td>–</td></tr></table> |
b8c8a05ec61d775e5b2f72d5462549fa06c2a38b48d359d2b71a602a1f243fb4.png | complex | <table><tr><td rowspan="2">Indicator</td><td colspan="2">Participants<sup>a</sup></td><td rowspan="2"><i>P</i></td></tr><tr><td>With probable depression at baseline(<i>n</i> = 309)</td><td>Without probable depression at baseline(<i>n</i> = 266)</td></tr><tr><td>Treatment outcome, no. (%)</td><td></td><td></td><td></td></tr><tr><td>Treatment success</td><td>269 (87.1)</td><td>257 (96.6)</td><td>< 0.001</td></tr><tr><td>Treatment failure</td><td>4 (1.3)</td><td>2 (0.8)</td><td>ND</td></tr><tr><td>Treatment default</td><td>12 (3.9)</td><td>2 (0.8)</td><td>< 0.05</td></tr><tr><td>Death</td><td>24 (7.8)</td><td>5 (1.9)</td><td>< 0.01</td></tr><tr><td>Quality-of-life score, mean(SD)<sup>b,c</sup></td><td></td><td></td><td></td></tr><tr><td>At baseline before tuberculosis treatment</td><td>4.7 (2.7)</td><td>5.7 (2.4)</td><td>< 0.001</td></tr><tr><td>After 6 months of treatment</td><td>5.0 (2.4)</td><td>6.0 (2.2)</td><td>< 0.001</td></tr><tr><td>Disability score, median(IQR)<sup>c,d</sup></td><td></td><td></td><td></td></tr><tr><td>At baseline before tuberculosis treatment</td><td>30 (16)</td><td>18 (8)</td><td>< 0.001</td></tr><tr><td>After 6 months of treatment</td><td>22 (19)</td><td>14 (4)</td><td>< 0.001</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.